WO2024049982A2 - Methods of using itraconazole dry powders - Google Patents
Methods of using itraconazole dry powders Download PDFInfo
- Publication number
- WO2024049982A2 WO2024049982A2 PCT/US2023/031675 US2023031675W WO2024049982A2 WO 2024049982 A2 WO2024049982 A2 WO 2024049982A2 US 2023031675 W US2023031675 W US 2023031675W WO 2024049982 A2 WO2024049982 A2 WO 2024049982A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- itraconazole
- less
- respirable dry
- therapeutic agent
- subject
- Prior art date
Links
- 229960004130 itraconazole Drugs 0.000 title claims abstract description 304
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title claims abstract description 280
- 239000000843 powder Substances 0.000 title claims abstract description 234
- 238000000034 method Methods 0.000 title claims abstract description 111
- 239000003814 drug Substances 0.000 claims abstract description 149
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 110
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 32
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 29
- 239000000411 inducer Substances 0.000 claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 208000035475 disorder Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims description 190
- 239000002775 capsule Substances 0.000 claims description 42
- 229940112141 dry powder inhaler Drugs 0.000 claims description 39
- 239000003381 stabilizer Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 35
- -1 cobimetiniba Chemical compound 0.000 claims description 29
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 28
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims description 23
- 229940068968 polysorbate 80 Drugs 0.000 claims description 23
- 108020003175 receptors Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 21
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- 229960003793 midazolam Drugs 0.000 claims description 19
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 15
- 159000000000 sodium salts Chemical class 0.000 claims description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 15
- 235000011152 sodium sulphate Nutrition 0.000 claims description 15
- UNBRKDKAWYKMIV-QWQRMKEZSA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 UNBRKDKAWYKMIV-QWQRMKEZSA-N 0.000 claims description 12
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 12
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 claims description 12
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 claims description 12
- 229960001405 ergometrine Drugs 0.000 claims description 12
- 239000010419 fine particle Substances 0.000 claims description 12
- 229960000328 methylergometrine Drugs 0.000 claims description 12
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 12
- 208000023504 respiratory system disease Diseases 0.000 claims description 12
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 11
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 10
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 claims description 7
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims description 7
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 6
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 6
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 6
- 230000009798 acute exacerbation Effects 0.000 claims description 6
- 230000001773 anti-convulsant effect Effects 0.000 claims description 6
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- 229960003965 antiepileptics Drugs 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 229960005132 cisapride Drugs 0.000 claims description 6
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 6
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 6
- 229960002626 clarithromycin Drugs 0.000 claims description 6
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 6
- 229960001338 colchicine Drugs 0.000 claims description 6
- 229960004704 dihydroergotamine Drugs 0.000 claims description 6
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 6
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001066 disopyramide Drugs 0.000 claims description 6
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002994 dofetilide Drugs 0.000 claims description 6
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960002084 dronedarone Drugs 0.000 claims description 6
- FJZZPCZKBUKGGU-AUSIDOKSSA-N eliglustat Chemical compound C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 claims description 6
- 229960002856 eliglustat Drugs 0.000 claims description 6
- 229960001208 eplerenone Drugs 0.000 claims description 6
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 6
- 229960003133 ergot alkaloid Drugs 0.000 claims description 6
- 229960004943 ergotamine Drugs 0.000 claims description 6
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 6
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003580 felodipine Drugs 0.000 claims description 6
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims description 6
- 229960002978 fesoterodine Drugs 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960003445 idelalisib Drugs 0.000 claims description 6
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 229960003825 ivabradine Drugs 0.000 claims description 6
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 claims description 6
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 claims description 6
- 229940087121 levomethadyl Drugs 0.000 claims description 6
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 claims description 6
- 229960003566 lomitapide Drugs 0.000 claims description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
- 229960004844 lovastatin Drugs 0.000 claims description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 6
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 6
- 229960001432 lurasidone Drugs 0.000 claims description 6
- 229960001797 methadone Drugs 0.000 claims description 6
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 6
- XNKCCCKFOQNXKV-ZRSCBOBOSA-N naloxegol Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC[C@@H]3OCCOCCOCCOCCOCCOCCOCCOC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 XNKCCCKFOQNXKV-ZRSCBOBOSA-N 0.000 claims description 6
- 229960005171 naloxegol Drugs 0.000 claims description 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 6
- 229960000227 nisoldipine Drugs 0.000 claims description 6
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003634 pimozide Drugs 0.000 claims description 6
- 229960001404 quinidine Drugs 0.000 claims description 6
- 229960000213 ranolazine Drugs 0.000 claims description 6
- 229960000885 rifabutin Drugs 0.000 claims description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 6
- 229960002855 simvastatin Drugs 0.000 claims description 6
- 229960003855 solifenacin Drugs 0.000 claims description 6
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 6
- 229940063138 sporanox Drugs 0.000 claims description 6
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims description 6
- 229960002528 ticagrelor Drugs 0.000 claims description 6
- 229960003386 triazolam Drugs 0.000 claims description 6
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 6
- 108010044467 Isoenzymes Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 claims description 4
- MVRHVFSOIWFBTE-INIZCTEOSA-N N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide Chemical compound CN1N=C(C(=C1)S(=O)(=O)NC(=O)C=1C(=NC(=CC=1)N1N=C(C=C1)OCC(C(F)(F)F)(C)C)N1C(C[C@@H](C1)C)(C)C)C MVRHVFSOIWFBTE-INIZCTEOSA-N 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 229940012392 elexacaftor Drugs 0.000 claims description 4
- 229960004508 ivacaftor Drugs 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 229950005823 tezacaftor Drugs 0.000 claims description 4
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 claims description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims description 3
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims description 3
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 3
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims description 3
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 3
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 3
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 3
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 3
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 3
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 3
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000009858 acid secretion Effects 0.000 claims description 3
- 229960001391 alfentanil Drugs 0.000 claims description 3
- 229960004601 aliskiren Drugs 0.000 claims description 3
- 229960001445 alitretinoin Drugs 0.000 claims description 3
- 239000002160 alpha blocker Substances 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000000507 anthelmentic effect Effects 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 230000000842 anti-protozoal effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 229940124433 antimigraine drug Drugs 0.000 claims description 3
- 229940127218 antiplatelet drug Drugs 0.000 claims description 3
- 239000003904 antiprotozoal agent Substances 0.000 claims description 3
- 239000002249 anxiolytic agent Substances 0.000 claims description 3
- 230000000949 anxiolytic effect Effects 0.000 claims description 3
- 229960003886 apixaban Drugs 0.000 claims description 3
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 3
- 229960001372 aprepitant Drugs 0.000 claims description 3
- 229960004372 aripiprazole Drugs 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- 229960003005 axitinib Drugs 0.000 claims description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 3
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims description 3
- 229960000508 bedaquiline Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960003065 bosentan Drugs 0.000 claims description 3
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003736 bosutinib Drugs 0.000 claims description 3
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 3
- 229960004436 budesonide Drugs 0.000 claims description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 3
- 229960001736 buprenorphine Drugs 0.000 claims description 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002495 buspirone Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960004596 cabergoline Drugs 0.000 claims description 3
- 229960001292 cabozantinib Drugs 0.000 claims description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229930003827 cannabinoid Natural products 0.000 claims description 3
- 239000003557 cannabinoid Substances 0.000 claims description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- 239000002327 cardiovascular agent Substances 0.000 claims description 3
- 229940125692 cardiovascular agent Drugs 0.000 claims description 3
- 229960001602 ceritinib Drugs 0.000 claims description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 3
- 229960004588 cilostazol Drugs 0.000 claims description 3
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 claims description 3
- 229960003315 cinacalcet Drugs 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- ZVAQGQOEHFIYMQ-PRLJFWCFSA-N co-artemether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OOC1(C)O4.C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 ZVAQGQOEHFIYMQ-PRLJFWCFSA-N 0.000 claims description 3
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims description 3
- 229960002402 cobicistat Drugs 0.000 claims description 3
- JGBBVDFNZSRLIF-UHFFFAOYSA-N conivaptan Chemical compound C12=CC=CC=C2C=2[N]C(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 JGBBVDFNZSRLIF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000562 conivaptan Drugs 0.000 claims description 3
- 239000003433 contraceptive agent Substances 0.000 claims description 3
- 230000002254 contraceptive effect Effects 0.000 claims description 3
- 229960005061 crizotinib Drugs 0.000 claims description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 3
- 229960003850 dabigatran Drugs 0.000 claims description 3
- 229960002465 dabrafenib Drugs 0.000 claims description 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 3
- 229960005449 daclatasvir Drugs 0.000 claims description 3
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims description 3
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 3
- 229960002677 darifenacin Drugs 0.000 claims description 3
- 229960005107 darunavir Drugs 0.000 claims description 3
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 229960003529 diazepam Drugs 0.000 claims description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 3
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 3
- 229960003309 dienogest Drugs 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 229960005156 digoxin Drugs 0.000 claims description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 3
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 3
- 229960004166 diltiazem Drugs 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 3
- 229960004199 dutasteride Drugs 0.000 claims description 3
- 229960003804 efavirenz Drugs 0.000 claims description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 3
- 229960002472 eletriptan Drugs 0.000 claims description 3
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims description 3
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims description 3
- 229960003586 elvitegravir Drugs 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229960002428 fentanyl Drugs 0.000 claims description 3
- 229960002714 fluticasone Drugs 0.000 claims description 3
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
- 229960003142 fosamprenavir Drugs 0.000 claims description 3
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000004083 gastrointestinal agent Substances 0.000 claims description 3
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002048 guanfacine Drugs 0.000 claims description 3
- 229960003242 halofantrine Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 claims description 3
- 230000000147 hypnotic effect Effects 0.000 claims description 3
- 229960001507 ibrutinib Drugs 0.000 claims description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 claims description 3
- 229960000788 isavuconazole Drugs 0.000 claims description 3
- RSWOJTICKMKTER-QXLBVTBOSA-N isavuconazonium Chemical compound CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C=2SC=C(N=2)C=2C=CC(=CC=2)C#N)C=2C(=CC=C(F)C=2)F)N=C1 RSWOJTICKMKTER-QXLBVTBOSA-N 0.000 claims description 3
- 229960004922 isavuconazonium Drugs 0.000 claims description 3
- 229960003350 isoniazid Drugs 0.000 claims description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 229940005405 kalydeco Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001571 loperamide Drugs 0.000 claims description 3
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000998 lumacaftor Drugs 0.000 claims description 3
- 229960004710 maraviroc Drugs 0.000 claims description 3
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 3
- 229960001929 meloxicam Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- YQCGOSZYHRVOFW-UHFFFAOYSA-N n-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1h-quinoline-3-carboxamide;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 YQCGOSZYHRVOFW-UHFFFAOYSA-N 0.000 claims description 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 3
- 229960004255 nadolol Drugs 0.000 claims description 3
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 claims description 3
- 229960005163 netupitant Drugs 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 229960001346 nilotinib Drugs 0.000 claims description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004378 nintedanib Drugs 0.000 claims description 3
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 3
- 229940080152 orkambi Drugs 0.000 claims description 3
- 229960005434 oxybutynin Drugs 0.000 claims description 3
- 229960002085 oxycodone Drugs 0.000 claims description 3
- 229960005184 panobinostat Drugs 0.000 claims description 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 3
- 229960000639 pazopanib Drugs 0.000 claims description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 3
- 229960002695 phenobarbital Drugs 0.000 claims description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002036 phenytoin Drugs 0.000 claims description 3
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 3
- 229960001131 ponatinib Drugs 0.000 claims description 3
- 229960002957 praziquantel Drugs 0.000 claims description 3
- 239000000612 proton pump inhibitor Substances 0.000 claims description 3
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- 229960000948 quinine Drugs 0.000 claims description 3
- 229960001150 ramelteon Drugs 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004836 regorafenib Drugs 0.000 claims description 3
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001225 rifampicin Drugs 0.000 claims description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 3
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000529 riociguat Drugs 0.000 claims description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001534 risperidone Drugs 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
- 229960001148 rivaroxaban Drugs 0.000 claims description 3
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 3
- 229960000215 ruxolitinib Drugs 0.000 claims description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 3
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 229960001852 saquinavir Drugs 0.000 claims description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 3
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 3
- 229960004937 saxagliptin Drugs 0.000 claims description 3
- 108010033693 saxagliptin Proteins 0.000 claims description 3
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 claims description 3
- 229960004953 silodosin Drugs 0.000 claims description 3
- 229960002091 simeprevir Drugs 0.000 claims description 3
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 claims description 3
- 229960005325 sonidegib Drugs 0.000 claims description 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004739 sufentanil Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- JYTNQNCOQXFQPK-MRXNPFEDSA-N suvorexant Chemical compound C([C@H]1C)CN(C=2OC3=CC=C(Cl)C=C3N=2)CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1 JYTNQNCOQXFQPK-MRXNPFEDSA-N 0.000 claims description 3
- 229960001198 suvorexant Drugs 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 229960002613 tamsulosin Drugs 0.000 claims description 3
- 229960000235 temsirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims description 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 3
- 229960004045 tolterodine Drugs 0.000 claims description 3
- 229960000977 trabectedin Drugs 0.000 claims description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 3
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 3
- 229960001099 trimetrexate Drugs 0.000 claims description 3
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 3
- 229960000200 ulipristal Drugs 0.000 claims description 3
- 229940124354 urologic drug Drugs 0.000 claims description 3
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 3
- 229960000241 vandetanib Drugs 0.000 claims description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- 229960001722 verapamil Drugs 0.000 claims description 3
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 claims description 3
- 229960005044 vorapaxar Drugs 0.000 claims description 3
- 229960005080 warfarin Drugs 0.000 claims description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 3
- 229960000820 zopiclone Drugs 0.000 claims description 3
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004607 alfuzosin Drugs 0.000 claims description 2
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 2
- 229960000307 avanafil Drugs 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 95
- 238000009472 formulation Methods 0.000 description 76
- 210000004072 lung Anatomy 0.000 description 37
- 239000000725 suspension Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- 229960003136 leucine Drugs 0.000 description 19
- 238000003801 milling Methods 0.000 description 18
- 239000007921 spray Substances 0.000 description 18
- 230000008406 drug-drug interaction Effects 0.000 description 17
- 238000001694 spray drying Methods 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000000443 aerosol Substances 0.000 description 14
- 230000003068 static effect Effects 0.000 description 13
- 238000009826 distribution Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 201000003883 Cystic fibrosis Diseases 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000009885 systemic effect Effects 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 9
- 206010035664 Pneumonia Diseases 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000001238 wet grinding Methods 0.000 description 8
- 239000012296 anti-solvent Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 201000002909 Aspergillosis Diseases 0.000 description 4
- 208000036641 Aspergillus infections Diseases 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000010902 jet-milling Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 238000010951 particle size reduction Methods 0.000 description 4
- 231100000651 physiologically based pharmacokinetic modelling Toxicity 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000006965 reversible inhibition Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000006070 nanosuspension Substances 0.000 description 3
- 229940068965 polysorbates Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HKDLNTKNLJPAIY-WKWWZUSTSA-N Ulipristal Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 238000010296 bead milling Methods 0.000 description 2
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- 101150022946 CYP3 gene Proteins 0.000 description 1
- 101100136727 Caenorhabditis elegans psd-1 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 101100137368 Dictyostelium discoideum cypD gene Proteins 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 101150009380 PPIF gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 1
- 101100222691 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CPR3 gene Proteins 0.000 description 1
- 101100276454 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYC7 gene Proteins 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940003775 itraconazole oral solution Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052572 stoneware Inorganic materials 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Definitions
- Itraconazole is a triazole antifungal with a broad spectrum of activity, which is typically administered orally. Itraconazole is the active ingredient in the FDA-approved oral antifungal drug SPORANOX®. However, the clinical use of oral itraconazole is limited by unpredictable and variable pharmacokinetics, poor tolerability, adverse effects, and concerns related to its high drug-drug interaction (DDI) potential.
- DPI drug-drug interaction
- the DDT potential of itraconazole is related to its activity as a potent inhibitor of the cytochrome P450 3 A4 (CYP3 A4) isoenzyme.
- CYP3 A4 cytochrome P450 3 A4
- the impact of itraconazole on the CPY3 A4 pathway alters the metabolism and consequently the plasma concentrations of other drugs metabolized by this pathway. Consequently, co-administration of a long list of drugs and drug classes with itraconazole is currently contraindicated due to the potential for DDIs.
- the package insert for SPORANOX® lists over 40 contraindicated drugs and another 256 drugs for which special precautions should be taken. (See Bergagnini-Kolev, et al. The AAPS Journal (2023) 25:62; incorporated herein by reference in its entirety).
- the potential DDIs of oral itraconazole greatly limit its use, particularly in patient populations that would benefit from itraconazole treatment.
- itraconazole has shown benefits in treating allergic bronchopulmonary aspergillosis which has a prevalence of up to 15% in people with cystic fibrosis and an estimated 1.5% of patients in the general population with asthma. (See Bergagnani-Kolev, supra).
- numerous drugs used in the treatment of exacerbations of asthma or maintenance therapies for cystic fibrosis cannot be used safely with oral itraconazole (See Bergagnani-Kolev, supra).
- the present disclosure relates to respirable dry powders and methods for administering itraconazole to subjects for whom oral itraconazole is contraindicated, and for co-administering itraconazole with a second therapeutic agent that is contraindicated with use of oral itraconazole.
- the compositions and methods disclosed herein can be used to safely achieve therapeutic concentrations of itraconazole in the lungs of a patient population that is otherwise not treatable with itraconazole, such as subjects already taking a CYP3A4 substrate.
- cystic fibrosis (CF) patients are commonly treated with medications including elexacaftor, ivacaftor, and tezacaftor, which are extensively metabolized by CYP3A4 and therefore oral itraconazole cannot be administered to those patients.
- This is problematic, because cystic fibrosis patients are highly susceptible to lung infections and may greatly benefit from being treated with itraconazole.
- the methods disclosed herein address this problem, as they may be used concomitantly with CYP3A4 substrates.
- the compositions and methods disclosed herein may be useful in treating allergic bronchopulmonary aspergillosis (ABPA) in subjects with cystic fibrosis (CF) or asthma, for whom oral itraconazole is contraindicated.
- ABPA allergic bronchopulmonary aspergillosis
- the present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole.
- the subject can be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- the present disclosure relates to a method of co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- the second therapeutic agent can be a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.
- the second therapeutic agent may be one that is contraindicated with oral itraconazole (e.g., SPORANOX®).
- the second therapeutic agent is an alpha blocker, a beta blocker, an analgesic, an antiarrhythmic, an antibacterial, an anticoagulant, an antiplatelet drug, an anticonvulsant, an antidiabetic drug, an anthelminthic, an antifungal, an antiprotozoal, an antimigraine drug, an antineoplastic, an antipsychotic, an anxiolytic, a hypnotic, an antiviral, a calcium channel blocker, a cardiovascular drug, a contraceptive, a diuretic, an anticonvulsant, an immunosuppressant, a lipid-lowering drug, a respiratory drug (e.g., an asthma treatment), an antidepressant drug (e g., a tricyclic or a selective serotonin reuptake inhibitor (SSRI)), a urologic drug, a vasopressin receptor antagonist, a nonsteroidal anti-inflammatory drug (NSAID), or a gastrointestinal
- a respiratory drug e
- the second therapeutic agent is alfuzosin, silodosin, tamsulosin, methadone, fentanyl, alfentanil, buprenorphine, oxycodone, sufentanil, disopyramide, dofetilide, dronedarone, quinidine, digoxin, bedaquiline, rifabutin, clarithromycin, trimetrexate, ticagrelor, apixaban, rivaroxaban, vorapaxar, cilostazol, dabigatran, warfarin, carbamazepine, repaglinidea, saxagliptin, isavuconazonium, praziquantel, artemether-lumefantrine, quinine, an ergot alkaloid (e g., dihydroergotamine, ergometrine, ergonovine, methylergometrine, methylergon
- the second therapeutic agent is methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, an ergot alkaloid (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafd, ticagrelor, colchicine, fesoterodine, solifenacin, or eliglustat.
- an ergot alkaloid such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrin
- the respirable dry powder comprising itraconazole is administered to the respiratory tract of the subject at a nominal dose of between about 1 mg and about 60 mg, between about 5 mg and about 40 mg, between about 1 mg and about 10 mg, between about 10 mg and about 20 mg, between about 20 mg and about 30 mg, or between about 30 mg and about 40 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg.
- the respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject no more than about 14 days before or after administering the second therapeutic agent, less than about 14 days, less than about 12 days, less than about 10 days, less than about 8 days, less than about 7 days, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, less than about 2 days, or less than about 1 day before or after administering the second therapeutic agent.
- the respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject on the same day as administering the second therapeutic agent, less than about 20 hours, less than about 18 hours, less than about 16 hours, less than about 14 hours, less than about 12 hours, less than about 11 hours, less than about 10 hours, less than about 9 hours, less than about 8 hours, less than about 7 hours, less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, less than about 45 minutes, less than about 30 minutes, less than about 20 minutes, less than about 10 minutes, or less than about 5 minutes, before or after administering the second therapeutic agent.
- the respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject less than about 5 minutes before or after administering the second therapeutic agent.
- the respirable dry powder comprises homogenous respirable dry particles that comprise crystalline itraconazole, a stabilizer, a sodium salt, and an excipient.
- the sodium salt may be sodium sulfate.
- the stabilizer may be polysorbate 80.
- the excipient may be leucine.
- the itraconazole can be in a crystalline sub-particle form, where the sub-particle has a size of about 50 nm to about 5,000 nm (Dv50), about 50 nm to about 800 nm (Dv50), about 50 nm to about 300 nm (Dv50), about 50 nm to about 200 nm (Dv50), or about 100 nm to about 300 nm (Dv50).
- the itraconazole may be present in the respirable dry particles in an amount of about 30% to about 70% by weight, about 40% to about 60% by weight, about 45%, about 50%, or about 55% by weight. In some embodiments, the itraconazole is at least 50% crystalline.
- the ratio of itraconazole stabilizer (wt:wt) in the respirable dry particles can be about 10: 1.
- the stabilizer e.g., polysorbate 80
- the stabilizer is present in the respirable dry particles in an amount of about 3% to about 7% by weight. In some embodiments, the stabilizer (e.g., polysorbate 80) is present in the respirable dry particles in an amount of about 5% by weight.
- the excipient e.g., leucine
- the excipient is present in the respirable dry particles in an amount of about 5% to about 20% by weight. In some embodiments, the excipient (e.g., leucine) is present in the respirable dry particles in an amount of about 10% by weight.
- the stabilizer is polysorbate 80.
- the excipient is leucine.
- the respirable dry powder comprises homogenous respirable dry particles that comprise about 50 wt% crystalline itraconazole, about 35 wt% sodium sulfate, about 10 wt% leucine, and about 5 wt% polysorbate 80.
- the respirable dry particles may have: (i) a volume median geometric diameter (VMGD) of about 10 microns or less, or about 5 microns or less; (ii) a tap density of about 0.2 g/cc or greater, or a tap density of between 0.2 g/cc and 1.0 g/cc; (iii) a 1 bar/4 bar dispersibility ratio (1/4 bar) of less than about 1.5, as measured by laser diffraction; and/or (iv) a 0.5 bar/4 bar dispersibility ratio (0.5/4 bar) of about 1.5 or less, as measured by laser diffraction.
- VMGD volume median geometric diameter
- the respirable dry powder may have: (i) a mass median aerodynamic diameter (MMAD) of between about 1 micron and about 5 microns; and/or (ii) a fine particle fraction (FPF) of the total dose less than 5 microns of about 25% or more.
- MMAD mass median aerodynamic diameter
- FPF fine particle fraction
- the respirable dry particles have a capsule emitted powder mass of at least 80% when emitted from a passive dry powder inhaler that has a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions; an inhalation flow rate of 30 LPM for a period of 3 seconds using a size 3 capsule that contains a total mass of 10 mg, said total mass consisting of the respirable dry particles, and wherein the volume median geometric diameter of the respirable dry particles emitted from the inhaler as measured by laser diffraction is 5 microns or less.
- the respirable dry powder can be delivered to the respiratory tract of the subject with a capsule-based passive dry powder inhaler.
- the subject may have an infection, allergic bronchopulmonary aspergillosis, a respiratory disease, an acute exacerbation of a respiratory disease, an immunodeficiency disorder, cancer, a cardiovascular disorder, hypertension, hypercholesterolemia, an autoimmune disorder, diabetes, a gastrointestinal disorder, a thrombotic disorder, epilepsy, a psychiatric disorder, migraine, or pain.
- the subject can have a fungal infection, such as aspergillosis.
- the subject may have cystic fibrosis, asthma, or pneumonia (e.g., fungal pneumonia).
- the subject may have HIV or AIDS).
- the subject may have a form of cancer such as lung cancer (e.g., non-small cell lung cancer).
- the subject may have congestive heart failure, cardiac dysrhythmias, or cardiac disease.
- the subject may have bipolar disorder, depression, psychosis, or anxiety.
- the subject may have acute pain or chronic pain.
- the subject may have surgical pain (e.g., perioperative pain or postoperative pain).
- the present disclosure relates to a respirable dry powder disclosed herein for use in a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject.
- the subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- the present disclosure relates to a respirable dry powder disclosed herein for use in a method of co-administering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- the present disclosure relates to use of a respirable dry powder disclosed herein in the manufacture of a medicament for treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject.
- the subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- the present disclosure relates to use a respirable dry powder disclosed herein in the manufacture of a medicament for co-administering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
- FIG. 1 is a diagram depicting a structural model of first-order absorption from the lungs to the systemic circulation.
- the present disclosure relates to methods for administering itraconazole to the respiratory tract of a subject for whom oral itraconazole is contraindicated, e.g., due to the subject being treated with a second therapeutic agent that is not usually combined with oral itraconazole due to potential DDIs.
- a high and consistent lung exposure with substantially lower systemic exposure can be achieved following inhaled delivery of itraconazole relative to conventional oral dosing.
- this limited systemic exposure may be beneficial for use in subjects for whom oral itraconazole is contraindicated, and using inhaled respirable dry powders containing itraconazole, it is possible to safely achieve therapeutic concentrations of itraconazole in the lungs of this patient population, e.g., to treat certain diseases or disorders affecting the respiratory system.
- the present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole.
- the subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme).
- CYP3A4 cytochrome P450 3A4
- the present disclosure relates to a method of coadministering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme).
- CYP3A4 cytochrome P450 3A4
- the term “about” refers to a relative range of plus or minus 20% of a stated value, e.g., “about 20 mg” would be “20 mg plus or minus 4 mg”.
- administering refers to the introduction of a therapeutic agent, or a composition comprising a therapeutic agent, to a subject.
- administering may refer to introducing a respirable dry powder disclosed herein to the respiratory tract of a subject.
- amorphous indicates lack of significant crystallinity when analyzed via powder X-ray diffraction (XRD).
- CEPM capsule emitted powder mass
- CEPM capsule emitted powder mass
- CEPM is measured gravimetrically, typically by weighing a capsule before and after the emission event to determine the mass of powder removed.
- CEPM can be expressed either as the mass of powder removed, in milligrams, or as a percentage of the initial filled powder mass in the capsule prior to the emission event.
- crystalline particulate form refers to itraconazole (including pharmaceutically acceptable forms thereof including salts, polymorphs, solvates, hydrates, and the like), that is in the form of a particle (i.e., sub-particle that is smaller than the respirable dry particles that comprise the dry powders disclosed herein) and in which the itraconazole is at least about 50% crystalline.
- the percent crystallinity of itraconazole refers to the percentage of the compound that is in crystalline form relative to the total amount of compound present in the subparticle. If desired, the itraconazole can be at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% crystalline.
- Itraconazole in crystalline particulate form may be in the form of a particle that is about 50 nanometers (nm) to about 5,000 nm volume median diameter (Dv50), preferably 80 nm to 1750 nm Dv50, or preferably 50 nm to 800 nm Dv50.
- Dispersible is a term of art that describes the characteristic of a dry powder or respirable dry particles to be dispelled into a respirable aerosol. Dispersibility of a dry powder or respirable dry particles is expressed herein, in one aspect, as the quotient of the volumetric median geometric diameter (VMGD) measured at a dispersion (i.e., regulator) pressure of 1 bar divided by the VMGD measured at a dispersion (i.e., regulator) pressure of 4 bar, or VMGD at 0.5 bar divided by the VMGD at 4 bar as measured by laser diffraction, such as with a HELOS/RODOS.
- VMGD volumetric median geometric diameter
- 1 bar/4 bar dispersibility ratio refers to the VMGD of a dry powder or respirable dry particles emitted from the orifice of a RODOS dry powder disperser (or equivalent technique) at about 1 bar, as measured by a HELOS or other laser diffraction system, divided by the VMGD of the same dry powder or respirable dry particles measured at 4 bar by HELOS/RODOS.
- a highly dispersible dry powder or respirable dry particles will have a 1 bar/4 bar dispersibility ratio or 0.5 bar/4 bar dispersibility ratio that is close to 1.0.
- Highly dispersible powders have a low tendency to agglomerate, aggregate or clump together and/or, if agglomerated, aggregated or clumped together, are easily dispersed or de-agglomerated as they emit from an inhaler and are breathed in by a subject.
- dispersibility is assessed by measuring the particle size emitted from an inhaler as a function of flowrate. As the flow rate through the inhaler decreases, the amount of energy in the airflow available to be transferred to the powder to disperse it decreases.
- a highly dispersible powder will have a size distribution such as is characterized aerodynamically by its mass median aerodynamic diameter (MMAD) or geometrically by its VMGD that does not substantially increase over a range of flow rates typical of inhalation by humans, such as about 15 to about 60 liters per minute (LPM), about 20 to about 60 LPM, or about 30 LPM to about 60 LPM.
- MMAD mass median aerodynamic diameter
- VMGD volume median diameter
- x50 x50
- Dv50 volume median diameter
- dry particles refers to respirable particles that may comprise up to about 15% total of water and/or another solvent.
- the dry particles comprise water and/or another solvent up to about 10% total, up to about 5% total, up to about 1% total, or between 0.01% and 1% total, by weight of the dry particles, or can be substantially free of water and/or other solvent.
- dry powder refers to compositions that comprise respirable dry particles.
- a dry powder may comprise up to about 15% total of water and/or another solvent.
- the dry powder comprise water and/or another solvent up to about 10% total, up to about 5% total, up to about 1% total, or between 0.01% and 1% total, by weight of the dry powder, or can be substantially free of water and/or other solvent.
- the dry powder is a respirable dry powder.
- the term “effective amount,” as used herein, refers to the amount of agent needed to achieve the desired effect; such as treating a fungal infection or related disorder, e.g., allergic bronchopulmonary aspergillosis (ABPA).
- ABPA allergic bronchopulmonary aspergillosis
- the actual effective amount for a particular use can vary according to the particular dry powder or respirable dry particle, the mode of administration, and the age, weight, general health of the subject, and severity of the symptoms or condition being treated. Suitable amounts of dry powders and dry particles to be administered, and dosage schedules for a particular patient can be determined by a clinician of ordinary skill based on these and other considerations.
- the term “emitted dose” or “ED” refers to an indication of the delivery of a drug formulation from a suitable inhaler device after a firing or dispersion event. More specifically, for dry powders, the ED is a measure of the percentage of powder that is drawn out of a unit dose package and that exits the mouthpiece of an inhaler device. The ED is defined as the ratio of the drug or powder delivered by an inhaler device to the nominal dose (i.e., the mass of drug or powder per unit dose placed into a suitable inhaler device prior to firing).
- the ED is an experimentally-measured parameter, and can be determined using the method of USP Section 601 Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, Delivered-Dose Uniformity, Sampling the Delivered Dose from Dry Powder Inhalers, United States Pharmacopeia convention, Rockville, MD, 13 th Revision, 222-225, 2007.
- This method utilizes an in vitro device set up to mimic patient dosing. It can also be calculated from the results generated by Next Generation Impactor (NGI) experiments, through summation of all of the drug or powder assayed from the mouthpiece adapter, NGI induction port, and all of the stages within the NGI.
- NGI Next Generation Impactor
- lung to plasma ratio refers to the ratio of a concentration of itraconazole in the lung versus the concentration of the itraconazole in the plasma at either a specific point in time or over a specific range of time.
- the lung:plasma ratio may be calculated based on concurrent measurements at the maximum concentration (i.e., the “Cmax”) of itraconazole in the lung or in the serum, or at any point in time.
- the lung:plasma ratio may also be calculated for a total exposure over a certain period of time (i.e., the “area under the curve” or “AUC”) such as over a 24 hour period
- the lung concentrations of the itraconazole may be assessed by measuring the levels in the sputum, by lung lavage, by biopsy or by some other method.
- the lung:plasma ratio may be calculated based on concurrent measurements at any point in the dosing cycle and may be calculated based on concurrent measurements before or at steady state.
- nominal dose refers to an individual dose of itraconazole.
- the nominal dose is the total dose of the itraconazole within one receptacle, e.g., capsule, blister, or ampule.
- FPF ( ⁇ X), “FPF ( ⁇ X microns),” and “fine particle fraction of less than X microns” as used herein, wherein X equals, for example, 3.4 microns, 4.4 microns, 5.0 microns or 5.6 microns, refer to the fraction of a sample of dry particles that have an aerodynamic diameter of less than X microns.
- FPF ( ⁇ X) can be determined by dividing the mass of respirable dry particles deposited on stage two and on the final collection filter of a two- stage collapsed Andersen Cascade Impactor (ACI) by the mass of respirable dry particles weighed into a capsule for delivery to the instrument.
- This parameter may also be identified as “FPF_TD( ⁇ X),” where TD means total dose.
- FPF_TD( ⁇ X) TD means total dose.
- a similar measurement can be conducted using an eight-stage ACI. An eight-stage ACI cutoffs are different at the standard 60 L/min flowrate, but the FPF_TD( ⁇ X) can be extrapolated from the eight-stage complete data set. The eight-stage ACI result can also be calculated by the USP method of using the dose collected in the ACI instead of what was in the capsule to determine FPF. Similarly, a seven-stage Next Generation Impactor (NGI) can be used.
- NTI Next Generation Impactor
- FPD ( ⁇ X) ‘FPD ⁇ X microns”, FPD( ⁇ X microns)” and “fine particle dose of less than X microns” as used herein, wherein X equals, for example, 3.4 microns, 4.4 microns, 5.0 microns or 5.6 microns, refer to the mass of a therapeutic agent delivered by respirable dry particles that have an aerodynamic diameter of less than X micrometers.
- FPD ⁇ X microns can be determined by using an eight-stage Andersen Cascade Impactor (ACI) or a Next Generation Impactor (NGI) at the standard 60L/min flowrate and summing the mass deposited on the final collection filter, and either directly calculating or extrapolating the FPD value. Similarly, a seven-stage Next Generation Impactor (NGI) can be used.
- ACI Andersen Cascade Impactor
- NTI Next Generation Impactor
- Respirable refers to dry particles or dry powders that are suitable for delivery to the respiratory tract (e g., pulmonary delivery) in a subject by inhalation.
- Respirable dry powders or dry particles have a mass median aerodynamic diameter (MMAD) of less than about 10 microns, preferably about 5 microns or less.
- MMAD mass median aerodynamic diameter
- the term “respiratory tract” includes the upper respiratory tract (e.g., nasal passages, nasal cavity, throat, pharynx, and larynx), respiratory airways (e.g., trachea, bronchi, and bronchioles) and lungs (e.g., respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli).
- respiratory airways e.g., trachea, bronchi, and bronchioles
- lungs e.g., respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli.
- respirable dry particles refers to particles that have a volume median geometric diameter (VMGD) of about 10 microns or less, preferably about 5 microns or less, or less than 5 microns.
- VMGD volume median geometric diameter
- stabilizer refers to a compound that improves the physical stability of the itraconazole in crystalline particulate form when suspended in a liquid in which the itraconazole is poorly soluble (e.g., reduces the aggregation, agglomeration, Ostwald ripening and/or flocculation of the particulates).
- Suitable stabilizers are surfactants and amphiphilic materials and include polysorbates (PS; polyoxy ethylated sorbitan fatty acid esters), such as polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60), and polysorbate 80 (PS80); fatty acids such as lauric acid, palmitic acid, myristic acid, oleic acid and stearic acid, and their salts; sorbitan fatty acid esters, such as Span20, Span40, Span60, Span80, and Span 85; phospholipids such as dipalmitoylphosphosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero- 3-phospho-L-serine (DPPS), l,2-dipalmitoyl-sn-glycero-3 -phosphocholine (DSPC), 1-palmitoyl- 2-oleoylphosphatidyl choline (POPC), and
- homogenous dry particles refers to particles that are compositionally homogenous. Homogenous dry particles disclosed herein are substantially the same in their composition of itraconazole, stabilizer, and optionally one or more excipients, and exclude a blend of two or more particles.
- a dry powder comprising itraconazole disclosed herein can achieve a lung concentration of the itraconazole that is substantially greater than those achievable by oral dosing, while maintaining relatively low systemic concentration of itraconazole.
- the administration can achieve therapeutic concentrations of itraconazole in the respiratory system while minimizing the systemic concentration of the itraconazole.
- the respirable dry powders of the present disclosure can be used to avoid DDIs when the subject is treated with a second therapeutic agent contraindicated with use of itraconazole, e.g., due to it being a substrate of, or an inducer or inhibitor of, the same enzymes or receptors (e.g., CYP3A4).
- the respirable dry powders of the present application are particularly useful for coadministration with therapeutic agents that are CYP3A4 inhibitors or inducers, and/or are metabolized by the same metabolic pathway(s) as itraconazole.
- a therapeutic concentration of the itraconazole in the lung can be achieved even with a relatively low amount of total dose administered, e.g., relative to conventional oral administration.
- a relatively low amount of total dose administered e.g., relative to conventional oral administration.
- studies have documented the systemic and pulmonary pharmacokinetics of oral itraconazole in adults and children, and pharmacokinetic studies examining respirable dry powders comprising itraconazole have shown that it is possible to achieve lung exposures that would be considered therapeutic for the treatment of pulmonary aspergillosis, after a relatively low single inhaled dose of 20 mg of dry powder. (See Conte, J.E., et al. Antimicrob. Agents Chemother.
- the relatively low total dose of itraconazole that is needed to be administered to achieve a therapeutic effect using a dry powder disclosed herein can reduce the risk of DDIs, which provides the opportunity to combine the dry powder comprising itraconazole with a second therapeutic agent, particularly those known to have DDTs and/or those contraindicated with itraconazole use, such as a substrate, inducer, or inhibitor of CYP3A4.
- Dry powders that comprise itraconazole in amorphous form have shorter lung residence times, reduced lung to plasma exposure ratios, and undesirable toxic effects on lung tissue when inhaled at therapeutic doses. Without wishing to be bound by any particular theory, it is believed that the dry powders disclosed herein comprising crystalline forms (e.g., nanocrystalline forms) of itraconazole have a slower dissolution rate in the lung relative to the amorphous form, providing more continuous exposure over a 24 hour period after administration and minimizing systemic exposure and DDT potential.
- crystalline forms e.g., nanocrystalline forms
- the dry powders described herein can be formulated using itraconazole in crystalline particulate form that a desired crystalline size or range of crystalline sizes within the dry powders, and optionally with suitable excipients and stabilizers in a suitable ratio with the itraconazole, each of which can be tailored to affect, for example, dissolution rate, and achieve desired pharmacokinetic properties while avoiding unacceptable toxicity in the lungs in addition to avoiding DDTs with a second therapeutic agent.
- Administering a dry powder disclosed herein can obtain a relatively high ratio of lung concentration: systemic concentration of the itraconazole. Without wishing to be bound by any particular theory, it is believed that a relatively high ratio of lung concentration: systemic concentration can not only minimize off-target effects and/or toxicity associated with itraconazole, but allow for coadministration with a second therapeutic agent that is contraindicated with itraconazole use and lower risk of DDTs. As such, the methods disclosed herein provide an advantage over commercially available formulations of itraconazole which are typically administered orally and in large amounts, and which cannot be co-administered with many other useful therapeutic agents due to high potential of DDTs and the associated safety concerns.
- Methods disclosed herein may comprise treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole (e.g., crystalline itraconazole). Additionally, methods disclosed herein may comprise co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject.
- a respirable dry powder comprising itraconazole (e.g., crystalline itraconazole).
- the second therapeutic agent may be a substrate of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e g., CYP3A4).
- the second therapeutic agent may be an inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., CYP3A4).
- the second therapeutic agent may be an inducer of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., CYP3A4).
- the second therapeutic agent may be contraindicated with oral itraconazole (e.g., SPORANOX®).
- the second therapeutic agent may be a substance that is listed as contraindicated for use with itraconazole by a regulatory authority, e g., as stated in the FDA label for SPORANOX®.
- respirable dry powders disclosed herein may be combined with many different classes of drugs, without significant risk of DDI or other adverse reactions, and/or without requiring careful adjustment or limiting doses to avoid potential DDIs or adverse reactions.
- a method disclosed herein may comprise coadministration of the respirable dry powder with, or administration of the respirable dry powder to a subject that is also administered with, a second therapeutic agent selected from the group consisting of an alpha blocker, a beta blocker, an analgesic, an antiarrhythmic, an antibacterial, an anticoagulant, an antiplatelet drug, an anticonvulsant, an antidiabetic drug, an anthelminthic, an antifungal, an antiprotozoal, an antimigraine drug, an antineoplastic, an antipsychotic, an anxiolytic, a hypnotic, an antiviral, a calcium channel blocker, a cardiovascular drug, a contraceptive, a diuretic, an anticonvulsant, an immunosuppressant, a lipid-lowering drug, a respiratory drug (e.g., an asthma treatment), an antidepressant drug (e g., a tricyclic or a selective serotonin reuptake
- the second therapeutic agent may be alfiizosin, silodosin, or tamsulosin.
- the second therapeutic agent may be methadone, fentanyl, alfentanil, buprenorphine, oxycodone, or sufentanil.
- the second therapeutic agent may be disopyramide, dofetilide, dronedarone, quinidine, or digoxin.
- the second therapeutic agent may be bedaquiline, rifabutin, clarithromycin, or trimetrexate.
- the second therapeutic agent may be ticagrelor, apixaban, rivaroxaban, vorapaxar, cilostazol, dabigatran, warfarin, or carbamazepine.
- the second therapeutic agent may be repaglinidea or saxagliptin.
- the second therapeutic agent may be isavuconazonium, praziquantel, artemether-lumefantrine, or quinine.
- the second therapeutic agent may be an ergot alkaloid, such as dihydroergotamine, ergometrine, ergonovine, methylergometrine, methylergonovine, ergotamine.
- the second therapeutic agent may be eletriptan.
- the second therapeutic agent may be irinotecan, axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetiniba, crizotinib, dabrafenib, dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olapariba, pazopanib, regorafenib, sunitinib, trabectedin, trastuzumab- emtansine, vinca alkaloids, bortezomib, brentuximab-vedotin, busulfan, erlotinib, gefitinib, idelalisib, nintedanib, panobinostat, ponatinib, ruxolitinib, sonidegib, vandetanib, imatinib
- the second therapeutic agent may be alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam, quetiapine, ramelteon, risperidone, suvorexant, zopiclone, lurasidone, pimozide, or triazolam.
- the second therapeutic agent may be levacetylmethadol (levomethadyl), simeprevir, daclatasvir, indinavir, maraviroc, cobicistat, elvitegravir, ritonavir, saquinavir, or tenofovir disoproxil fumarate.
- the second therapeutic agent may be nadolol.
- the second therapeutic agent may be felodipine, nisoldipine, diltiazem, dihydropyridines, or verapamil.
- the second therapeutic agent may be ivabradine, ranolazine, aliskiren, riociguat, sildenafd, tadalafd, bosentan, guanfacine, dienogest, or ulipristal.
- the second therapeutic agent may be eplerenone.
- the second therapeutic agent may be cisapride, naloxegol, aprepitant, loperamide, or netupitant.
- the second therapeutic agent may be everolimus, sirolimus, temsirolimus, budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, or tacrolimus.
- the second therapeutic agent may be lomitapide, lovastatin, simvastatin, or atorvastatin.
- the second therapeutic agent may be salmeterol.
- the second therapeutic agent may be venlafaxine.
- the second therapeutic agent may be avanafd, fesoterodine, solifenacin, darifenacin, vardenafil, dutasteride, oxybutynin, or tolterodine.
- the second therapeutic agent may be colchicine, eliglustat, lumacaftor, ivacaftor, elexacaftor, tezacaftor, SYMDEKO®, ORKAMBI®, KALYDECO®, alitretinoin, or cabergoline.
- the second therapeutic agent may be a cannabinoid.
- the second therapeutic agent may be cinacalcet, conivaptan, or volvaptan.
- the second therapeutic agent may be a Saccharomyces boulardii composition.
- the second therapeutic agent may be meloxicam.
- the second therapeutic agent may be ciprofloxacin, erythromycin, or clarithromycin.
- the second therapeutic agent may be idelalisib.
- the second therapeutic agent may be darunavir or fosamprenavir.
- the second therapeutic agent may be isoniazid, rifampicin, or rifabutin.
- the second therapeutic agent may be phenobarbital, phenytoin, efavirenz, or nevirapine.
- the second therapeutic agent may be a drug that reduces gastric acidity, such as an acid neutralizing medicines, e.g., aluminum hydroxide, an acid secretion suppressors such as H2-receptor antagonists, or a proton pump inhibitor.
- the second therapeutic agent may be halofantrine.
- the second therapeutic agent is methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, an ergot alkaloid (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, or methyl ergometrine (methyl ergonovine)), irinotecan, lurasidone, midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, colchicine, fesoterodine, solifenacin, or eliglustat.
- an ergot alkaloid such as dihydroergotamine, ergometrine (ergonovine), ergotamine, or methyl
- the respirable dry powder may be administered at a nominal dose of between about 1 mg and about 60 mg, e.g., between about 5 mg and about 40 mg, between about 1 mg and about 10 mg, between about 10 mg and about 20 mg, between about 20 mg and about 30 mg, or between about 30 mg and about 40 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg.
- Coadministration may refer to administering the respirable dry powder to the subject no more than about 14 days before or after administering the second therapeutic agent, e.g., less than about 14 days, less than about 12 days, less than about 10 days, less than about 8 days, less than about 7 days, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, less than about 2 days, or less than about 1 day before or after administering the second therapeutic agent.
- coadministration refers to administering the dry powder to the subject on the same day as administering the second therapeutic agent, e.g., administering the respirable dry powder less than about 20 hours, less than about 18 hours, less than about 16 hours, less than about 14 hours, less than about 12 hours, less than about 11 hours, less than about 10 hours, less than about 9 hours, less than about 8 hours, less than about 7 hours, less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, less than about 45 minutes, less than about 30 minutes, less than about 20 minutes, less than about 10 minutes, or less than about 5 minutes, before or after administering the second therapeutic agent.
- the itraconazole is administered to the subject less than about 5 minutes before or after administering the second therapeutic agent.
- the subject to be treated with the itraconazole may be a subject for whom oral itraconazole is contraindicated. That may be due to the subject having been administered the second therapeutic agent disclosed herein (e.g., a therapeutic agent that is contraindicated with itraconazole use). Due to the favorable pharmacokinetic properties achieved using the respirable dry powder disclosed herein, the subject may nevertheless be administered a respirable dry powder disclosed herein to achieve therapeutic local concentrations of itraconazole in the lungs, in a safe manner and avoiding DDTs or adverse events that would be expected when a different formulation of itraconazole, e.g., oral itraconazole, is administered.
- the second therapeutic agent disclosed herein e.g., a therapeutic agent that is contraindicated with itraconazole use. Due to the favorable pharmacokinetic properties achieved using the respirable dry powder disclosed herein, the subject may nevertheless be administered a respirable dry powder disclosed herein to achieve therapeutic local concentrations of itraconazole in the lungs
- the subject to be treated with the itraconazole who may be a subject for whom oral itraconazole is contraindicated, may have a disease or disorder.
- the particular disease or disorder may be a condition that the itraconazole is being administered to treat, or it may be a condition that is not being treated with itraconazole, or a condition that is unrelated to the use of the itraconazole.
- the subject may have an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, an immunodeficiency disorder (e.g., HIV or AIDS), cancer (e.g., lung cancer, such as non-small cell lung cancer), a cardiovascular disorder (e.g., congestive heart failure, cardiac dysrhythmias, cardiac disease), hypertension, hypercholesterolemia, an autoimmune disorder, diabetes, a gastrointestinal disorder, a thrombotic disorder, epilepsy, a psychiatric disorder (e.g., bipolar disorder, depression, psychosis, anxiety), migraine, pain (e.g., acute pain, pain caused by surgery, or chronic pain).
- an infection e.g., a fungal infection, such as aspergillosis), allergic
- the disease or disorder is a condition that the itraconazole is used to treat, such as an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, or cancer (e.g., lung cancer, such as non-small cell lung cancer).
- an infection e.g., a fungal infection, such as aspergillosis
- allergic bronchopulmonary aspergillosis e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)
- a respiratory disease e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)
- an acute exacerbation of a respiratory disease e.g., lung cancer, such as non-small cell lung cancer.
- a method disclosed herein is for treating an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, or cancer (e.g., lung cancer, such as non-small cell lung cancer) in a subject in need thereof.
- an infection e.g., a fungal infection, such as aspergillosis
- a respiratory disease e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)
- an acute exacerbation of a respiratory disease e.g., lung cancer, such as non-small cell lung cancer
- the dry powders disclosed herein may be administered to a subject by inhalation, such as oral inhalation.
- a dry powder inhaler may be used, such as a passive dry powder inhaler.
- Respirable dry powders comprising itraconazole for use in treating a fungal infection have been described in WO 2018/071757, WO 2019/204583, and WO 2019/204597, the entire contents of which are incorporated herein by reference in their entireties
- the respirable dry powders used in the methods disclosed herein may include homogenous respirable dry particles that comprise 1) itraconazole in crystalline particulate form, 2) a stabilizer, and optionally 3) one or more excipients.
- Such respirable dry particles can be prepared using any suitable method, such as by preparing a feedstock in which itraconazole in crystalline particulate form is suspended in an aqueous solution of excipients, and spray drying the feedstock.
- the respirable dry particles may comprise itraconazole in an amount of about 1% to about 95% by weight (wt%). It is preferred that the respirable dry particle comprises an amount of itraconazole so that a therapeutically effective dose can be administered and maintained without the need to inhale large volumes of dry powder, and also without the need to inhale the dry powder too frequently, e.g., more than three time a day. For example, it is preferred that the respirable dry particles comprise about 30% to about 70%, or about 40% to about 60%, e.g., about 45%, about 50%, or about 55% itraconazole by weight (wt%).
- the amount of itraconazole present in the respirable dry particles by weight may also be referred to as the “drug load.”
- the itraconazole may be present in the respirable dry particles in crystalline particulate form (e.g., nano-crystalline). More specifically, in the form of a sub-particle that is about 50 nm to about 5,000 nm (Dv50), preferably, with the itraconazole being at least 50% crystalline.
- the subparticle size can be about 100 nm, about 300 nm, about 1500 nm, about 80 nm to about 300 nm, about 80 nm to about 250 nm, about 80 nm to about 200 nm, about 100 nm to about 150 nm, about 1200 nm to about 1500 nm, about 1500 nm to about 1750 nm, about 1200 nm to about 1400 nm, or about 1200 nm to about 1350 nm (Dv50).
- the subparticle is between about 50 nm to about 2500 nm, between about 80 and 1750 nm, between about 50 nm and 1000 nm, between about 50 nm and 800 nm, between about 50 nm and 600 nm, between about 50 nm and 500 nm, between about 50 nm and 400 nm, between about 50 nm and 300 nm, between about 50 nm and 200 nm, or between about 100 nm and 300 nm.
- the degree of itraconazole crystallinity can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% crystalline.
- the itraconazole is about 100% crystalline.
- the dry powder administered comprises homogenous respirable dry particles that comprise itraconazole that is at least 50% crystalline, e g., 55% crystalline, 60% crystalline, 65% crystalline, 70% crystalline, 75% crystalline, 80% crystalline, 85% crystalline, 90% crystalline, 95% crystalline, 96% crystalline, 97% crystalline, 98% crystalline, 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than 99% crystalline, or more than
- the itraconazole in crystalline particulate form can be prepared in any desired subparticle size using a suitable method, including a stabilizer if desired, such as by wet milling, jet milling or other suitable method.
- the respirable dry particles also include a stabilizer.
- the stabilizer helps maintain the desired size of the itraconazole in crystalline particulate form during wet milling, in spray drying feedstock, and aids in wetting and dispersing and maintaining the physical stability of the itraconazole crystalline particulate suspension. It is preferred to use as little stabilizer as is needed to achieve the aforementioned benefits.
- the amount of stabilizer is typically in a fixed ratio to the amount of itraconazole present in the dry particle and can range from about 1 : 1 (itraconazole: stabilizer (wt:wt)) to about 50:1 (wt:wt), about 10:1 being preferred.
- the ratio of itraconazole: stabilizer (wt:wt) in the dry particles can be about 8: 1, about 9: 1, about 10: 1, about 11 :1, or about 12:1.
- the amount of stabilizer that is present in the dry particles can be in a range of about 1 wt% to about 15 wt%, such as about 3 wt% to about 7 wt%, or about 5 wt%. It is generally preferred that the respirable dry particles comprise less than about 10% stabilizer by weight (wt%), such as 9 wt% or less, 8 wt% or less, 7 wt% or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, or 1 wt% or less.
- a particularly preferred stabilizer for use in the dry powders described herein is polysorbate 80. In contrast to conventional dry powders which use surfactant to prevent the onset of crystallization in the dry powder, the surfactant in the presently disclosed dry powders is added to stabilize a colloidal suspension of the crystalline itraconazole in an anti-solvent.
- the dry powder administered comprises homogenous respirable dry particles that comprise itraconazole and polysorbate 80, wherein the ratio of itraconazole:polysorbate 80 (wt:wt) is about 10:1.
- the respirable dry particles also include a sodium salt (e.g., sodium sulfate or sodium chloride).
- the dry particles may comprise sodium sulfate.
- the respirable dry particles comprise about 15 wt% to about 50 wt% of a sodium salt (e g., sodium sulfate).
- the respirable dry particles can comprise between about 25 wt% and about 45 wt% sodium salt, e.g., about 30 wt%, 35 wt%, or 40 wt% sodium salt (e.g., sodium sulfate).
- the respirable dry particles also include any suitable and desired amount of one or more excipients.
- the one or more excipients are present in an amount of about 5% to about 20% by weight.
- Many excipients are well-known in the art and can be included in the dry powders and dry particles described herein.
- Pharmaceutically acceptable excipients that are particularly preferred for the dry powders and dry particles described herein include leucine.
- the respirable dry particles comprise an excipient (e.g., leucine), in an amount of about 1 wt% to about 20 wt %, e.g., between about 5 wt% and about 20 wt%, e.g., about 10 wt%.
- the respirable dry particles comprise leucine in an amount of about 10 wt%.
- the dry powders disclosed herein may dissolve in the lungs more slowly, compared to a formulation combining relatively low amounts of itraconazole (e.g., less than 40 wt%) with a hydrophilic excipient such as mannitol.
- the dissolution of dry powders used in the methods disclosed herein may be measured in terms of the dissolution half-life.
- the dry powders used in a method disclosed herein have a dissolution half-life that is at least about 2 minutes, e.g., between about 2 minutes and about 20 minutes, e.g., about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes.
- the dissolution half-life is about 4.1 minutes, about 4.2 minutes, about 4.3 minutes, or about 4.4 minutes.
- the dissolution half-life is between about 4.13 minutes and about 16.84 minutes.
- the dry powder comprises respirable dry particles comprising: (i) about 50 wt% itraconazole in crystalline particulate form, about 5 wt% of a stabilizer, about 35 wt% of a sodium salt, and about 10 wt% leucine.
- the dry powder may comprise respirable dry particles comprising: (i) 50 wt% itraconazole in crystalline particulate form, 5 wt% of a stabilizer (e.g., polysorbate 80), 35 wt% of a sodium salt (e.g., sodium sulfate), and 10 wt% leucine.
- the dry powder may consist essentially of respirable dry particles that consist essentially of: (i) 50 wt% itraconazole in crystalline particulate form, 5 wt% of a stabilizer (e.g., polysorbate 80), 35 wt% of a sodium salt (e.g., sodium sulfate), and 10 wt% leucine.
- a stabilizer e.g., polysorbate 80
- a sodium salt e.g., sodium sulfate
- dry powders disclosed herein may be free of lactose or other carrier particles.
- the dry powders and/or respirable dry particles are preferably small, mass dense, and dispersible.
- a laser diffraction system may be used, e.g., a Spraytec system (particle size analysis instrument, Malvern Instruments) and a HELOS/RODOS system (laser diffraction sensor with dry dispensing unit, Sympatec GmbH).
- the respirable dry particles have a VMGD as measured by laser diffraction at the dispersion pressure setting (also called regulator pressure) of 1.0 bar at a maximum orifice ring pressure using a HELOS/RODOS system of about 10 microns or less, about 5 microns or less, about 4 pm or less, about 3 pm or less, about 1 pm to about 5 pm, about 1 pm to about 4 pm, about 1.5 pm to about 3.5 pm, about 2 pm to about 5 pm, about 2 pm to about 4 pm, or about 2 pm to about 3 pm.
- the VMGD is about 5 microns or less, or about 4 pm or less.
- the dry powders and/or respirable dry particles have a minimum VMGD of about 0.5 microns or about 1.0 micron.
- the dry powders and/or respirable dry particles preferably have 1 bar/4 bar dispersibility ratio and/or 0.5 bar/4 bar dispersibility ratio of less than about 2.0 (e.g., about 0.9 to less than about 2), about 1.7 or less (e.g., about 0.9 to about 1.7) about 1.5 or less (e.g., about 0.9 to about 1.5), about 1.4 or less (e.g., about 0.9 to about 1.4), or about 1.3 or less (e.g., about 0.9 to about 1.3), and preferably have a 1 bar/4 bar and/or a 0.5 bar/4 bar of about 1.5 or less (e.g., about 1.0 to about 1.5), and/or about 1.4 or less (e.g., about 1.0 to about 1.4).
- the dry powders and/or respirable dry particles preferably have a tap density of at least about 0.2 g/cm 3 , of at least about 0.25 g/cm 3 , a tap density of at least about 0.3 g/cm 3 , of at least about 0.35 g/cm 3 , a tap density of at least 0.4 g/cm 3 .
- the dry powders and/or respirable dry particles have a tap density of greater than 0.4 g/cm 3 (e.g., greater than 0.4 g/cm 3 to about 1.2 g/cm 3 ), a tap density of at least about 0.45 g/cm 3 (e.g., about 0.45 g/cm 3 to about 1.2 g/cm 3 ), at least about 0.5 g/cm 3 (e.g., about 0.5 g/cm 3 to about 1.2 g/cm 3 ), at least about 0.55 g/cm 3 (e g., about 0.55 g/cm 3 to about 1.2 g/cm 3 ), at least about 0.6 g/cm 3 (e g., about 0.6 g/cm 3 to about 1 .2 g/cm 3 ) or at least about 0.6 g/cm 3 to about 1 .0 g/cm 3 .
- the dry powders and/or respirable dry particles preferably have a tap density of about 0.01 g/cm 3 to about 0.5 g/cm 3 , about 0.05 g/cm 3 to about 0.5 g/cm 3 , about 0.1 g/cm 3 to about 0.5 g/cm 3 , about 0.1 g/cm 3 to about 0.4 g/cm 3 , or about 0.1 g/cm 3 to about 0.4 g/cm 3 .
- the dry powders and/or respirable dry particles have a tap density of about 0.15 g/cm 3 to about 1.0 g/cm 3 .
- the dry powders and/or respirable dry particles have a tap density of about 0.2 g/cm 3 to about 0.8 g/cm 3 .
- the dry powders and/or respirable dry particles have a bulk density of at least about 0.1 g/cm 3 , or at least about 0.8 g/cm 3 .
- the dry powders and/or respirable dry particles have a bulk density of about 0.1 g/cm 3 to about 0.6 g/cm 3 , about 0.2 g/cm 3 to about 0.7 g/cm 3 , about 0.3 g/cm 3 to about 0.8 g/cm 3 .
- the respirable dry particles, and the dry powders when the dry powders are respirable dry powders preferably have an MMAD of less than 10 microns, preferably an MMAD of about 5 microns or less, or about 4 microns or less.
- the respirable dry powders and/or respirable dry particles preferably have a minimum MMAD of about 0.5 microns, or about 1.0 micron.
- the respirable dry powders and/or respirable dry particles preferably have a minimum MMAD of about 2.0 microns, about 3.0 microns, or about 4.0 microns.
- the dry powders and/or respirable dry particles preferably have a FPF of less than about 5.6 microns (FPF ⁇ 5.6 pm) of the total dose of at least about 35%, preferably at least about 45%, at least about 60%, between about 45% to about 80%, or between about 60% and about 80%.
- the dry powders and/or respirable dry particles preferably have a FPF of less than about 3.4 microns (FPF ⁇ 3.4 pm) of the total dose of at least about 20%, preferably at least about 25%, at least about 30%, at least about 40%, between about 25% and about 60%, or between about 40% and about 60%.
- FPF 3.4 microns
- the dry powders and/or respirable dry particles preferably have a total water and/or solvent content of up to about 15% by weight, up to about 10% by weight, up to about 5% by weight, up to about 1%, or between about 0.01% and about 1%, or may be substantially free of water or other solvent.
- the dry powders and/or respirable dry particles preferably may be administered with low inhalation energy.
- the energy required to perform the inhalation maneuver may be calculated.
- Healthy adult populations are predicted to be able to achieve inhalation energies ranging from 2.9 Joules for comfortable inhalations to 22 Joules for maximum inhalations by using values of peak inspiratory flow rate (PIFR) measured by Clarke et al. (Journal of Aerosol Med, 6(2), p.99-110, 1993) for the flow rate Q from two inhaler resistances of 0.02 and 0.055 kPa 1/2 /LPM, with an inhalation volume of 2L based on both FDA guidance documents for dry powder inhalers and on the work of Tiddens et al. (Journal of Aerosol Med, 19(4), p.456-465, 2006) who found adults averaging 2.2L inhaled volume through a variety of DPIs.
- PIFR peak inspiratory flow rate
- Healthy adults and children are capable of providing sufficient inhalation energy to disperse a dry powder of the present disclosure, e.g., from a suitable inhalation device (e.g., dry powder inhaler).
- a suitable inhalation device e.g., dry powder inhaler
- the dry powders and/or respirable dry particles useful in a method disclosed herein are preferably characterized by a high emitted dose, such as a CEPM of at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, from a passive dry powder inhaler subject to a total inhalation energy of about 5 Joules, about 3.5 Joules, about 2.4 Joules, about 2 Joules, about 1 Joule, about 0.8 Joules, about 0.5 Joules, or about 0.3 Joules is applied to the dry powder inhaler.
- a high emitted dose such as a CEPM of at least 75%, at least 80%, at least 85%, at least 90%, at least 95%
- a passive dry powder inhaler subject to a total inhalation energy of about 5 Joules, about 3.5 Joules, about 2.4 Joules, about 2 Joules, about 1 Joule, about 0.8 Joule
- the receptacle holding the dry powders and/or respirable dry particles may comprise about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, or about 30 mg.
- the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 30 LPM, run for 3 seconds using a size 3 capsule that comprises a total mass of 10 mg.
- the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 20 LPM, run for 3 seconds using a size 3 capsule that comprises a total mass of 10 mg.
- the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 15 LPM, run for 4 seconds using a size 3 capsule that comprises a total mass of 10 mg.
- the dry powder can fdl the unit dose container, or the unit dose container can be at least 2% full, at least 5% full, at least 10% full, at least 20% full, at least 30% full, at least 40% full, at least 50% full, at least 60% full, at least 70% full, at least 80% full, or at least 90% full.
- the unit dose container can be a capsule (e. , size 000, 00, 0E, 0, 1, 2, 3, and 4, with respective volumetric capacities of 1.37 mL, 950 pL, 770 pL, 680 pL, 480 pL, 360 pL, 270 pL, and 200 pL).
- the capsule can be at least about 2% full, at least about 5% full, at least about 10% full, at least about 20% full, at least about 30% full, at least about 40% full, or at least about 50% full.
- the unit dose container can be a blister.
- the blister can be packaged as a single blister or as part of a set of blisters, for example, 7 blisters, 14 blisters, 28 blisters or 30 blisters.
- the one or more blister can be preferably at least 30% full, at least 50% full or at least 70% full.
- dry powders disclosed herein are that they disperse well across a wide range of flow rates and are relatively flowrate independent.
- the dry powders and/or respirable dry particles permit the use of a simple, passive DPI for a wide patient population.
- the dry powders and/or respirable dry particles useful in a method described herein are preferably characterized by: 1) a VMGD at 1 bar as measured using a HELOS/RODOS system of about 10 microns or less, preferably about 5 microns or less; 2) a 1 bar/4 bar dispersibility ratio and/or a 0.5 bar/4 bar dispersibility ratio of about 1.5 or less, about 1.4 or less or about 1.3 or less; 3) a MMAD of about 10 microns or less, preferably about 5 microns or less; 4) a FPF ⁇ 5.6 pm of the total dose of at least about 45% or at least about 60%; and/or 5) a FPF ⁇ 3.4 pm of the total dose of at least about 25% or at least about 40%.
- the dry powders and/or respirable dry particles are further characterized by a tap density of about 0.2 g/cm 3 or greater, about 0.3 g/cm 3 or greater, about 0.4 g/cm 3 or greater, greater than 0.4 g/cm 3 , about 0.45 g/cm 3 or greater or about 0.5 g/cm 3 or greater.
- Formulation I is an exemplary dry powder that can be used in a method disclosed herein.
- the composition and properties of Formulation I are provided below in Table 1. [00106] Table 1. Composition and properties of Formulation I.
- Formulation I has a fine particle fraction (FPF) less than 5 microns of the total dose of 57%, leading to a fine particle dose less than 5 microns of 2.8 mg for a 10.0 mg total dry powder capsule fill.
- FPF fine particle fraction
- Formulation I has a dissolution half-life of 4.35 mins, as determined by the following protocol: powder formulations, capsules and packaging materials were equilibrated at 22.5 ⁇ 2.5 °C and 30 ⁇ 5% RH. Formulation I was encapsulated into a size 3 HPMC capsule under the same conditions. The fill weight for the powder preparation was 10 mg. The formulation were aerosolized from the capsule in a unit-dose, capsule-based DPI device (RS01, Plastiape, Osnago, Italy), at 60 L/min (4L inhaled volume) using the Plastiape RS01 dry powder inhaler (DPI). The aerosol dose was collected in the UniDose system.
- DPI Plastiape RS01 dry powder inhaler
- the UniDose collection system was used to uniformly deposit the whole impactor stage mass (i.e., below stage 2 of an NGI) onto a glass microfiber filter membrane, which can be seen as where the circles (representing particles or droplets) deposit.
- the filter was placed into a disk cassette and dissolution studies were undertaken using 500ml PBS pH 7.4 + 2.0% SDS in a USP Apparatus II POD (Paddle Over Disk, USP V) at 37 °C. Sink conditions were maintained within the vessel. Samples were taken at specified time points and tested for drug content on an Agilent (Santa Clara, CA, USA) 1260 Infinity series HPLC.
- the dry powders and/or respirable dry particles disclosed herein may be filled into a receptacle, for example a capsule or a blister.
- the capsule is, for example, a size 2 or a size 3 capsule, and is preferably a size 3 capsule.
- the capsule material may be, for example, gelatin or HPMC (hydroxypropyl methylcellulose), and is preferably HPMC.
- the dry powder and/or respirable dry particles described and characterized herein be contained in a dry powder inhaler (DPI).
- the DPI may be a capsule-based DPI or a blister-based DPI, and is preferably a capsule-based DPI.
- the dry powder inhaler is selected from the RS01TM family of dry powder inhalers (Plastiape S.p.A., Italy). More preferably, the dry powder inhaler is selected from the RS01TM HR or the RS01TM UHR2. Most preferably, the dry powder inhaler is the RS01TM HR.
- respirable dry particles and dry powders for use in a method disclosed herein can be prepared using any suitable method, with the proviso that the dry powders cannot be an extemporaneous dispersion.
- Many suitable methods for preparing dry powders and/or respirable dry particles are conventional in the art, and include single and double emulsion solvent evaporation, spray drying, spray-freeze drying, milling (e.g., jet milling), blending, solvent extraction, solvent evaporation, phase separation, simple and complex coacervation, interfacial polymerization, suitable methods that involve the use of supercritical carbon dioxide (CO2), sonocrystallization, nanoparticle aggregate formation and other suitable methods, including combinations thereof.
- CO2 supercritical carbon dioxide
- Respirable dry particles can be made using methods for making microspheres or microcapsules known in the art. These methods can be employed under conditions that result in the formation of respirable dry particles with desired aerodynamic properties (e.g., aerodynamic diameter and geometric diameter). If desired, respirable dry particles with desired properties, such as size and density, can be selected using suitable methods, such as sieving.
- respirable dry particles with desired properties include wet sieving, dry sieving, and aerodynamic classifiers (such as cyclones).
- the respirable dry particles are preferably spray dried. Suitable spray-drying techniques are described, for example, by K. Masters in “Spray Drying Handbook”, John Wiley & Sons, New York (1984). Generally, during spray-drying, heat from a hot gas such as heated air or nitrogen is used to evaporate a solvent from droplets formed by atomizing a continuous liquid feed. When hot air is used, the moisture in the air is at least partially removed before its use. When nitrogen is used, the nitrogen gas can be run “dry”, meaning that no additional water vapor is combined with the gas. If desired the moisture level of the nitrogen or air can be set before the beginning of spray dry run at a fixed value above “dry” nitrogen.
- a hot gas such as heated air or nitrogen
- the spray drying or other instruments used to prepare the dry particles can include an inline geometric particle sizer that determines a geometric diameter of the respirable dry particles as they are being produced, and/or an inline aerodynamic particle sizer that determines the aerodynamic diameter of the respirable dry particles as they are being produced.
- a suitable solvent e.g., aqueous solvent, organic solvent, aqueous-organic mixture or emulsion
- a nozzle or a rotary atomizer may be used to distribute the solution or suspension to the drying vessel.
- the nozzle can be a two-fluid nozzle, which can be in an internal mixing setup or an external mixing setup.
- a rotary atomizer having a 4- or 24-vaned wheel may be used.
- suitable spray dryers that can be outfitted with a rotary atomizer and/or a nozzle, include, a Mobile Minor Spray Dryer or the Model PSD-1, both manufactured by GEA Niro, Inc. (Denmark), Btichi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland), ProCepT Formatrix R&D spray dryer (ProCepT nv, Zelzate, Belgium), among several other spray dryer options.
- the inlet temperature to the spray dryer is about 90°C to about 300°C.
- the spray dryer outlet temperature will vary depending upon such factors as the feed temperature and the properties of the materials being dried. Generally, the outlet temperature is about 50°C to about 150°C.
- the respirable dry particles that are produced can be fractionated by volumetric size, for example, using a sieve, or fractioned by aerodynamic size, for example, using a cyclone, and/or further separated according to density using techniques known to those of skill in the art.
- an emulsion or suspension that contains the desired components of the dry powder i.e., a feedstock
- spray dried under suitable conditions.
- the dissolved or suspended solids concentration in the feedstock is at least about Ig/L, at least about 2 g/L, at least about 5 g/L, at least about 10 g/L, at least about 15 g/L, at least about 20 g/L, at least about 30 g/L, at least about 40 g/L, at least about 50 g/L, at least about 60 g/L, at least about 70 g/L, at least about 80 g/L, at least about 90 g/L or at least about 100 g/L.
- the feedstock can be provided by preparing a single solution, suspension or emulsion by dissolving, suspending, or emulsifying suitable components (e.g., salts, excipients, other active ingredients) in a suitable solvent.
- suitable components e.g., salts, excipients, other active ingredients
- the solution, emulsion or suspension can be prepared using any suitable methods, such as bulk mixing of dry and/or liquid components or static mixing of liquid components to form a combination.
- a hydrophilic component e.g., an aqueous solution
- a hydrophobic component e.g., an organic solution
- the combination can then be atomized to produce droplets, which are dried to form respirable dry particles.
- the atomizing step is performed immediately after the components are combined in the static mixer.
- the atomizing step is performed on a bulk mixed solution.
- the feedstock can be prepared using any solvent in which the itraconazole in particulate form has low solubility, such as an organic solvent, an aqueous solvent or mixtures thereof.
- Suitable organic solvents that can be employed include but are not limited to alcohols such as, for example, ethanol, methanol, propanol, isopropanol, butanols, and others.
- Other organic solvents include but are not limited to tetrahydrofuran (THF), perfluorocarbons, di chloromethane, chloroform, ether, ethyl acetate, methyl tert-butyl ether and others.
- Cosolvents that can be employed include an aqueous solvent and an organic solvent, such as, but not limited to, the organic solvents as described above.
- Aqueous solvents include water and buffered solutions.
- a preferred solvent is water.
- feedstocks can be used as feedstocks, which are known in the art.
- other suitable methods of mixing may be used.
- additional components that cause or facilitate the mixing can be included in the feedstock.
- carbon dioxide produces fizzing or effervescence and thus can serve to promote physical mixing of the solute and solvents.
- the feedstock or components of the feedstock can have any desired pH, viscosity or other properties.
- a pH buffer can be added to the solvent or co-solvent or to the formed mixture. Generally, the pH of the mixture ranges from about 3 to about 8.
- Dry powder and/or respirable dry particles can be fabricated and then separated, for example, by fdtration or centrifugation by means of a cyclone, to provide a particle sample with a preselected size distribution.
- a particle sample with a preselected size distribution.
- greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90% of the respirable dry particles in a sample can have a diameter within a selected range.
- the selected range within which a certain percentage of the respirable dry particles fall can be, for example, any of the size ranges described herein, such as between about 0.1 to about 3 microns VMGD.
- the suspension may be a nano-suspension, similar to an intermediate for making dry powder comprising nano-crystalline itraconazole.
- the dry powder may be itraconazole embedded in a matrix material, such as a matrix material comprising sodium sulfate and leucine.
- a matrix material such as a matrix material comprising sodium sulfate and leucine.
- the dry powder may be spray dried such that the dry particles are small, dense, and dispersible.
- the dry powders can consist solely of the respirable dry particles described herein without other carrier or excipient particles (referred to as “neat powders”). If desired the dry powders can comprise blends of the respirable dry particles described herein and other carrier or excipient particles, such as lactose carrier particles that are greater than 10 microns, 20 microns to 500 microns, and preferably between 25 microns and 250 microns. In some embodiments, dry powders comprising carrier particles (blended powders) are excluded.
- the dry powders do not comprise carrier particles.
- the itraconazole is embedded in a matrix comprising a sodium salt, leucine, and stabilizer.
- the dry powder may comprise respirable dry particles of uniform content, wherein each particle comprises the itraconazole.
- uniform content means that every respirable particle comprises some amount of itraconazole, with the stabilizer, sodium salt, and leucine.
- the dry powders can comprise respirable dry particles wherein at least 98%, at least 99%, or substantially all of the particles (by weight) comprise itraconazole.
- the dry powders are typically manufactured by first processing the itraconazole in crystalline form to adjust the particle size using any number of techniques that are familiar to those of skill in the art (e g., wet millingjet milling).
- crystalline itraconazole may be processed in an antisolvent with a stabilizer to form a suspension.
- Preferred stabilizers include polysorbates (also known as TWEEN®), such as polysorbate 80 (PS80).
- the stabilized suspension of crystalline itraconazole is then spray dried with the sodium salt and leucine.
- the resulting dry particles comprise crystalline itraconazole dispersed throughout an excipient matrix with each dry particle having a homogenous composition.
- a dry powder of the present invention is made by starting with crystalline itraconazole, which is usually obtainable in a micro-crystalline size range.
- the particle size of the micro-crystalline itraconazole is reduced into the nano-crystalline size using any of a number of techniques familiar to those of skill in the art, including but not limited to, high-pressure homogenization, high-shear homogenization, jet-milling, pin milling, microfluidization, or wet milling (also known as ball milling, pearl milling or bead milling).
- Wet milling is often preferred, as it is able to achieve a wide range of particle size distributions, including those in the nanometer ( ⁇ 1 pm) size domain.
- surfactants e.g., polysorbate 80, also known as TWEEN® 80.
- surfactants enable the creation of submicron particles during milling and the formation of physically stable suspensions, as they sequester the many high energy surfaces created during milling preventing aggregation and sedimentation.
- the presence of the surfactant is important to spray drying homogenous micro-particles as the surfactant allows for the formation of a uniform and stable suspension ensuring compositional homogeneity across particles.
- the use of surfactant allows for formation of micro-suspension or nano-suspensions.
- the nano-crystalline itraconazole particles are suspended in a stable colloidal suspension in the anti-solvent.
- the anti-solvent for the drug can utilize water, or a combination of water and other miscible solvents such as alcohols or ketones as the continuous anti-solvent phase for the colloidal suspension.
- a spray drying feedstock may be prepared by dissolving the soluble components in a desired solvent(s) followed by dispersing the surfactant-stabilized crystalline itraconazole nanosuspension in the resulting feedstock while mixing, although the process is not limited to this specific order of operations. [00127] Methods for analyzing the dry powders and/or respirable dry particles are found in the Exemplification section below. EXEMPLIFICATION
- Sodium sulfate, polysorbate 80, and L-leucine were obtained from Sigma-Aldrich Co. (St. Louis, MO), Spectrum Chemicals (Gardena, CA), Applichem (Maryland Heights, MO), Alfa Aesar (Tewksbury, MA), Thermo Fisher (Waltham, MA), Croda Chemicals (East Yorkshire, United Kingdom) or Merck (Darmstadt, Germany).
- Itraconazole was obtained from Neuland (Princeton, NJ).
- Ultrapure (Type II ASTM) water was from a water purification system (Millipore Corp., Billerica, MA), or equivalent.
- volume median diameter (x50 or Dv50), which may also be referred to as volume median geometric diameter (VMGD), of the dry powders was determined using a laser diffraction technique.
- the equipment consisted of a HELOS diffractometer and a RODOS dry powder disperser (Sympatec, Inc., Princeton, NJ).
- the RODOS disperser applies a shear force to a sample of particles, controlled by the regulator pressure (typically set at 1.0 bar with maximum orifice ring pressure) of the incoming compressed dry air.
- the pressure settings may be varied to vary the amount of energy used to disperse the powder.
- the dispersion energy may be modulated by changing the regulator pressure from 0.2 bar to 4.0 bar.
- Powder sample is dispensed from a microspatula into the RODOS funnel.
- the dispersed particles travel through a laser beam where the resulting diffracted light pattern produced is collected, typically using an R1 lens, by a series of detectors.
- the ensemble diffraction pattern is then translated into a volume-based particle size distribution using the Fraunhofer diffraction model, on the basis that smaller particles diffract light at larger angles.
- the span of the distribution was also determined per the formula ((Dv[90]-Dv[10)/(Dv[50]). The span value gives a relative indication of the poly dispersity of the particle size distribution.
- Aerodynamic Performance The aerodynamic properties of the powders dispersed from an inhaler device were assessed with a Next Generation Impactor (Copley Scientific Limited, Nottingham, UK) (NGI).
- NGI Next Generation Impactor
- the NGI instrument was run in controlled environmental conditions of 18 to 25°C and relative humidity (RH) between 25 and 35%.
- the instrument consists of seven stages that separate aerosol particles based on inertial impaction and can be operated at a variety of air flow rates. At each stage, the aerosol stream passes through a set of nozzles and impinges on a corresponding impaction surface. Particles having small enough inertia will continue with the aerosol stream to the next stage, while the remaining particles will impact upon the surface.
- the aerosol passes through nozzles at a higher velocity and aerodynamically smaller particles are collected on the plate.
- a micro-orifice collector collects the smallest particles that remain. Gravimetric and/or chemical analyses can then be performed to determine the particle size distribution.
- the capsules HPMC, Size 3; Capsugel Vcaps, Peapack, NJ
- DPI breath-activated dry powder inhaler
- the capsule was punctured and the powder was drawn through the cascade impactor operated at a specified flow rate for 2.0 Liters of inhaled air. At the specified flow rate, the cut-off diameters for the stages were calculated. The fractions were collected by placing wetted filters in the apparatus and determining the amount of powder that impinged on them by chemical measurements on an HPLC.
- Fine Particle Dose indicates the mass of itraconazole in a specific size range and can be used to predict the mass which will reach a certain region in the respiratory tract.
- the fine particle dose can be measured gravimetrically or chemically via either an ACI or NGI. If measured gravimetrically, since the dry particles are assumed to be homogenous, the mass of the powder on each stage and collection filter can be multiplied by the fraction of itraconazole in the formulation to determine the mass of itraconazole. If measured chemically, the powder from each stage or filter is collected, separated, and assayed for example on an HPLC to determine the content of the itraconazole.
- the cumulative mass deposited on each of the stages at the specified flow rate is calculated and the cumulative mass corresponding to a 5.0 micrometer diameter particle is interpolated.
- This cumulative mass for a single dose of powder, contained in one or more capsules, actuated into the impactor is equal to the fine particle dose less than 5.0 microns (FPD ⁇ 5.0 microns).
- Mass Median Aerodynamic Diameter MMAD was determined using the information obtained by the Next Generation Impactor (NGI). The cumulative mass under the stage cut-off diameter is calculated for each stage and normalized by the recovered dose of powder The MMAD of the powder is then calculated by linear interpolation of the stage cut-off diameters that bracket the 50th percentile.
- NGI Next Generation Impactor
- ACI Andersen Cascade Impactor
- the MMAD is calculated with the cumulative mass under the stage cut-off diameter is calculated for each stage and normalized by the recovered dose of powder.
- the MMAD of the powder is then calculated by linear interpolation of the stage cut-off diameters that bracket the 50th percentile.
- Emitted Geometric or Volume Diameter The volume median diameter (Dv50) of the powder after it is emitted from a dry powder inhaler, which may also be referred to as volume median geometric diameter (VMGD), was determined using a laser diffraction technique via the Spraytec diffractometer (Malvern, Inc.). Powder was fdled into size 3 capsules (V-Caps, Capsugel) and placed in a capsule based dry powder inhaler (RS01TM Model 7 High resistance, Plastiape, Italy), or DPI, and the DPI sealed inside a cylinder. The cylinder was connected to a positive pressure air source with steady air flow through the system measured with a mass flow meter and its duration controlled with a timer controlled solenoid valve.
- VMGD volume median geometric diameter
- the exit of the dry powder inhaler was exposed to room pressure and the resulting aerosol jet passed through the laser of the diffraction particle sizer (Spraytec) in its open bench configuration before being captured by a vacuum extractor.
- the steady air flow rate through the system was initiated using the solenoid valve.
- a steady air flow rate was drawn through the DPI typically at 60 L/min for a set duration, typically of 2 seconds.
- the air flow rate drawn through the DPI was sometimes run at 15 L/min, 20 L/min, or 30 L/min.
- the resulting geometric particle size distribution of the aerosol was calculated from the software based on the measured scatter pattern on the photodetectors with samples typically taken at 1000Hz for the duration of the inhalation.
- the Emitted Dose refers to the mass of itraconazole which exits a suitable inhaler device after a firing or dispersion event.
- the ED is determined using a method based on USP Section 601 Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, Delivered-Dose Uniformity, Sampling the Delivered Dose from Dry Powder Inhalers, United States Pharmacopeia convention, Rockville, MD, 13th Revision, 222-225, 2007.
- Contents of capsules are dispersed using either the RS01 HR inhaler at a pressure drop of 4kPa and a typical flow rate of 60 LPM or the UHR2 RS01 at a pressure drop of 4kPa and a typical flow rate of 39 LPM.
- the emitted powder is collected on a filter in a filter holder sampling apparatus.
- the sampling apparatus is rinsed with a suitable solvent such as water and analyzed using an HPLC method.
- a shorter length fdter holder sampling apparatus is used to reduce deposition in the apparatus and the filter is weighed before and after to determine the mass of powder delivered from the DPI to the filter.
- the emitted dose of therapeutic is then calculated based on the content of therapeutic in the delivered powder. Emitted dose can be reported as the mass of therapeutic delivered from the DPI or as a percentage of the filled dose.
- Thermogravimetric analysis was performed using either the Q500 model or the Discovery model thermogravimetric analyzer (TA Instruments, New Castle, DE). The samples were either placed into an open aluminum DSC pan or a sealed aluminum DSC pan that was then automatically punched open prior to the time of test. Tare weights were previously recorded by the instrument. The following method was employed: Ramp 5.00 °C/min from ambient ( ⁇ 35 °C ) to 200 °C. The weight loss was reported as a function of temperature up to 140°C. TGA allows for the calculation of the content of volatile compounds within the dry powder. When utilizing processes with water alone, or water in conjunction with volatile solvents, the weight loss via TGA is a good estimate of water content.
- X-Ray Powder Diffraction The crystalline character of the formulations was assessed via powder X-ray diffraction (PXRD). A 20-30 mg sample of material is analyzed in a powder X-ray diffractometer (D8 Discover with LINXEYE detector; Bruker Corporation, Billerica, MA or equivalent) using a Cu X-ray tube with 1.5418A at a data accumulation time 1.2 second/step over a scan range of 5 to 45°20 and a step size of 0.02°20.
- PXRD powder X-ray diffraction
- HPLC high performance liquid chromatography
- a high performance liquid chromatography (HPLC) method utilizing a reverse phase Cl 8 column coupled to an ultraviolet (UV) detector has been developed for the identification, bulk content, assay, CUPMD and impurities analysis of itraconazole dry powders.
- the reverse phase column is equilibrated to 30°C and the autosampler is set to 5°C.
- the mobile phases, 20 mM sodium phosphate monobasic at a pH of 2.0 (mobile phase A) and acetonitrile (mobile phase B) are used in a gradient elution from a ratio of 59:41 (A:B) to 5:95 (A:B), over the course of a 19.5 minute run time.
- Detection is by UV at 258 nm and the injection volume is 10 pL. Itraconazole content in powders are quantified relative to a standard curve.
- Identification of known impurities A, B, C, D, E, F and G (shown in monograph Ph. Eur. 01/2011 : 1335) is confirmed by comparing the retention time of the impurity peaks in the itraconazole dry powder samples to that of the itraconazole USP impurity mix reference standard spiked with impurity A.
- Unknown impurities are identified and quantified by relative retention time to that of the itraconazole main peak and with area above the limit of detection (LOD). All impurities are measured by area percent, with respect to the itraconazole peak.
- Particle Size Reduction The particle size distribution of the crystalline itraconazole can be modulated using a number of techniques familiar to those of skill in the art, including but not limited to, high-pressure homogenization, high-shear homogenizationjetmilling, pin milling, microfluidization, or wet milling (also known as ball milling, pearl milling or bead milling). Wet milling is often preferred, as it is able to achieve a wide range of particle size distributions, including those in the nanometer ( ⁇ 1 pm) size domain.
- Particle Size Reduction using Low Energy Wet Milling One technique for reducing the particle size of the itraconazole was via low energy wet milling (also known as roller milling, or jar milling). Suspensions of the itraconazole were prepared in an anti-solvent, which can be water, or any solvent in which the active agent is not appreciably soluble.
- Stabilizers which can be, but are not limited to, non-ionic surfactants or amphiphilic polymers, are then added to the suspension along with milling media, which can be, but are not limited to, spherical with high wear resistance and in the size range from 0.03 to 0.70 millimeters in diameter.
- the vessels containing the suspensions are then rotated using aj r mill (US Stoneware, East furniture, OH USA) while taking samples periodically to assess particle size (LA-950, HORIBA, Kyoto, Japan).
- the suspension is strained through a sieve to remove the milling media, and the product recovered.
- Particle Size Reduction using High Energy Wet Milling Another technique for reducing the particle size of the itraconazole was via high-energy wet milling using a rotorstator, or agitated media mill. Suspensions of the itraconazole were prepared in an anti-solvent, which can be water, or any solvent in which the active agent is not appreciably soluble. Stabilizers, which can be, but are not limited to, non-ionic surfactants or amphiphilic polymers, are then added to the suspension along with milling media, which can be, but are not limited to, spherical with high wear resistance and in the size range from 0.03 to 0.70 millimeters in diameter.
- an anti-solvent can be water, or any solvent in which the active agent is not appreciably soluble.
- Stabilizers which can be, but are not limited to, non-ionic surfactants or amphiphilic polymers, are then added to the suspension along with milling media, which can be, but are not limited to,
- the suspensions are then charged into the mill, which can be operated in either batch or recirculation mode.
- the process consists of the suspension and milling media being agitated within the milling chamber, which increases the energy input to the system and accelerates the particle size reduction process.
- the milling chamber and recirculation vessel are jacketed and actively cooled to avoid temperature increases in the product.
- the agitation rate and recirculation rate of the suspension are controlled during the process. Samples are taken periodically to assess particle size (LA-950, HORIBA, Kyoto, Japan). When the particle size is sufficiently reduced, or when a particle size minimum is reached, the suspension is discharged from the mill.
- Spray Drying Dry powders were prepared by spray drying on a Buchi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland) with powder collection from either a standard or High Performance cyclone. The system was run with nitrogen as the drying and atomization gas in open-loop (single pass) mode. When run using air, the system used the Buchi B-296 dehumidifier to ensure stable temperature and humidity of the air used to spray dry. Furthermore, when the relative humidity in the room exceeded 30% RH, an external LG dehumidifier (model 49007903, LG Electronics, Englewood Cliffs, NJ) was run constantly. When run using nitrogen, a pressurized source of nitrogen was used.
- the aspirator of the system was adjusted to maintain the system pressure at -2.0” water column.
- Atomization of the liquid feed utilized a Buchi nozzle with 1.5mm cap and 0.7 liquid tip.
- the liquid feedstock solids concentration was 3%
- the process gas inlet temperature was 127 °C to 140 °C
- the process gas outlet temperature was 60°C
- the drying gas flowrate was 17.0 kg/hr
- the atomization gas flowrate was 30.0 g/min
- the liquid feedstock flowrate was 6.0mL/min.
- Stability Assessment The physicochemical stability and aerosol performance of select formulations were assessed at 2-8 °C, 25°C/60% RH, and when material quantities permitted, 40°C/75% RH as detailed in the International Conference on Harmonisation (ICH) QI guidance. Stability samples were stored in calibrated chambers (Darwin Chambers Company Models PH024 and PH074, St. Louis. MO). Bulk powder samples were weighed into amber glass vials, sealed under 30% RH, and induction-sealed in aluminum pouches (Drishield 3000, 3M, St. Paul, MN) with silica desiccant (2.0g, Multisorb Technologies, Buffalo, NY ).
- the target mass of powder was weighed by hand into a size 3, HPMC capsule (Capsugel Vcaps, Peapack, NJ) with a +/- 0.2 mg tolerance at 30% RH. Filled capsules were then aliquoted into high-density polyethylene (HDPE) bottles and induction sealed in aluminum pouches with silica desiccant.
- HPMC capsule Capsugel Vcaps, Peapack, NJ
- the nanocrystalline itraconazole for Formulation I was prepared by compounding 30.090 g of itraconazole (Neuland ITI0114005 and ITI0714011) in 87 g of water and 3 g of polysorbate 80. Polystyrene milling media (130 g of 500 pm; Dow Chemical, Midland MI) was then added to the suspension, and the suspension was milled at 1800 rpm for one hour before being collected. The final median particle size (Dv(50)) of the milled suspension was 132 nm. [00146] A feedstock solution was then prepared and used to manufacture the dry powder. A drug load of 50 wt% itraconazole, on a dry basis, was targeted.
- the feedstock solution that was used to spray dry particles were made as follows.
- the required quantity of water (1.18 kg) was weighed into a suitably sized glass vessel.
- Sodium sulfate (12.8 g) and leucine (3.7 g) were added to the water and the solution allowed to stir until visually clear.
- the itraconazole- containing suspension (containing 18.3 grams itraconazole and 1.83 grams polysorbate 80) was then added to the excipient solution and stirred until visually homogenous.
- the feedstock was then spray-dried. Feedstocks were stirred while spray dried. Feedstock mass was approximately 1.22 kg.
- Dry powders Formulation I was manufactured from the feedstock by spray drying on the Buchi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland) with cyclone powder collection, following the protocol described above.
- Formulation I has the following dry powder composition (w/w) on a dry basis: 50% itraconazole, 35% sodium sulfate, 10% leucine, and 5% polysorbate 80.
- the bulk particle size characteristics for Formulation I is provided below in Table 2.
- the span at 1 bar of less than 2.10 indicates a relatively narrow size distribution.
- the 1 bar/4 bar dispersibility ratio less than 1.25 indicates the powder is relatively independent of dispersion energy, a desirable characteristic which allows similar particle dispersion across a range of dispersion energies.
- Table 2 Bulk particle size characteristics of Formulation T
- the aerodynamic particle size, fine particle fractions and fine particle doses were also measured and/or calculated with a Next Generation Impactor (NGI).
- NTI Next Generation Impactor
- Formulation I had a MMAD of 4.22 pm, and an FPD ⁇ 5 pm of 38.3% of nominal dose. In other words, more than 30% of the nominal dose reaches the impactor stages and so would be predicted to be delivered to the lungs.
- the MMAD of 4.22 is also indicative of deposition in the central and conducting airways.
- a physiological-based pharmacokinetics (PBPK) model originally developed to simulate the concentration-time profiles of itraconazole and OH-itraconazole after administration of itraconazole as an oral solution (Simcyp Simulator, VI 9) was modified to simulate administration by oral inhalation.
- the data could be used to determine the DDI potential of a maximum 40 mg dose of orally inhaled itraconazole, by applying basic static model, a mechanistic static model, and a physiologically based pharmacokinetic (PBPK) model of itraconazole and OH-itraconazole, the primary metabolite of itraconazole, to evaluate the potential risk of itraconazole dry powders as “perpetrators” of CYP3A4 DDIs, using midazolam as a “victim” drug and Formulation I as an exemplary itraconazole based dry powder.
- PBPK physiologically based pharmacokinetic
- AUCR plasma concentration-time curve ratio
- PBPK Modelling - Model Optimization' To simulate the plasma concentrationtime profiles of itraconazole and OH-itraconazole after the inhaled administration of 35 mg Formulation T (QD for 14 days), the Simcyp VI 9 itraconazole oral solution PBPK model was adapted to include absorption of itraconazole through the lung as well as the gut. The model assumes first-order absorption from the lungs to the systemic circulation. The structural model is shown in FIG. 1. The trial design used for the optimization of first-order inhalation parameters was based on the study described in Hava et al. (supra) in which subjects received Formulation I at 35 mg QD for 14 days. That study measured itraconazole and OH-itraconazole data as summarized in Table 4.
- the pro- portion of dose inhaled and Fa,l was optimized to match the itraconazole AUC0-24h on study day 14. Then, ka,l was optimized to capture Cmax. Once the simulated multiple dose and Cmax were within 0.8 to 1.25 of the observed values, the absorption parameters were further optimized to best predict the OH- itraconazole concentration-time profiles. Intestinal absorption, distribution, and elimination parameters of itraconazole and OH-itraconazole were unchanged from the verified itraconazole and OH-itraconazole models, assuming itraconazole follows linear kinetics even at low doses. This model assumes no metabolism of itraconazole to OH-itraconazole in the lung. [00165] The first-order inhalation parameters were manually optimized by comparing the simulated profiles of Formulation I to observed data. The first-order inhalation parameters used to simulate the plasma concentration profile of Formulation I are shown in Table 5.
- PBPK Modelling - Model Application' The CYP3A4 inhibition potential of Formulation I was predicted using a representative virtual healthy population consisting of ten virtual trials of ten healthy subjects (50% female), aged 20 to 50 years.
- the victim drug (midazolam) was administered as a single dose of 5 mg without administration of Formulation I, then again on day 14 of daily administration of Formulation I 35 mg.
- the virtual DDI trials were repeated with the same virtual trial design and study population, with 40 mg of Formulation I administered daily for 14 days.
- R1 was calculated for Formulation I using the observed maximum concentration of itraconazole and OH- itraconazole following multiple inhaled doses of Formulation I (35 mg QD) for 14 days.
- R1 was calculated to be 1.35. Because this value exceeded the cutoff value of 1.02 specified by the FDA guidance document (supra), further investigation of DDI liability was required. Additionally, Rl,gut was calculated to be greater than the threshold value of 11, indicating that additional assessment of DDI liability was required. Based on these results, a mechanistic static model was applied to further investigate the CYP3A4 inhibition potential of Formulation I.
- AUCR of midazolam was calculated for Formulation I using the observed maximum concentration of itraconazole and OH-itraconazole following multiple simulated inhaled doses of Formulation I (35 mg QD) for 14 days. To calculate the worst-case scenario, it was assumed that all itraconazole absorption occurred through the gut. The AUCR of midazolam was calculated to be 5.36, further indicating a risk of Formulation I as a perpetrator of CYP3A4 DDIs. Based on these results, a PBPK model was developed to further understand the CYP3A4 inhibition potential of Formulation I.
- Formulation I (35 mg or 40 mg QD for 14 days) in healthy subjects.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole. The present disclosure also relates to methods of co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
Description
METHODS OF USING ITRACONAZOLE DRY POWDERS
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63/402,577, filed on August 31, 2022, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] Itraconazole is a triazole antifungal with a broad spectrum of activity, which is typically administered orally. Itraconazole is the active ingredient in the FDA-approved oral antifungal drug SPORANOX®. However, the clinical use of oral itraconazole is limited by unpredictable and variable pharmacokinetics, poor tolerability, adverse effects, and concerns related to its high drug-drug interaction (DDI) potential.
[0003] The DDT potential of itraconazole is related to its activity as a potent inhibitor of the cytochrome P450 3 A4 (CYP3 A4) isoenzyme. The impact of itraconazole on the CPY3 A4 pathway alters the metabolism and consequently the plasma concentrations of other drugs metabolized by this pathway. Consequently, co-administration of a long list of drugs and drug classes with itraconazole is currently contraindicated due to the potential for DDIs. For example, the package insert for SPORANOX® lists over 40 contraindicated drugs and another 256 drugs for which special precautions should be taken. (See Bergagnini-Kolev, et al. The AAPS Journal (2023) 25:62; incorporated herein by reference in its entirety).
[0004] The potential DDIs of oral itraconazole greatly limit its use, particularly in patient populations that would benefit from itraconazole treatment. For example, itraconazole has shown benefits in treating allergic bronchopulmonary aspergillosis which has a prevalence of up to 15% in people with cystic fibrosis and an estimated 1.5% of patients in the general population with asthma. (See Bergagnani-Kolev, supra). However, numerous drugs used in the treatment of exacerbations of asthma or maintenance therapies for cystic fibrosis cannot be used safely with oral itraconazole (See Bergagnani-Kolev, supra).
[0005] As such, there is an unmet need for formulations and methods to treat patients with itraconazole and avoid drug-drug interactions (DDI), particularly in patients taking other medications which are substrates for CYP3A4.
SUMMARY OF THE INVENTION
[0006] The present disclosure relates to respirable dry powders and methods for administering itraconazole to subjects for whom oral itraconazole is contraindicated, and for co-administering itraconazole with a second therapeutic agent that is contraindicated with use of oral itraconazole. In particular, the compositions and methods disclosed herein can be used to safely achieve therapeutic concentrations of itraconazole in the lungs of a patient population that is otherwise not treatable with itraconazole, such as subjects already taking a CYP3A4 substrate. For example, cystic fibrosis (CF) patients are commonly treated with medications including elexacaftor, ivacaftor, and tezacaftor, which are extensively metabolized by CYP3A4 and therefore oral itraconazole cannot be administered to those patients. This is problematic, because cystic fibrosis patients are highly susceptible to lung infections and may greatly benefit from being treated with itraconazole. The methods disclosed herein address this problem, as they may be used concomitantly with CYP3A4 substrates. In particular, the compositions and methods disclosed herein may be useful in treating allergic bronchopulmonary aspergillosis (ABPA) in subjects with cystic fibrosis (CF) or asthma, for whom oral itraconazole is contraindicated.
[0007] In some aspects, the present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole. The subject can be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
[0008] In some aspects, the present disclosure relates to a method of co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
[0009] The second therapeutic agent can be a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. The second therapeutic agent may be one that is contraindicated with oral itraconazole (e.g., SPORANOX®).
[0010] In some embodiments, the second therapeutic agent is an alpha blocker, a beta blocker, an analgesic, an antiarrhythmic, an antibacterial, an anticoagulant, an antiplatelet drug, an anticonvulsant, an antidiabetic drug, an anthelminthic, an antifungal, an antiprotozoal, an
antimigraine drug, an antineoplastic, an antipsychotic, an anxiolytic, a hypnotic, an antiviral, a calcium channel blocker, a cardiovascular drug, a contraceptive, a diuretic, an anticonvulsant, an immunosuppressant, a lipid-lowering drug, a respiratory drug (e.g., an asthma treatment), an antidepressant drug (e g., a tricyclic or a selective serotonin reuptake inhibitor (SSRI)), a urologic drug, a vasopressin receptor antagonist, a nonsteroidal anti-inflammatory drug (NSAID), or a gastrointestinal drug.
[0011] In some embodiments, the second therapeutic agent is alfuzosin, silodosin, tamsulosin, methadone, fentanyl, alfentanil, buprenorphine, oxycodone, sufentanil, disopyramide, dofetilide, dronedarone, quinidine, digoxin, bedaquiline, rifabutin, clarithromycin, trimetrexate, ticagrelor, apixaban, rivaroxaban, vorapaxar, cilostazol, dabigatran, warfarin, carbamazepine, repaglinidea, saxagliptin, isavuconazonium, praziquantel, artemether-lumefantrine, quinine, an ergot alkaloid (e g., dihydroergotamine, ergometrine, ergonovine, methylergometrine, methylergonovine, ergotamine), eletriptan, irinotecan, axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetiniba, crizotinib, dabrafenib, dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olapariba, pazopanib, regorafenib, sunitinib, trabectedin, trastuzumab-emtansine, vinca alkaloids, bortezomib, brentuximab-vedotin, busulfan, erlotinib, gefitinib, idelalisib, nintedanib, panobinostat, ponatinib, ruxolitinib, sonidegib, vandetanib, imatinib, ixabepilone, alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam, quetiapine, ramelteon, risperidone, suvorexant, zopiclone, lurasidone, pimozide, triazolam, levacetylmethadol (levomethadyl), simeprevir, daclatasvir, indinavir, maraviroc, cobicistat, elvitegravir, ritonavir, saquinavir, tenofovir disoproxil fumarate, nadolol, felodipine, nisoldipine, diltiazem, dihydropyridines, verapamil, ivabradine, ranolazine, aliskiren, riociguat, sildenafd, tadalafd, bosentan, guanfacine, dienogest, ulipristal, eplerenone, cisapride, naloxegol, aprepitant, loperamide, netupitant, everolimus, sirolimus, temsirolimus, budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus, lomitapide, lovastatin, simvastatin, atorvastatin, salmeterol, venlafaxine, avanafd, fesoterodine, solifenacin, darifenacin, vardenafd, dutasteride, oxybutynin, tolterodine, colchicine, eliglustat, lumacaftor, ivacaftor, elexacaftor, tezacaftor, SYMDEKO®, ORKAMBI®, KALYDECO®, alitretinoin, cabergoline, cannabinoids, cinacalcet, conivaptan, volvaptan, Saccharomyces boulardii, meloxicam, ciprofloxacin, erythromycin, clarithromycin, idelalisib, darunavir, fosamprenavir, isoniazid, rifampicin, rifabutin, phenobarbital, phenytoin, efavirenz, nevirapine, or drugs that reduce gastric acidity (e.g., acid
neutralizing medicines such as aluminum hydroxide, acid secretion suppressors such as H2- receptor antagonists and proton pump inhibitors), or halofantrine.
[0012] In some embodiments, the second therapeutic agent is methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, an ergot alkaloid (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafd, ticagrelor, colchicine, fesoterodine, solifenacin, or eliglustat.
[0013] In a method disclosed herein, the respirable dry powder comprising itraconazole is administered to the respiratory tract of the subject at a nominal dose of between about 1 mg and about 60 mg, between about 5 mg and about 40 mg, between about 1 mg and about 10 mg, between about 10 mg and about 20 mg, between about 20 mg and about 30 mg, or between about 30 mg and about 40 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg.
[0014] The respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject no more than about 14 days before or after administering the second therapeutic agent, less than about 14 days, less than about 12 days, less than about 10 days, less than about 8 days, less than about 7 days, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, less than about 2 days, or less than about 1 day before or after administering the second therapeutic agent. The respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject on the same day as administering the second therapeutic agent, less than about 20 hours, less than about 18 hours, less than about 16 hours, less than about 14 hours, less than about 12 hours, less than about 11 hours, less than about 10 hours, less than about 9 hours, less than about 8 hours, less than about 7 hours, less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, less than about 45 minutes, less than about 30 minutes, less than about 20 minutes, less than about 10 minutes, or less than about 5 minutes, before or after administering the second therapeutic agent. The respirable dry powder comprising itraconazole may be administered to the respiratory tract of the subject less than about 5 minutes before or after administering the second therapeutic agent.
[0015] Tn some embodiments, the respirable dry powder comprises homogenous respirable dry particles that comprise crystalline itraconazole, a stabilizer, a sodium salt, and an excipient. The sodium salt may be sodium sulfate. The stabilizer may be polysorbate 80. The excipient may be leucine.
[0016] The itraconazole can be in a crystalline sub-particle form, where the sub-particle has a size of about 50 nm to about 5,000 nm (Dv50), about 50 nm to about 800 nm (Dv50), about 50 nm to about 300 nm (Dv50), about 50 nm to about 200 nm (Dv50), or about 100 nm to about 300 nm (Dv50). The itraconazole may be present in the respirable dry particles in an amount of about 30% to about 70% by weight, about 40% to about 60% by weight, about 45%, about 50%, or about 55% by weight. In some embodiments, the itraconazole is at least 50% crystalline.
[0017] The ratio of itraconazole stabilizer (wt:wt) in the respirable dry particles can be about 10: 1.
[0018] In some embodiments, the stabilizer (e.g., polysorbate 80) is present in the respirable dry particles in an amount of about 3% to about 7% by weight. In some embodiments, the stabilizer (e.g., polysorbate 80) is present in the respirable dry particles in an amount of about 5% by weight.
[0019] In some embodiments, the excipient (e.g., leucine) is present in the respirable dry particles in an amount of about 5% to about 20% by weight. In some embodiments, the excipient (e.g., leucine) is present in the respirable dry particles in an amount of about 10% by weight.
[0020] In some embodiments, the stabilizer is polysorbate 80. In some embodiments, the excipient is leucine.
[0021] In some embodiments, the respirable dry powder comprises homogenous respirable dry particles that comprise about 50 wt% crystalline itraconazole, about 35 wt% sodium sulfate, about 10 wt% leucine, and about 5 wt% polysorbate 80.
[0022] The respirable dry particles may have: (i) a volume median geometric diameter (VMGD) of about 10 microns or less, or about 5 microns or less; (ii) a tap density of about 0.2 g/cc or greater, or a tap density of between 0.2 g/cc and 1.0 g/cc; (iii) a 1 bar/4 bar dispersibility ratio (1/4 bar) of less than about 1.5, as measured by laser diffraction; and/or (iv) a 0.5 bar/4 bar dispersibility ratio (0.5/4 bar) of about 1.5 or less, as measured by laser diffraction.
[0023] The respirable dry powder may have: (i) a mass median aerodynamic diameter (MMAD) of between about 1 micron and about 5 microns; and/or (ii) a fine particle fraction (FPF) of the total dose less than 5 microns of about 25% or more.
[0024] In some embodiments, the respirable dry particles have a capsule emitted powder mass of at least 80% when emitted from a passive dry powder inhaler that has a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions; an inhalation flow rate of 30 LPM for a period of 3 seconds using a size 3 capsule that contains a total mass of 10 mg, said total mass consisting of the respirable dry particles, and wherein the volume median geometric diameter of the respirable dry particles emitted from the inhaler as measured by laser diffraction is 5 microns or less.
[0025] In a method disclosed herein, the respirable dry powder can be delivered to the respiratory tract of the subject with a capsule-based passive dry powder inhaler.
[0026] In a method disclosed herein, the subject may have an infection, allergic bronchopulmonary aspergillosis, a respiratory disease, an acute exacerbation of a respiratory disease, an immunodeficiency disorder, cancer, a cardiovascular disorder, hypertension, hypercholesterolemia, an autoimmune disorder, diabetes, a gastrointestinal disorder, a thrombotic disorder, epilepsy, a psychiatric disorder, migraine, or pain. For example, the subject can have a fungal infection, such as aspergillosis. The subject may have cystic fibrosis, asthma, or pneumonia (e.g., fungal pneumonia). The subject may have HIV or AIDS). The subject may have a form of cancer such as lung cancer (e.g., non-small cell lung cancer). The subject may have congestive heart failure, cardiac dysrhythmias, or cardiac disease. The subject may have bipolar disorder, depression, psychosis, or anxiety. The subject may have acute pain or chronic pain. The subject may have surgical pain (e.g., perioperative pain or postoperative pain).
[0027] In some aspects, the present disclosure relates to a respirable dry powder disclosed herein for use in a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject. For example, the subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
[0028] In some aspects, the present disclosure relates to a respirable dry powder disclosed herein for use in a method of co-administering itraconazole and a second therapeutic agent to a subject
in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
[0029] In some aspects, the present disclosure relates to use of a respirable dry powder disclosed herein in the manufacture of a medicament for treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject. The subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
[0030] In some aspects, the present disclosure relates to use a respirable dry powder disclosed herein in the manufacture of a medicament for co-administering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
BRIEF DESCRIPTION OF THE DRAWINGS
[0031] FIG. 1 is a diagram depicting a structural model of first-order absorption from the lungs to the systemic circulation.
[0032] FIGS. 2A and 2B are log-linear plots depicting simulated and observed plasmaconcentration time profiles of itraconazole (FIG. 2A) and OH-itraconazole (FIG. 2B) after multiple doses of an exemplary itraconazole dry powder (Formulation I; 35 mg QD for 14 days) in healthy subjects. Depicted are simulated (lines) and observed data (circles; mean of n = 6 individuals). The gray lines represent the 5th and 95th percentiles and the solid black line the mean data for the simulated population (n = 60).
[0033] FIGS. 3A and 3B are log-linear plots depicting simulated mean plasma concentrationtime profiles of itraconazole (FIG. 3A) and OH-itraconazole (FIG. 3B) after multiple oral dose of an exemplary itraconazole dry powder (Formulation I; 40 mg QD for 14 days) in healthy subjects. Depicted are simulated (lines). The gray lines represent the 5th and 95th percentiles, and the solid black line the mean data for the simulated population (n = 100).
[0034] FTGS. 4A and 4B are log-linear plots depicting simulated plasma concentration-time profdes of a single 5 mg dose of midazolam, co-administered with steady state Formulation I at 35 mg (FIG. 4A) and at 40 mg (FIG. 4B) healthy subjects. Depicted are simulated midazolam plasma concentration-time profdes in the absence of Formulation I (solid line) and on the 14th day of 14 days of dosing of Formulation I (dashed line). The lines represent the mean data for the simulated population (n = 100).
DETAILED DESCRIPTION OF THE INVENTION
[0035] The present disclosure relates to methods for administering itraconazole to the respiratory tract of a subject for whom oral itraconazole is contraindicated, e.g., due to the subject being treated with a second therapeutic agent that is not usually combined with oral itraconazole due to potential DDIs. A high and consistent lung exposure with substantially lower systemic exposure can be achieved following inhaled delivery of itraconazole relative to conventional oral dosing. Without wishing to be bound by theory, it is believed that this limited systemic exposure may be beneficial for use in subjects for whom oral itraconazole is contraindicated, and using inhaled respirable dry powders containing itraconazole, it is possible to safely achieve therapeutic concentrations of itraconazole in the lungs of this patient population, e.g., to treat certain diseases or disorders affecting the respiratory system.
[0036] As such, in some aspects the present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole. The subject may be treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme). In some aspects, the present disclosure relates to a method of coadministering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme).
Definitions
[0037] As used herein, the term “about” refers to a relative range of plus or minus 20% of a stated value, e.g., “about 20 mg” would be “20 mg plus or minus 4 mg”.
[0038] As used herein, the terms “administration” or “administering” refer to the introduction of a therapeutic agent, or a composition comprising a therapeutic agent, to a subject. For example, administering may refer to introducing a respirable dry powder disclosed herein to the respiratory tract of a subject.
[0039] As used herein, the term “amorphous” indicates lack of significant crystallinity when analyzed via powder X-ray diffraction (XRD).
[0040] The term “capsule emitted powder mass” or “CEPM” as used herein refers to the amount of dry powder emitted from a capsule or dose unit container during actuation from the dry powder inhaler, such as during an inhalation maneuver. CEPM is measured gravimetrically, typically by weighing a capsule before and after the emission event to determine the mass of powder removed. CEPM can be expressed either as the mass of powder removed, in milligrams, or as a percentage of the initial filled powder mass in the capsule prior to the emission event. [0041] The term “crystalline particulate form” as used herein refers to itraconazole (including pharmaceutically acceptable forms thereof including salts, polymorphs, solvates, hydrates, and the like), that is in the form of a particle (i.e., sub-particle that is smaller than the respirable dry particles that comprise the dry powders disclosed herein) and in which the itraconazole is at least about 50% crystalline. The percent crystallinity of itraconazole refers to the percentage of the compound that is in crystalline form relative to the total amount of compound present in the subparticle. If desired, the itraconazole can be at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% crystalline. Itraconazole in crystalline particulate form may be in the form of a particle that is about 50 nanometers (nm) to about 5,000 nm volume median diameter (Dv50), preferably 80 nm to 1750 nm Dv50, or preferably 50 nm to 800 nm Dv50.
[0042] The term “dispersible” is a term of art that describes the characteristic of a dry powder or respirable dry particles to be dispelled into a respirable aerosol. Dispersibility of a dry powder or respirable dry particles is expressed herein, in one aspect, as the quotient of the volumetric median geometric diameter (VMGD) measured at a dispersion (i.e., regulator) pressure of 1 bar divided by the VMGD measured at a dispersion (i.e., regulator) pressure of 4 bar, or VMGD at
0.5 bar divided by the VMGD at 4 bar as measured by laser diffraction, such as with a HELOS/RODOS. These quotients are referred to herein as “1 bar/4 bar dispersibility ratio” and "0.5 bar/4 bar dispersibility ratio", respectively, and dispersibility correlates with a low quotient. For example, 1 bar/4 bar dispersibility ratio refers to the VMGD of a dry powder or respirable dry particles emitted from the orifice of a RODOS dry powder disperser (or equivalent technique) at about 1 bar, as measured by a HELOS or other laser diffraction system, divided by the VMGD of the same dry powder or respirable dry particles measured at 4 bar by HELOS/RODOS. Thus, a highly dispersible dry powder or respirable dry particles will have a 1 bar/4 bar dispersibility ratio or 0.5 bar/4 bar dispersibility ratio that is close to 1.0. Highly dispersible powders have a low tendency to agglomerate, aggregate or clump together and/or, if agglomerated, aggregated or clumped together, are easily dispersed or de-agglomerated as they emit from an inhaler and are breathed in by a subject. In another aspect, dispersibility is assessed by measuring the particle size emitted from an inhaler as a function of flowrate. As the flow rate through the inhaler decreases, the amount of energy in the airflow available to be transferred to the powder to disperse it decreases. A highly dispersible powder will have a size distribution such as is characterized aerodynamically by its mass median aerodynamic diameter (MMAD) or geometrically by its VMGD that does not substantially increase over a range of flow rates typical of inhalation by humans, such as about 15 to about 60 liters per minute (LPM), about 20 to about 60 LPM, or about 30 LPM to about 60 LPM. A highly dispersible powder will also have an emitted powder mass or dose, or a capsule emitted powder mass or dose, of about 80% or greater even at the lower inhalation flow rates. VMGD may also be called the volume median diameter (VMD), x50, or Dv50.
[0043] The term “dry particles” as used herein refers to respirable particles that may comprise up to about 15% total of water and/or another solvent. Preferably, the dry particles comprise water and/or another solvent up to about 10% total, up to about 5% total, up to about 1% total, or between 0.01% and 1% total, by weight of the dry particles, or can be substantially free of water and/or other solvent.
[0044] The term “dry powder” as used herein refers to compositions that comprise respirable dry particles. A dry powder may comprise up to about 15% total of water and/or another solvent. Preferably the dry powder comprise water and/or another solvent up to about 10% total, up to about 5% total, up to about 1% total, or between 0.01% and 1% total, by weight of the dry
powder, or can be substantially free of water and/or other solvent. Tn one aspect, the dry powder is a respirable dry powder.
[0045] The term “effective amount,” as used herein, refers to the amount of agent needed to achieve the desired effect; such as treating a fungal infection or related disorder, e.g., allergic bronchopulmonary aspergillosis (ABPA). The actual effective amount for a particular use can vary according to the particular dry powder or respirable dry particle, the mode of administration, and the age, weight, general health of the subject, and severity of the symptoms or condition being treated. Suitable amounts of dry powders and dry particles to be administered, and dosage schedules for a particular patient can be determined by a clinician of ordinary skill based on these and other considerations.
[0046] As used herein, the term “emitted dose” or “ED” refers to an indication of the delivery of a drug formulation from a suitable inhaler device after a firing or dispersion event. More specifically, for dry powders, the ED is a measure of the percentage of powder that is drawn out of a unit dose package and that exits the mouthpiece of an inhaler device. The ED is defined as the ratio of the drug or powder delivered by an inhaler device to the nominal dose (i.e., the mass of drug or powder per unit dose placed into a suitable inhaler device prior to firing). The ED is an experimentally-measured parameter, and can be determined using the method of USP Section 601 Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, Delivered-Dose Uniformity, Sampling the Delivered Dose from Dry Powder Inhalers, United States Pharmacopeia convention, Rockville, MD, 13th Revision, 222-225, 2007. This method utilizes an in vitro device set up to mimic patient dosing. It can also be calculated from the results generated by Next Generation Impactor (NGI) experiments, through summation of all of the drug or powder assayed from the mouthpiece adapter, NGI induction port, and all of the stages within the NGI. The results generated through ED testing per USP 601 and the results generated via the NGI are typically in good agreement.
[0047] The term “lung to plasma ratio” or “lung:plasma ratio” refers to the ratio of a concentration of itraconazole in the lung versus the concentration of the itraconazole in the plasma at either a specific point in time or over a specific range of time. For example, the lung:plasma ratio may be calculated based on concurrent measurements at the maximum concentration (i.e., the “Cmax”) of itraconazole in the lung or in the serum, or at any point in time. The lung:plasma ratio may also be calculated for a total exposure over a certain period of time
(i.e., the “area under the curve” or “AUC”) such as over a 24 hour period The lung concentrations of the itraconazole may be assessed by measuring the levels in the sputum, by lung lavage, by biopsy or by some other method. The lung:plasma ratio may be calculated based on concurrent measurements at any point in the dosing cycle and may be calculated based on concurrent measurements before or at steady state.
[0048] The term “nominal dose” as used herein refers to an individual dose of itraconazole. The nominal dose is the total dose of the itraconazole within one receptacle, e.g., capsule, blister, or ampule.
[0049] The terms “FPF (<X),” “FPF (<X microns),” and “fine particle fraction of less than X microns” as used herein, wherein X equals, for example, 3.4 microns, 4.4 microns, 5.0 microns or 5.6 microns, refer to the fraction of a sample of dry particles that have an aerodynamic diameter of less than X microns. For example, FPF (<X) can be determined by dividing the mass of respirable dry particles deposited on stage two and on the final collection filter of a two- stage collapsed Andersen Cascade Impactor (ACI) by the mass of respirable dry particles weighed into a capsule for delivery to the instrument. This parameter may also be identified as “FPF_TD(<X),” where TD means total dose. A similar measurement can be conducted using an eight-stage ACI. An eight-stage ACI cutoffs are different at the standard 60 L/min flowrate, but the FPF_TD(<X) can be extrapolated from the eight-stage complete data set. The eight-stage ACI result can also be calculated by the USP method of using the dose collected in the ACI instead of what was in the capsule to determine FPF. Similarly, a seven-stage Next Generation Impactor (NGI) can be used.
[0050] The terms “FPD (<X)”, ‘FPD <X microns”, FPD(<X microns)” and “fine particle dose of less than X microns” as used herein, wherein X equals, for example, 3.4 microns, 4.4 microns, 5.0 microns or 5.6 microns, refer to the mass of a therapeutic agent delivered by respirable dry particles that have an aerodynamic diameter of less than X micrometers. FPD <X microns can be determined by using an eight-stage Andersen Cascade Impactor (ACI) or a Next Generation Impactor (NGI) at the standard 60L/min flowrate and summing the mass deposited on the final collection filter, and either directly calculating or extrapolating the FPD value. Similarly, a seven-stage Next Generation Impactor (NGI) can be used.
[0051] The term "respirable" as used herein refers to dry particles or dry powders that are suitable for delivery to the respiratory tract (e g., pulmonary delivery) in a subject by inhalation.
Respirable dry powders or dry particles have a mass median aerodynamic diameter (MMAD) of less than about 10 microns, preferably about 5 microns or less.
[0052] As used herein, the term “respiratory tract” includes the upper respiratory tract (e.g., nasal passages, nasal cavity, throat, pharynx, and larynx), respiratory airways (e.g., trachea, bronchi, and bronchioles) and lungs (e.g., respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli).
[0053] The term “small” as used herein to describe respirable dry particles refers to particles that have a volume median geometric diameter (VMGD) of about 10 microns or less, preferably about 5 microns or less, or less than 5 microns.
[0054] The term “stabilizer” as used herein refers to a compound that improves the physical stability of the itraconazole in crystalline particulate form when suspended in a liquid in which the itraconazole is poorly soluble (e.g., reduces the aggregation, agglomeration, Ostwald ripening and/or flocculation of the particulates). Suitable stabilizers are surfactants and amphiphilic materials and include polysorbates (PS; polyoxy ethylated sorbitan fatty acid esters), such as polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60), and polysorbate 80 (PS80); fatty acids such as lauric acid, palmitic acid, myristic acid, oleic acid and stearic acid, and their salts; sorbitan fatty acid esters, such as Span20, Span40, Span60, Span80, and Span 85; phospholipids such as dipalmitoylphosphosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero- 3-phospho-L-serine (DPPS), l,2-dipalmitoyl-sn-glycero-3 -phosphocholine (DSPC), 1-palmitoyl- 2-oleoylphosphatidyl choline (POPC), and l,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC); phosphatidylglycerols (PGs) such as diphosphatidyl glycerol (DPPG), DSPG, DPPG, POPG, etc.; l,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE); fatty alcohols; benzyl alcohol, polyoxyethylene-9-lauryl ether; glycocholate; surfactin; poloxomers; polyvinylpyrrolidone (PVP); PEG/PPG block co-polymers (Pluronics/Poloxamers); polyoxy ethyene chloresteryl ethers; POE alky ethers; tyloxapol; lecithin; and the like. Preferred stabilizers are polysorbates and fatty acids. A particularly preferred stabilizer is polysorbate 80 (PS80).
[0055] The term “homogenous dry particles” as used herein refers to particles that are compositionally homogenous. Homogenous dry particles disclosed herein are substantially the same in their composition of itraconazole, stabilizer, and optionally one or more excipients, and exclude a blend of two or more particles.
Methods of Administering Itraconazole Dry Powders
[0056] The inventors have discovered that administration of a dry powder comprising itraconazole disclosed herein can achieve a lung concentration of the itraconazole that is substantially greater than those achievable by oral dosing, while maintaining relatively low systemic concentration of itraconazole. Without wishing to be bound by theory, it is believed that by achieving greater lung concentration of the itraconazole using the dry powder disclosed herein, the administration can achieve therapeutic concentrations of itraconazole in the respiratory system while minimizing the systemic concentration of the itraconazole. Not only can minimizing the systemic concentration of itraconazole help to prevent side-effects and toxicity that are associated with itraconazole, but it is also possible to minimize inhibition of enzymes or receptors that itraconazole and OH-itraconazole are inhibitors or substates of, such as CYP3A4. In other words, by minimizing systemic concentration of itraconazole, the respirable dry powders of the present disclosure can be used to avoid DDIs when the subject is treated with a second therapeutic agent contraindicated with use of itraconazole, e.g., due to it being a substrate of, or an inducer or inhibitor of, the same enzymes or receptors (e.g., CYP3A4). The respirable dry powders of the present application are particularly useful for coadministration with therapeutic agents that are CYP3A4 inhibitors or inducers, and/or are metabolized by the same metabolic pathway(s) as itraconazole.
[0057] It is further believed that a therapeutic concentration of the itraconazole in the lung can be achieved even with a relatively low amount of total dose administered, e.g., relative to conventional oral administration. For example, studies have documented the systemic and pulmonary pharmacokinetics of oral itraconazole in adults and children, and pharmacokinetic studies examining respirable dry powders comprising itraconazole have shown that it is possible to achieve lung exposures that would be considered therapeutic for the treatment of pulmonary aspergillosis, after a relatively low single inhaled dose of 20 mg of dry powder. (See Conte, J.E., et al. Antimicrob. Agents Chemother. (2004) 48:3823-3827; see also Hava, D.L., et al., Brit. J. Clin. Pharmacol. (2020) 86(4):723-733; each of which are incorporated herein by reference in their entireties). Advantageously, the relatively low total dose of itraconazole that is needed to be administered to achieve a therapeutic effect using a dry powder disclosed herein, compared to the large amounts required for oral dosing, can reduce the risk of DDIs, which provides the opportunity to combine the dry powder comprising itraconazole with a second therapeutic agent,
particularly those known to have DDTs and/or those contraindicated with itraconazole use, such as a substrate, inducer, or inhibitor of CYP3A4.
[0058] Dry powders that comprise itraconazole in amorphous form have shorter lung residence times, reduced lung to plasma exposure ratios, and undesirable toxic effects on lung tissue when inhaled at therapeutic doses. Without wishing to be bound by any particular theory, it is believed that the dry powders disclosed herein comprising crystalline forms (e.g., nanocrystalline forms) of itraconazole have a slower dissolution rate in the lung relative to the amorphous form, providing more continuous exposure over a 24 hour period after administration and minimizing systemic exposure and DDT potential.
[0059] Further, wishing to be bound by any particular theory, it is believed that smaller crystalline particles of the itraconazole (e.g., nano-crystalline or micro-crystalline itraconazole) will dissolve in the airway lining fluid more rapidly than larger crystalline particles, in part due to the larger total amount of surface area. It is also believed that crystalline itraconazole will dissolve more slowly in the airway lining fluid than the amorphous itraconazole, in part due to the lower aqueous solubility. Accordingly, the dry powders described herein can be formulated using itraconazole in crystalline particulate form that a desired crystalline size or range of crystalline sizes within the dry powders, and optionally with suitable excipients and stabilizers in a suitable ratio with the itraconazole, each of which can be tailored to affect, for example, dissolution rate, and achieve desired pharmacokinetic properties while avoiding unacceptable toxicity in the lungs in addition to avoiding DDTs with a second therapeutic agent.
[0060] Administering a dry powder disclosed herein can obtain a relatively high ratio of lung concentration: systemic concentration of the itraconazole. Without wishing to be bound by any particular theory, it is believed that a relatively high ratio of lung concentration: systemic concentration can not only minimize off-target effects and/or toxicity associated with itraconazole, but allow for coadministration with a second therapeutic agent that is contraindicated with itraconazole use and lower risk of DDTs. As such, the methods disclosed herein provide an advantage over commercially available formulations of itraconazole which are typically administered orally and in large amounts, and which cannot be co-administered with many other useful therapeutic agents due to high potential of DDTs and the associated safety concerns.
[0061] As detailed in the exemplification section herein, the impact of inhaled itraconazole on the metabolism of a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole was evaluated using PBPK techniques, with midazolam as the model second therapeutic agent. Specifically, an existing oral PBPK model for itraconazole and OH-itraconazole was adapted within the Simcyp compound library, which have undergone robust verification with clinical DDI data, giving a high confidence in the model predictions for respirable dry powders comprising itraconazole. Despite pharmacologic concentrations of itraconazole in the tissues of the lungs, there is minimal itraconazole exposure in the intestines and liver. As a result, there was minimal impact predicted on the metabolism of midazolam, despite the overprediction of the primary active metabolite, OH-itraconazole. These results indicate that itraconazole can be safely and effectively administered via an inhaled formulation even in patients taking a second therapeutic agent that is substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., CYP3A4). The clinical implications of being able to safely administer itraconazole with one of those second therapeutic agents are clear, and should improve the treatment possibilities for vulnerable patients maintained on medications that are contraindicated in the presence of oral itraconazole.
[0062] Methods disclosed herein may comprise treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole (e.g., crystalline itraconazole). Additionally, methods disclosed herein may comprise co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject.
[0063] The second therapeutic agent may be a substrate of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e g., CYP3A4). The second therapeutic agent may be an inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., CYP3A4). The second therapeutic agent may be an inducer of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole (e.g., CYP3A4).
[0064] The second therapeutic agent may be contraindicated with oral itraconazole (e.g., SPORANOX®). For example, the second therapeutic agent may be a substance that is listed as
contraindicated for use with itraconazole by a regulatory authority, e g., as stated in the FDA label for SPORANOX®.
[0065] There are many different classes of drugs that are contraindicated, or otherwise not recommended to be combined with oral itraconazole at normal doses. As such, the respirable dry powders disclosed herein may be combined with many different classes of drugs, without significant risk of DDI or other adverse reactions, and/or without requiring careful adjustment or limiting doses to avoid potential DDIs or adverse reactions.
[0066] For example, a method disclosed herein may comprise coadministration of the respirable dry powder with, or administration of the respirable dry powder to a subject that is also administered with, a second therapeutic agent selected from the group consisting of an alpha blocker, a beta blocker, an analgesic, an antiarrhythmic, an antibacterial, an anticoagulant, an antiplatelet drug, an anticonvulsant, an antidiabetic drug, an anthelminthic, an antifungal, an antiprotozoal, an antimigraine drug, an antineoplastic, an antipsychotic, an anxiolytic, a hypnotic, an antiviral, a calcium channel blocker, a cardiovascular drug, a contraceptive, a diuretic, an anticonvulsant, an immunosuppressant, a lipid-lowering drug, a respiratory drug (e.g., an asthma treatment), an antidepressant drug (e g., a tricyclic or a selective serotonin reuptake inhibitor (SSRI)), a urologic drug, a vasopressin receptor antagonist, a nonsteroidal anti-inflammatory drug (NS AID), or a gastrointestinal drug.
[0067] The second therapeutic agent may be alfiizosin, silodosin, or tamsulosin. The second therapeutic agent may be methadone, fentanyl, alfentanil, buprenorphine, oxycodone, or sufentanil. The second therapeutic agent may be disopyramide, dofetilide, dronedarone, quinidine, or digoxin. The second therapeutic agent may be bedaquiline, rifabutin, clarithromycin, or trimetrexate. The second therapeutic agent may be ticagrelor, apixaban, rivaroxaban, vorapaxar, cilostazol, dabigatran, warfarin, or carbamazepine. The second therapeutic agent may be repaglinidea or saxagliptin. The second therapeutic agent may be isavuconazonium, praziquantel, artemether-lumefantrine, or quinine. The second therapeutic agent may be an ergot alkaloid, such as dihydroergotamine, ergometrine, ergonovine, methylergometrine, methylergonovine, ergotamine. The second therapeutic agent may be eletriptan. The second therapeutic agent may be irinotecan, axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetiniba, crizotinib, dabrafenib, dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olapariba, pazopanib, regorafenib, sunitinib, trabectedin, trastuzumab-
emtansine, vinca alkaloids, bortezomib, brentuximab-vedotin, busulfan, erlotinib, gefitinib, idelalisib, nintedanib, panobinostat, ponatinib, ruxolitinib, sonidegib, vandetanib, imatinib, or ixabepilone. The second therapeutic agent may be alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam, quetiapine, ramelteon, risperidone, suvorexant, zopiclone, lurasidone, pimozide, or triazolam. The second therapeutic agent may be levacetylmethadol (levomethadyl), simeprevir, daclatasvir, indinavir, maraviroc, cobicistat, elvitegravir, ritonavir, saquinavir, or tenofovir disoproxil fumarate. The second therapeutic agent may be nadolol. The second therapeutic agent may be felodipine, nisoldipine, diltiazem, dihydropyridines, or verapamil. The second therapeutic agent may be ivabradine, ranolazine, aliskiren, riociguat, sildenafd, tadalafd, bosentan, guanfacine, dienogest, or ulipristal. The second therapeutic agent may be eplerenone. The second therapeutic agent may be cisapride, naloxegol, aprepitant, loperamide, or netupitant. The second therapeutic agent may be everolimus, sirolimus, temsirolimus, budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, or tacrolimus. The second therapeutic agent may be lomitapide, lovastatin, simvastatin, or atorvastatin. The second therapeutic agent may be salmeterol. The second therapeutic agent may be venlafaxine. The second therapeutic agent may be avanafd, fesoterodine, solifenacin, darifenacin, vardenafil, dutasteride, oxybutynin, or tolterodine. The second therapeutic agent may be colchicine, eliglustat, lumacaftor, ivacaftor, elexacaftor, tezacaftor, SYMDEKO®, ORKAMBI®, KALYDECO®, alitretinoin, or cabergoline. The second therapeutic agent may be a cannabinoid. The second therapeutic agent may be cinacalcet, conivaptan, or volvaptan. The second therapeutic agent may be a Saccharomyces boulardii composition. The second therapeutic agent may be meloxicam. The second therapeutic agent may be ciprofloxacin, erythromycin, or clarithromycin. The second therapeutic agent may be idelalisib. The second therapeutic agent may be darunavir or fosamprenavir. The second therapeutic agent may be isoniazid, rifampicin, or rifabutin. The second therapeutic agent may be phenobarbital, phenytoin, efavirenz, or nevirapine. The second therapeutic agent may be a drug that reduces gastric acidity, such as an acid neutralizing medicines, e.g., aluminum hydroxide, an acid secretion suppressors such as H2-receptor antagonists, or a proton pump inhibitor. The second therapeutic agent may be halofantrine.
[0068] In some embodiments, the second therapeutic agent is methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, an ergot alkaloid (such as dihydroergotamine,
ergometrine (ergonovine), ergotamine, or methyl ergometrine (methyl ergonovine)), irinotecan, lurasidone, midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, colchicine, fesoterodine, solifenacin, or eliglustat.
[0069] In a method disclosed herein, the respirable dry powder may be administered at a nominal dose of between about 1 mg and about 60 mg, e.g., between about 5 mg and about 40 mg, between about 1 mg and about 10 mg, between about 10 mg and about 20 mg, between about 20 mg and about 30 mg, or between about 30 mg and about 40 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg.
[0070] Coadministration may refer to administering the respirable dry powder to the subject no more than about 14 days before or after administering the second therapeutic agent, e.g., less than about 14 days, less than about 12 days, less than about 10 days, less than about 8 days, less than about 7 days, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, less than about 2 days, or less than about 1 day before or after administering the second therapeutic agent. In some embodiments, coadministration refers to administering the dry powder to the subject on the same day as administering the second therapeutic agent, e.g., administering the respirable dry powder less than about 20 hours, less than about 18 hours, less than about 16 hours, less than about 14 hours, less than about 12 hours, less than about 11 hours, less than about 10 hours, less than about 9 hours, less than about 8 hours, less than about 7 hours, less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, less than about 45 minutes, less than about 30 minutes, less than about 20 minutes, less than about 10 minutes, or less than about 5 minutes, before or after administering the second therapeutic agent. In some embodiments, the itraconazole is administered to the subject less than about 5 minutes before or after administering the second therapeutic agent.
[0071] In a method disclosed herein, the subject to be treated with the itraconazole may be a subject for whom oral itraconazole is contraindicated. That may be due to the subject having been administered the second therapeutic agent disclosed herein (e.g., a therapeutic agent that is contraindicated with itraconazole use). Due to the favorable pharmacokinetic properties achieved using the respirable dry powder disclosed herein, the subject may nevertheless be administered a respirable dry powder disclosed herein to achieve therapeutic local concentrations
of itraconazole in the lungs, in a safe manner and avoiding DDTs or adverse events that would be expected when a different formulation of itraconazole, e.g., oral itraconazole, is administered. [0072] The subject to be treated with the itraconazole, who may be a subject for whom oral itraconazole is contraindicated, may have a disease or disorder. The particular disease or disorder may be a condition that the itraconazole is being administered to treat, or it may be a condition that is not being treated with itraconazole, or a condition that is unrelated to the use of the itraconazole. The subject may have an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, an immunodeficiency disorder (e.g., HIV or AIDS), cancer (e.g., lung cancer, such as non-small cell lung cancer), a cardiovascular disorder (e.g., congestive heart failure, cardiac dysrhythmias, cardiac disease), hypertension, hypercholesterolemia, an autoimmune disorder, diabetes, a gastrointestinal disorder, a thrombotic disorder, epilepsy, a psychiatric disorder (e.g., bipolar disorder, depression, psychosis, anxiety), migraine, pain (e.g., acute pain, pain caused by surgery, or chronic pain). In some cases, the disease or disorder is a condition that the itraconazole is used to treat, such as an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, or cancer (e.g., lung cancer, such as non-small cell lung cancer).
[0073] In some embodiments, a method disclosed herein is for treating an infection (e.g., a fungal infection, such as aspergillosis), allergic bronchopulmonary aspergillosis, a respiratory disease (e.g., cystic fibrosis, asthma, pneumonia (e.g., fungal pneumonia)), an acute exacerbation of a respiratory disease, or cancer (e.g., lung cancer, such as non-small cell lung cancer) in a subject in need thereof.
Respirable Dry Powders
[0074] The dry powders disclosed herein may be administered to a subject by inhalation, such as oral inhalation. To achieve oral inhalation, a dry powder inhaler may be used, such as a passive dry powder inhaler. Respirable dry powders comprising itraconazole for use in treating a fungal infection have been described in WO 2018/071757, WO 2019/204583, and WO 2019/204597, the entire contents of which are incorporated herein by reference in their entireties
[0075] The respirable dry powders used in the methods disclosed herein may include homogenous respirable dry particles that comprise 1) itraconazole in crystalline particulate form, 2) a stabilizer, and optionally 3) one or more excipients. Such respirable dry particles can be prepared using any suitable method, such as by preparing a feedstock in which itraconazole in crystalline particulate form is suspended in an aqueous solution of excipients, and spray drying the feedstock.
[0076] The respirable dry particles may comprise itraconazole in an amount of about 1% to about 95% by weight (wt%). It is preferred that the respirable dry particle comprises an amount of itraconazole so that a therapeutically effective dose can be administered and maintained without the need to inhale large volumes of dry powder, and also without the need to inhale the dry powder too frequently, e.g., more than three time a day. For example, it is preferred that the respirable dry particles comprise about 30% to about 70%, or about 40% to about 60%, e.g., about 45%, about 50%, or about 55% itraconazole by weight (wt%). The amount of itraconazole present in the respirable dry particles by weight may also be referred to as the “drug load.” [0077] The itraconazole may be present in the respirable dry particles in crystalline particulate form (e.g., nano-crystalline). More specifically, in the form of a sub-particle that is about 50 nm to about 5,000 nm (Dv50), preferably, with the itraconazole being at least 50% crystalline. For example, for any desired load of the itraconazole (sometimes referred to as “drug load”), the subparticle size can be about 100 nm, about 300 nm, about 1500 nm, about 80 nm to about 300 nm, about 80 nm to about 250 nm, about 80 nm to about 200 nm, about 100 nm to about 150 nm, about 1200 nm to about 1500 nm, about 1500 nm to about 1750 nm, about 1200 nm to about 1400 nm, or about 1200 nm to about 1350 nm (Dv50). In particular embodiments, the subparticle is between about 50 nm to about 2500 nm, between about 80 and 1750 nm, between about 50 nm and 1000 nm, between about 50 nm and 800 nm, between about 50 nm and 600 nm, between about 50 nm and 500 nm, between about 50 nm and 400 nm, between about 50 nm and 300 nm, between about 50 nm and 200 nm, or between about 100 nm and 300 nm. In addition, for any desired drug load and sub-particle size, the degree of itraconazole crystallinity can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% crystalline. Preferably, the itraconazole is about 100% crystalline. In some embodiments, the dry powder administered comprises homogenous respirable dry particles that comprise itraconazole that is at least 50% crystalline, e g., 55%
crystalline, 60% crystalline, 65% crystalline, 70% crystalline, 75% crystalline, 80% crystalline, 85% crystalline, 90% crystalline, 95% crystalline, 96% crystalline, 97% crystalline, 98% crystalline, 99% crystalline, or more than 99% crystalline
[0078] The itraconazole in crystalline particulate form can be prepared in any desired subparticle size using a suitable method, including a stabilizer if desired, such as by wet milling, jet milling or other suitable method.
[0079] The respirable dry particles also include a stabilizer. The stabilizer helps maintain the desired size of the itraconazole in crystalline particulate form during wet milling, in spray drying feedstock, and aids in wetting and dispersing and maintaining the physical stability of the itraconazole crystalline particulate suspension. It is preferred to use as little stabilizer as is needed to achieve the aforementioned benefits. The amount of stabilizer is typically in a fixed ratio to the amount of itraconazole present in the dry particle and can range from about 1 : 1 (itraconazole: stabilizer (wt:wt)) to about 50:1 (wt:wt), about 10:1 being preferred. For example, the ratio of itraconazole: stabilizer (wt:wt) in the dry particles can be about 8: 1, about 9: 1, about 10: 1, about 11 :1, or about 12:1.
[0080] The amount of stabilizer that is present in the dry particles can be in a range of about 1 wt% to about 15 wt%, such as about 3 wt% to about 7 wt%, or about 5 wt%. It is generally preferred that the respirable dry particles comprise less than about 10% stabilizer by weight (wt%), such as 9 wt% or less, 8 wt% or less, 7 wt% or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, or 1 wt% or less. A particularly preferred stabilizer for use in the dry powders described herein is polysorbate 80. In contrast to conventional dry powders which use surfactant to prevent the onset of crystallization in the dry powder, the surfactant in the presently disclosed dry powders is added to stabilize a colloidal suspension of the crystalline itraconazole in an anti-solvent.
[0081] In some embodiments, the dry powder administered comprises homogenous respirable dry particles that comprise itraconazole and polysorbate 80, wherein the ratio of itraconazole:polysorbate 80 (wt:wt) is about 10:1.
[0082] The respirable dry particles also include a sodium salt (e.g., sodium sulfate or sodium chloride). For example, the dry particles may comprise sodium sulfate. In preferred embodiments, the respirable dry particles comprise about 15 wt% to about 50 wt% of a sodium salt (e g., sodium sulfate). For example, the respirable dry particles can comprise between about
25 wt% and about 45 wt% sodium salt, e.g., about 30 wt%, 35 wt%, or 40 wt% sodium salt (e.g., sodium sulfate).
[0083] The respirable dry particles also include any suitable and desired amount of one or more excipients. In some embodiments, the one or more excipients are present in an amount of about 5% to about 20% by weight. Many excipients are well-known in the art and can be included in the dry powders and dry particles described herein. Pharmaceutically acceptable excipients that are particularly preferred for the dry powders and dry particles described herein include leucine. For example, the respirable dry particles comprise an excipient (e.g., leucine), in an amount of about 1 wt% to about 20 wt %, e.g., between about 5 wt% and about 20 wt%, e.g., about 10 wt%. In some embodiments, the respirable dry particles comprise leucine in an amount of about 10 wt%.
[0084] Without wishing to be bound by theory, it is believed that combining the itraconazole in a dry powder with leucine and a sodium salt (e.g., sodium sulfate) can provide optimal dissolution rates for obtaining effective therapeutic levels of the itraconazole in the lungs without unacceptable toxicity or DDIs when the dry powder is coadministered with a second therapeutic agent. Additionally, maintaining a relatively high drug load (e.g., about 50 wt%) of the itraconazole may prevent rapid dissolution of the dry powder in the lungs. For example, the dry powders disclosed herein may dissolve in the lungs more slowly, compared to a formulation combining relatively low amounts of itraconazole (e.g., less than 40 wt%) with a hydrophilic excipient such as mannitol.
[0085] The dissolution of dry powders used in the methods disclosed herein may be measured in terms of the dissolution half-life. In some embodiments, the dry powders used in a method disclosed herein have a dissolution half-life that is at least about 2 minutes, e.g., between about 2 minutes and about 20 minutes, e.g., about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes. In some embodiments, the dissolution half-life is about 4.1 minutes, about 4.2 minutes, about 4.3 minutes, or about 4.4 minutes. In some embodiments the dissolution half-life is between about 4.13 minutes and about 16.84 minutes.
[0086] In one aspect, the dry powder comprises respirable dry particles comprising: (i) about 50 wt% itraconazole in crystalline particulate form, about 5 wt% of a stabilizer, about 35 wt% of a sodium salt, and about 10 wt% leucine. For example, the dry powder may comprise respirable
dry particles comprising: (i) 50 wt% itraconazole in crystalline particulate form, 5 wt% of a stabilizer (e.g., polysorbate 80), 35 wt% of a sodium salt (e.g., sodium sulfate), and 10 wt% leucine. The dry powder may consist essentially of respirable dry particles that consist essentially of: (i) 50 wt% itraconazole in crystalline particulate form, 5 wt% of a stabilizer (e.g., polysorbate 80), 35 wt% of a sodium salt (e.g., sodium sulfate), and 10 wt% leucine.
[0087] The dry powders disclosed herein may be free of lactose or other carrier particles.
[0088] The dry powders and/or respirable dry particles are preferably small, mass dense, and dispersible. To measure volumetric median geometric diameter (VMGD), a laser diffraction system may be used, e.g., a Spraytec system (particle size analysis instrument, Malvern Instruments) and a HELOS/RODOS system (laser diffraction sensor with dry dispensing unit, Sympatec GmbH). The respirable dry particles have a VMGD as measured by laser diffraction at the dispersion pressure setting (also called regulator pressure) of 1.0 bar at a maximum orifice ring pressure using a HELOS/RODOS system of about 10 microns or less, about 5 microns or less, about 4 pm or less, about 3 pm or less, about 1 pm to about 5 pm, about 1 pm to about 4 pm, about 1.5 pm to about 3.5 pm, about 2 pm to about 5 pm, about 2 pm to about 4 pm, or about 2 pm to about 3 pm. Preferably, the VMGD is about 5 microns or less, or about 4 pm or less. In one aspect, the dry powders and/or respirable dry particles have a minimum VMGD of about 0.5 microns or about 1.0 micron.
[0089] The dry powders and/or respirable dry particles preferably have 1 bar/4 bar dispersibility ratio and/or 0.5 bar/4 bar dispersibility ratio of less than about 2.0 (e.g., about 0.9 to less than about 2), about 1.7 or less (e.g., about 0.9 to about 1.7) about 1.5 or less (e.g., about 0.9 to about 1.5), about 1.4 or less (e.g., about 0.9 to about 1.4), or about 1.3 or less (e.g., about 0.9 to about 1.3), and preferably have a 1 bar/4 bar and/or a 0.5 bar/4 bar of about 1.5 or less (e.g., about 1.0 to about 1.5), and/or about 1.4 or less (e.g., about 1.0 to about 1.4).
[0090] The dry powders and/or respirable dry particles preferably have a tap density of at least about 0.2 g/cm3, of at least about 0.25 g/cm3, a tap density of at least about 0.3 g/cm3, of at least about 0.35 g/cm3, a tap density of at least 0.4 g/cm3. For example, the dry powders and/or respirable dry particles have a tap density of greater than 0.4 g/cm3 (e.g., greater than 0.4 g/cm3 to about 1.2 g/cm3), a tap density of at least about 0.45 g/cm3 (e.g., about 0.45 g/cm3 to about 1.2 g/cm3), at least about 0.5 g/cm3 (e.g., about 0.5 g/cm3 to about 1.2 g/cm3), at least about 0.55 g/cm3 (e g., about 0.55 g/cm3 to about 1.2 g/cm3), at least about 0.6 g/cm3 (e g., about 0.6 g/cm3
to about 1 .2 g/cm3) or at least about 0.6 g/cm3 to about 1 .0 g/cm3. Alternatively, the dry powders and/or respirable dry particles preferably have a tap density of about 0.01 g/cm3 to about 0.5 g/cm3, about 0.05 g/cm3 to about 0.5 g/cm3, about 0.1 g/cm3 to about 0.5 g/cm3, about 0.1 g/cm3 to about 0.4 g/cm3, or about 0.1 g/cm3 to about 0.4 g/cm3. Alternatively, the dry powders and/or respirable dry particles have a tap density of about 0.15 g/cm3 to about 1.0 g/cm3. Alternatively, the dry powders and/or respirable dry particles have a tap density of about 0.2 g/cm3 to about 0.8 g/cm3.
[0091] The dry powders and/or respirable dry particles have a bulk density of at least about 0.1 g/cm3, or at least about 0.8 g/cm3. For example, the dry powders and/or respirable dry particles have a bulk density of about 0.1 g/cm3 to about 0.6 g/cm3, about 0.2 g/cm3 to about 0.7 g/cm3, about 0.3 g/cm3 to about 0.8 g/cm3.
[0092] The respirable dry particles, and the dry powders when the dry powders are respirable dry powders, preferably have an MMAD of less than 10 microns, preferably an MMAD of about 5 microns or less, or about 4 microns or less. In one aspect, the respirable dry powders and/or respirable dry particles preferably have a minimum MMAD of about 0.5 microns, or about 1.0 micron. In one aspect, the respirable dry powders and/or respirable dry particles preferably have a minimum MMAD of about 2.0 microns, about 3.0 microns, or about 4.0 microns.
[0093] The dry powders and/or respirable dry particles preferably have a FPF of less than about 5.6 microns (FPF<5.6 pm) of the total dose of at least about 35%, preferably at least about 45%, at least about 60%, between about 45% to about 80%, or between about 60% and about 80%.
[0094] The dry powders and/or respirable dry particles preferably have a FPF of less than about 3.4 microns (FPF<3.4 pm) of the total dose of at least about 20%, preferably at least about 25%, at least about 30%, at least about 40%, between about 25% and about 60%, or between about 40% and about 60%.
[0095] The dry powders and/or respirable dry particles preferably have a total water and/or solvent content of up to about 15% by weight, up to about 10% by weight, up to about 5% by weight, up to about 1%, or between about 0.01% and about 1%, or may be substantially free of water or other solvent.
[0096] The dry powders and/or respirable dry particles preferably may be administered with low inhalation energy. In order to relate the dispersion of powder at different inhalation flow rates, volumes, and from inhalers of different resistances, the energy required to perform the inhalation
maneuver may be calculated. Inhalation energy can be calculated from the equation E=R2Q2V where E is the inhalation energy in Joules, R is the inhaler resistance in kPa1/2/LPM, Q is the steady flow rate in L/min and V is the inhaled air volume in L.
[0097] Healthy adult populations are predicted to be able to achieve inhalation energies ranging from 2.9 Joules for comfortable inhalations to 22 Joules for maximum inhalations by using values of peak inspiratory flow rate (PIFR) measured by Clarke et al. (Journal of Aerosol Med, 6(2), p.99-110, 1993) for the flow rate Q from two inhaler resistances of 0.02 and 0.055 kPa1/2/LPM, with an inhalation volume of 2L based on both FDA guidance documents for dry powder inhalers and on the work of Tiddens et al. (Journal of Aerosol Med, 19(4), p.456-465, 2006) who found adults averaging 2.2L inhaled volume through a variety of DPIs.
[0098] Mild, moderate and severe adult COPD patients are predicted to be able to achieve maximum inhalation energies of 5.1 to 21 Joules, 5.2 to 19 Joules, and 2.3 to 18 Joules respectively. This is again based on using measured PIFR values for the flow rate Q in the equation for inhalation energy. The PIFR achievable for each group is a function of the inhaler resistance that is being inhaled through. The work of Breeders et al. (Eur Respir J, 18, p.780- 783, 2001) was used to predict maximum and minimum achievable PIFR through two dry powder inhalers of resistances 0.021 and 0.032 kPa1/2/LPM for each.
[0099] Similarly, adult asthmatic patients are predicted to be able to achieve maximum inhalation energies of 7.4 to 21 Joules based on the same assumptions as the COPD population and PIFR data from Breeders et al.
[00100] Healthy adults and children, for example, are capable of providing sufficient inhalation energy to disperse a dry powder of the present disclosure, e.g., from a suitable inhalation device (e.g., dry powder inhaler).
[00101] The dry powders and/or respirable dry particles useful in a method disclosed herein are preferably characterized by a high emitted dose, such as a CEPM of at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, from a passive dry powder inhaler subject to a total inhalation energy of about 5 Joules, about 3.5 Joules, about 2.4 Joules, about 2 Joules, about 1 Joule, about 0.8 Joules, about 0.5 Joules, or about 0.3 Joules is applied to the dry powder inhaler. The receptacle holding the dry powders and/or respirable dry particles may comprise about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, or about 30 mg. In one aspect, the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or
greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 30 LPM, run for 3 seconds using a size 3 capsule that comprises a total mass of 10 mg. In another aspect, the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 20 LPM, run for 3 seconds using a size 3 capsule that comprises a total mass of 10 mg. In a further aspect, the dry powders and/or respirable dry particles are characterized by a CEPM of 80% or greater and a VMGD of 5 microns or less when emitted from a passive dry powder inhaler having a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions: an air flow rate of 15 LPM, run for 4 seconds using a size 3 capsule that comprises a total mass of 10 mg.
[00102] The dry powder can fdl the unit dose container, or the unit dose container can be at least 2% full, at least 5% full, at least 10% full, at least 20% full, at least 30% full, at least 40% full, at least 50% full, at least 60% full, at least 70% full, at least 80% full, or at least 90% full. The unit dose container can be a capsule (e. , size 000, 00, 0E, 0, 1, 2, 3, and 4, with respective volumetric capacities of 1.37 mL, 950 pL, 770 pL, 680 pL, 480 pL, 360 pL, 270 pL, and 200 pL). The capsule can be at least about 2% full, at least about 5% full, at least about 10% full, at least about 20% full, at least about 30% full, at least about 40% full, or at least about 50% full. The unit dose container can be a blister. The blister can be packaged as a single blister or as part of a set of blisters, for example, 7 blisters, 14 blisters, 28 blisters or 30 blisters. The one or more blister can be preferably at least 30% full, at least 50% full or at least 70% full.
[00103] An advantage of the dry powders disclosed herein is that they disperse well across a wide range of flow rates and are relatively flowrate independent. The dry powders and/or respirable dry particles permit the use of a simple, passive DPI for a wide patient population.
[00104] The dry powders and/or respirable dry particles useful in a method described herein are preferably characterized by: 1) a VMGD at 1 bar as measured using a HELOS/RODOS system of about 10 microns or less, preferably about 5 microns or less; 2) a 1 bar/4 bar dispersibility ratio and/or a 0.5 bar/4 bar dispersibility ratio of about 1.5 or less, about 1.4 or less or about 1.3 or less; 3) a MMAD of about 10 microns or less, preferably about 5
microns or less; 4) a FPF<5.6 pm of the total dose of at least about 45% or at least about 60%; and/or 5) a FPF<3.4 pm of the total dose of at least about 25% or at least about 40%. If desired, the dry powders and/or respirable dry particles are further characterized by a tap density of about 0.2 g/cm3 or greater, about 0.3 g/cm3 or greater, about 0.4 g/cm3 or greater, greater than 0.4 g/cm3, about 0.45 g/cm3 or greater or about 0.5 g/cm3 or greater.
[00105] Formulation I is an exemplary dry powder that can be used in a method disclosed herein. The composition and properties of Formulation I are provided below in Table 1. [00106] Table 1. Composition and properties of Formulation I.
[00107] Formulation I has a fine particle fraction (FPF) less than 5 microns of the total dose of 57%, leading to a fine particle dose less than 5 microns of 2.8 mg for a 10.0 mg total dry powder capsule fill.
[00108] Formulation I has a dissolution half-life of 4.35 mins, as determined by the following protocol: powder formulations, capsules and packaging materials were equilibrated at 22.5 ± 2.5 °C and 30 ±5% RH. Formulation I was encapsulated into a size 3 HPMC capsule under the same conditions. The fill weight for the powder preparation was 10 mg. The formulation were aerosolized from the capsule in a unit-dose, capsule-based DPI device (RS01, Plastiape, Osnago, Italy), at 60 L/min (4L inhaled volume) using the Plastiape RS01 dry powder inhaler (DPI). The aerosol dose was collected in the UniDose system. The UniDose collection system was used to uniformly deposit the whole impactor stage mass (i.e., below stage 2 of an NGI) onto a glass microfiber filter membrane, which can be seen as where the circles (representing particles or droplets) deposit. The filter was placed into a disk cassette and dissolution studies were undertaken using 500ml PBS pH 7.4 + 2.0% SDS in a USP Apparatus II POD (Paddle Over Disk, USP V) at 37 °C. Sink conditions were maintained within the vessel. Samples were taken at specified time points and tested for drug content on an Agilent (Santa Clara, CA, USA) 1260 Infinity series HPLC.
[00109] The dry powders and/or respirable dry particles disclosed herein may be filled into a receptacle, for example a capsule or a blister. When the receptacle is a capsule, the capsule is,
for example, a size 2 or a size 3 capsule, and is preferably a size 3 capsule. The capsule material may be, for example, gelatin or HPMC (hydroxypropyl methylcellulose), and is preferably HPMC.
[00110] The dry powder and/or respirable dry particles described and characterized herein be contained in a dry powder inhaler (DPI). The DPI may be a capsule-based DPI or a blister-based DPI, and is preferably a capsule-based DPI. More preferably, the dry powder inhaler is selected from the RS01™ family of dry powder inhalers (Plastiape S.p.A., Italy). More preferably, the dry powder inhaler is selected from the RS01™ HR or the RS01™ UHR2. Most preferably, the dry powder inhaler is the RS01™ HR.
Methods for Preparing Dry Powders and Dry Particles
[00111] The respirable dry particles and dry powders for use in a method disclosed herein can be prepared using any suitable method, with the proviso that the dry powders cannot be an extemporaneous dispersion. Many suitable methods for preparing dry powders and/or respirable dry particles are conventional in the art, and include single and double emulsion solvent evaporation, spray drying, spray-freeze drying, milling (e.g., jet milling), blending, solvent extraction, solvent evaporation, phase separation, simple and complex coacervation, interfacial polymerization, suitable methods that involve the use of supercritical carbon dioxide (CO2), sonocrystallization, nanoparticle aggregate formation and other suitable methods, including combinations thereof. Respirable dry particles can be made using methods for making microspheres or microcapsules known in the art. These methods can be employed under conditions that result in the formation of respirable dry particles with desired aerodynamic properties (e.g., aerodynamic diameter and geometric diameter). If desired, respirable dry particles with desired properties, such as size and density, can be selected using suitable methods, such as sieving.
[00112] Suitable methods for selecting respirable dry particles with desired properties, such as size and density, include wet sieving, dry sieving, and aerodynamic classifiers (such as cyclones).
[00113] The respirable dry particles are preferably spray dried. Suitable spray-drying techniques are described, for example, by K. Masters in “Spray Drying Handbook”, John Wiley & Sons, New York (1984). Generally, during spray-drying, heat from a hot gas such as heated
air or nitrogen is used to evaporate a solvent from droplets formed by atomizing a continuous liquid feed. When hot air is used, the moisture in the air is at least partially removed before its use. When nitrogen is used, the nitrogen gas can be run “dry”, meaning that no additional water vapor is combined with the gas. If desired the moisture level of the nitrogen or air can be set before the beginning of spray dry run at a fixed value above “dry” nitrogen. If desired, the spray drying or other instruments, e.g., jet milling instrument, used to prepare the dry particles can include an inline geometric particle sizer that determines a geometric diameter of the respirable dry particles as they are being produced, and/or an inline aerodynamic particle sizer that determines the aerodynamic diameter of the respirable dry particles as they are being produced. [00114] For spray drying, solutions, emulsions or suspensions that contain the components of the dry particles to be produced in a suitable solvent (e.g., aqueous solvent, organic solvent, aqueous-organic mixture or emulsion) are distributed to a drying vessel via an atomization device. For example, a nozzle or a rotary atomizer may be used to distribute the solution or suspension to the drying vessel. The nozzle can be a two-fluid nozzle, which can be in an internal mixing setup or an external mixing setup. Alternatively, a rotary atomizer having a 4- or 24-vaned wheel may be used. Examples of suitable spray dryers that can be outfitted with a rotary atomizer and/or a nozzle, include, a Mobile Minor Spray Dryer or the Model PSD-1, both manufactured by GEA Niro, Inc. (Denmark), Btichi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland), ProCepT Formatrix R&D spray dryer (ProCepT nv, Zelzate, Belgium), among several other spray dryer options. Actual spray drying conditions will vary depending, in part, on the composition of the spray drying solution or suspension and material flow rates. The person of ordinary skill will be able to determine appropriate conditions based on the compositions of the solution, emulsion or suspension to be spray dried, the desired particle properties and other factors. In general, the inlet temperature to the spray dryer is about 90°C to about 300°C. The spray dryer outlet temperature will vary depending upon such factors as the feed temperature and the properties of the materials being dried. Generally, the outlet temperature is about 50°C to about 150°C. If desired, the respirable dry particles that are produced can be fractionated by volumetric size, for example, using a sieve, or fractioned by aerodynamic size, for example, using a cyclone, and/or further separated according to density using techniques known to those of skill in the art.
[00115] To prepare the respirable dry particles, generally, an emulsion or suspension that contains the desired components of the dry powder (i.e., a feedstock) is prepared and spray dried under suitable conditions. Preferably, the dissolved or suspended solids concentration in the feedstock is at least about Ig/L, at least about 2 g/L, at least about 5 g/L, at least about 10 g/L, at least about 15 g/L, at least about 20 g/L, at least about 30 g/L, at least about 40 g/L, at least about 50 g/L, at least about 60 g/L, at least about 70 g/L, at least about 80 g/L, at least about 90 g/L or at least about 100 g/L. The feedstock can be provided by preparing a single solution, suspension or emulsion by dissolving, suspending, or emulsifying suitable components (e.g., salts, excipients, other active ingredients) in a suitable solvent. The solution, emulsion or suspension can be prepared using any suitable methods, such as bulk mixing of dry and/or liquid components or static mixing of liquid components to form a combination. For example, a hydrophilic component (e.g., an aqueous solution) and a hydrophobic component (e.g., an organic solution) can be combined using a static mixer to form a combination. The combination can then be atomized to produce droplets, which are dried to form respirable dry particles. Preferably, the atomizing step is performed immediately after the components are combined in the static mixer. Alternatively, the atomizing step is performed on a bulk mixed solution.
[00116] The feedstock can be prepared using any solvent in which the itraconazole in particulate form has low solubility, such as an organic solvent, an aqueous solvent or mixtures thereof. Suitable organic solvents that can be employed include but are not limited to alcohols such as, for example, ethanol, methanol, propanol, isopropanol, butanols, and others. Other organic solvents include but are not limited to tetrahydrofuran (THF), perfluorocarbons, di chloromethane, chloroform, ether, ethyl acetate, methyl tert-butyl ether and others. Cosolvents that can be employed include an aqueous solvent and an organic solvent, such as, but not limited to, the organic solvents as described above. Aqueous solvents include water and buffered solutions. A preferred solvent is water.
[00117] Various methods (e.g., static mixing, bulk mixing) can be used for mixing the solutes and solvents to prepare feedstocks, which are known in the art. If desired, other suitable methods of mixing may be used. For example, additional components that cause or facilitate the mixing can be included in the feedstock. For example, carbon dioxide produces fizzing or effervescence and thus can serve to promote physical mixing of the solute and solvents.
[00118] The feedstock or components of the feedstock can have any desired pH, viscosity or other properties. If desired, a pH buffer can be added to the solvent or co-solvent or to the formed mixture. Generally, the pH of the mixture ranges from about 3 to about 8.
[00119] Dry powder and/or respirable dry particles can be fabricated and then separated, for example, by fdtration or centrifugation by means of a cyclone, to provide a particle sample with a preselected size distribution. For example, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90% of the respirable dry particles in a sample can have a diameter within a selected range. The selected range within which a certain percentage of the respirable dry particles fall can be, for example, any of the size ranges described herein, such as between about 0.1 to about 3 microns VMGD.
[00120] The suspension may be a nano-suspension, similar to an intermediate for making dry powder comprising nano-crystalline itraconazole.
[00121] The dry powder may be itraconazole embedded in a matrix material, such as a matrix material comprising sodium sulfate and leucine. Optionally, the dry powder may be spray dried such that the dry particles are small, dense, and dispersible.
[00122] The dry powders can consist solely of the respirable dry particles described herein without other carrier or excipient particles (referred to as “neat powders”). If desired the dry powders can comprise blends of the respirable dry particles described herein and other carrier or excipient particles, such as lactose carrier particles that are greater than 10 microns, 20 microns to 500 microns, and preferably between 25 microns and 250 microns. In some embodiments, dry powders comprising carrier particles (blended powders) are excluded.
[00123] In a preferred embodiment, the dry powders do not comprise carrier particles. In one aspect, the itraconazole is embedded in a matrix comprising a sodium salt, leucine, and stabilizer. The dry powder may comprise respirable dry particles of uniform content, wherein each particle comprises the itraconazole. Thus, as used herein, “uniform content” means that every respirable particle comprises some amount of itraconazole, with the stabilizer, sodium salt, and leucine.
[00124] The dry powders can comprise respirable dry particles wherein at least 98%, at least 99%, or substantially all of the particles (by weight) comprise itraconazole.
[00125] The dry powders are typically manufactured by first processing the itraconazole in crystalline form to adjust the particle size using any number of techniques that are familiar to
those of skill in the art (e g., wet millingjet milling). For example, crystalline itraconazole may be processed in an antisolvent with a stabilizer to form a suspension. Preferred stabilizers include polysorbates (also known as TWEEN®), such as polysorbate 80 (PS80). The stabilized suspension of crystalline itraconazole is then spray dried with the sodium salt and leucine. The resulting dry particles comprise crystalline itraconazole dispersed throughout an excipient matrix with each dry particle having a homogenous composition.
[00126] In a particular embodiment, a dry powder of the present invention is made by starting with crystalline itraconazole, which is usually obtainable in a micro-crystalline size range. The particle size of the micro-crystalline itraconazole is reduced into the nano-crystalline size using any of a number of techniques familiar to those of skill in the art, including but not limited to, high-pressure homogenization, high-shear homogenization, jet-milling, pin milling, microfluidization, or wet milling (also known as ball milling, pearl milling or bead milling). Wet milling is often preferred, as it is able to achieve a wide range of particle size distributions, including those in the nanometer (< 1 pm) size domain. What becomes especially important in the sub-micron size domain is the use of surface stabilizing components, such as surfactants (e.g., polysorbate 80, also known as TWEEN® 80). Surfactants enable the creation of submicron particles during milling and the formation of physically stable suspensions, as they sequester the many high energy surfaces created during milling preventing aggregation and sedimentation. Thus, the presence of the surfactant is important to spray drying homogenous micro-particles as the surfactant allows for the formation of a uniform and stable suspension ensuring compositional homogeneity across particles. The use of surfactant allows for formation of micro-suspension or nano-suspensions. With the surfactant, the nano-crystalline itraconazole particles are suspended in a stable colloidal suspension in the anti-solvent. The anti-solvent for the drug can utilize water, or a combination of water and other miscible solvents such as alcohols or ketones as the continuous anti-solvent phase for the colloidal suspension. A spray drying feedstock may be prepared by dissolving the soluble components in a desired solvent(s) followed by dispersing the surfactant-stabilized crystalline itraconazole nanosuspension in the resulting feedstock while mixing, although the process is not limited to this specific order of operations. [00127] Methods for analyzing the dry powders and/or respirable dry particles are found in the Exemplification section below.
EXEMPLIFICATION
[00128] Materials used in the following Examples and their sources are listed below. Sodium sulfate, polysorbate 80, and L-leucine were obtained from Sigma-Aldrich Co. (St. Louis, MO), Spectrum Chemicals (Gardena, CA), Applichem (Maryland Heights, MO), Alfa Aesar (Tewksbury, MA), Thermo Fisher (Waltham, MA), Croda Chemicals (East Yorkshire, United Kingdom) or Merck (Darmstadt, Germany). Itraconazole was obtained from Neuland (Princeton, NJ). Ultrapure (Type II ASTM) water was from a water purification system (Millipore Corp., Billerica, MA), or equivalent.
[00129] PBMK studies were performed in silico. The methods and results of a Phase 1 clinical study using an exemplary respirable dry powder used for static equation calculation and model development are summarized in Hava et al. (supra).
[00130] Geometric or Volume Diameter: Volume median diameter (x50 or Dv50), which may also be referred to as volume median geometric diameter (VMGD), of the dry powders was determined using a laser diffraction technique. The equipment consisted of a HELOS diffractometer and a RODOS dry powder disperser (Sympatec, Inc., Princeton, NJ). The RODOS disperser applies a shear force to a sample of particles, controlled by the regulator pressure (typically set at 1.0 bar with maximum orifice ring pressure) of the incoming compressed dry air. The pressure settings may be varied to vary the amount of energy used to disperse the powder. For example, the dispersion energy may be modulated by changing the regulator pressure from 0.2 bar to 4.0 bar. Powder sample is dispensed from a microspatula into the RODOS funnel. The dispersed particles travel through a laser beam where the resulting diffracted light pattern produced is collected, typically using an R1 lens, by a series of detectors. The ensemble diffraction pattern is then translated into a volume-based particle size distribution using the Fraunhofer diffraction model, on the basis that smaller particles diffract light at larger angles. Using this method, the span of the distribution was also determined per the formula ((Dv[90]-Dv[10)/(Dv[50]). The span value gives a relative indication of the poly dispersity of the particle size distribution.
[00131] Aerodynamic Performance: The aerodynamic properties of the powders dispersed from an inhaler device were assessed with a Next Generation Impactor (Copley Scientific Limited, Nottingham, UK) (NGI). For measurements utilizing the NGI, the NGI instrument was run in controlled environmental conditions of 18 to 25°C and relative humidity (RH) between 25
and 35%. The instrument consists of seven stages that separate aerosol particles based on inertial impaction and can be operated at a variety of air flow rates. At each stage, the aerosol stream passes through a set of nozzles and impinges on a corresponding impaction surface. Particles having small enough inertia will continue with the aerosol stream to the next stage, while the remaining particles will impact upon the surface. At each successive stage, the aerosol passes through nozzles at a higher velocity and aerodynamically smaller particles are collected on the plate. After the aerosol passes through the final stage, a micro-orifice collector collects the smallest particles that remain. Gravimetric and/or chemical analyses can then be performed to determine the particle size distribution. The capsules (HPMC, Size 3; Capsugel Vcaps, Peapack, NJ) were filled with powder to a specific weight and placed in a hand-held, breath-activated dry powder inhaler (DPI) device, the high resistance RS01 DPI or the ultra-high resistance RS01 DPI (both by Plastiape, Osnago, Italy). The capsule was punctured and the powder was drawn through the cascade impactor operated at a specified flow rate for 2.0 Liters of inhaled air. At the specified flow rate, the cut-off diameters for the stages were calculated. The fractions were collected by placing wetted filters in the apparatus and determining the amount of powder that impinged on them by chemical measurements on an HPLC.
[00132] Fine Particle Dose: The fine particle dose indicates the mass of itraconazole in a specific size range and can be used to predict the mass which will reach a certain region in the respiratory tract. The fine particle dose can be measured gravimetrically or chemically via either an ACI or NGI. If measured gravimetrically, since the dry particles are assumed to be homogenous, the mass of the powder on each stage and collection filter can be multiplied by the fraction of itraconazole in the formulation to determine the mass of itraconazole. If measured chemically, the powder from each stage or filter is collected, separated, and assayed for example on an HPLC to determine the content of the itraconazole. The cumulative mass deposited on each of the stages at the specified flow rate is calculated and the cumulative mass corresponding to a 5.0 micrometer diameter particle is interpolated. This cumulative mass for a single dose of powder, contained in one or more capsules, actuated into the impactor is equal to the fine particle dose less than 5.0 microns (FPD < 5.0 microns).
[00133] Mass Median Aerodynamic Diameter (MMAD): MMAD was determined using the information obtained by the Next Generation Impactor (NGI). The cumulative mass under the stage cut-off diameter is calculated for each stage and normalized by the recovered dose of
powder The MMAD of the powder is then calculated by linear interpolation of the stage cut-off diameters that bracket the 50th percentile. An alternative method of measuring the MMAD is with an Andersen Cascade Impactor (ACI). Like the NGI, the MMAD is calculated with the cumulative mass under the stage cut-off diameter is calculated for each stage and normalized by the recovered dose of powder. The MMAD of the powder is then calculated by linear interpolation of the stage cut-off diameters that bracket the 50th percentile.
[00134] Emitted Geometric or Volume Diameter: The volume median diameter (Dv50) of the powder after it is emitted from a dry powder inhaler, which may also be referred to as volume median geometric diameter (VMGD), was determined using a laser diffraction technique via the Spraytec diffractometer (Malvern, Inc.). Powder was fdled into size 3 capsules (V-Caps, Capsugel) and placed in a capsule based dry powder inhaler (RS01TM Model 7 High resistance, Plastiape, Italy), or DPI, and the DPI sealed inside a cylinder. The cylinder was connected to a positive pressure air source with steady air flow through the system measured with a mass flow meter and its duration controlled with a timer controlled solenoid valve. The exit of the dry powder inhaler was exposed to room pressure and the resulting aerosol jet passed through the laser of the diffraction particle sizer (Spraytec) in its open bench configuration before being captured by a vacuum extractor. The steady air flow rate through the system was initiated using the solenoid valve. A steady air flow rate was drawn through the DPI typically at 60 L/min for a set duration, typically of 2 seconds. Alternatively, the air flow rate drawn through the DPI was sometimes run at 15 L/min, 20 L/min, or 30 L/min. The resulting geometric particle size distribution of the aerosol was calculated from the software based on the measured scatter pattern on the photodetectors with samples typically taken at 1000Hz for the duration of the inhalation. The Dv50, GSD, FPF<5.0 pm measured were then averaged over the duration of the inhalation. [00135] The Emitted Dose (ED) refers to the mass of itraconazole which exits a suitable inhaler device after a firing or dispersion event. The ED is determined using a method based on USP Section 601 Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, Delivered-Dose Uniformity, Sampling the Delivered Dose from Dry Powder Inhalers, United States Pharmacopeia convention, Rockville, MD, 13th Revision, 222-225, 2007. Contents of capsules are dispersed using either the RS01 HR inhaler at a pressure drop of 4kPa and a typical flow rate of 60 LPM or the UHR2 RS01 at a pressure drop of 4kPa and a typical flow rate of 39 LPM. The emitted powder is collected on a filter in a filter holder sampling apparatus. The sampling
apparatus is rinsed with a suitable solvent such as water and analyzed using an HPLC method. For gravimetric analysis a shorter length fdter holder sampling apparatus is used to reduce deposition in the apparatus and the filter is weighed before and after to determine the mass of powder delivered from the DPI to the filter. The emitted dose of therapeutic is then calculated based on the content of therapeutic in the delivered powder. Emitted dose can be reported as the mass of therapeutic delivered from the DPI or as a percentage of the filled dose.
[00136] Thermogravimetric Analysis: Thermogravimetric analysis (TGA) was performed using either the Q500 model or the Discovery model thermogravimetric analyzer (TA Instruments, New Castle, DE). The samples were either placed into an open aluminum DSC pan or a sealed aluminum DSC pan that was then automatically punched open prior to the time of test. Tare weights were previously recorded by the instrument. The following method was employed: Ramp 5.00 °C/min from ambient (~35 °C ) to 200 °C. The weight loss was reported as a function of temperature up to 140°C. TGA allows for the calculation of the content of volatile compounds within the dry powder. When utilizing processes with water alone, or water in conjunction with volatile solvents, the weight loss via TGA is a good estimate of water content.
[00137] X-Ray Powder Diffraction: The crystalline character of the formulations was assessed via powder X-ray diffraction (PXRD). A 20-30 mg sample of material is analyzed in a powder X-ray diffractometer (D8 Discover with LINXEYE detector; Bruker Corporation, Billerica, MA or equivalent) using a Cu X-ray tube with 1.5418A at a data accumulation time 1.2 second/step over a scan range of 5 to 45°20 and a step size of 0.02°20.
[00138] Itraconazole Content/Purity using HPLC: A high performance liquid chromatography (HPLC) method utilizing a reverse phase Cl 8 column coupled to an ultraviolet (UV) detector has been developed for the identification, bulk content, assay, CUPMD and impurities analysis of itraconazole dry powders. The reverse phase column is equilibrated to 30°C and the autosampler is set to 5°C. The mobile phases, 20 mM sodium phosphate monobasic at a pH of 2.0 (mobile phase A) and acetonitrile (mobile phase B) are used in a gradient elution from a ratio of 59:41 (A:B) to 5:95 (A:B), over the course of a 19.5 minute run time. Detection is by UV at 258 nm and the injection volume is 10 pL. Itraconazole content in powders are quantified relative to a standard curve.
[00139] Identification of known impurities A, B, C, D, E, F and G (shown in monograph Ph. Eur. 01/2011 : 1335) is confirmed by comparing the retention time of the impurity peaks in the itraconazole dry powder samples to that of the itraconazole USP impurity mix reference standard spiked with impurity A. Unknown impurities are identified and quantified by relative retention time to that of the itraconazole main peak and with area above the limit of detection (LOD). All impurities are measured by area percent, with respect to the itraconazole peak.
[00140] Particle Size Reduction: The particle size distribution of the crystalline itraconazole can be modulated using a number of techniques familiar to those of skill in the art, including but not limited to, high-pressure homogenization, high-shear homogenizationjetmilling, pin milling, microfluidization, or wet milling (also known as ball milling, pearl milling or bead milling). Wet milling is often preferred, as it is able to achieve a wide range of particle size distributions, including those in the nanometer (< 1 pm) size domain.
[00141] Particle Size Reduction using Low Energy Wet Milling. One technique for reducing the particle size of the itraconazole was via low energy wet milling (also known as roller milling, or jar milling). Suspensions of the itraconazole were prepared in an anti-solvent, which can be water, or any solvent in which the active agent is not appreciably soluble.
Stabilizers, which can be, but are not limited to, non-ionic surfactants or amphiphilic polymers, are then added to the suspension along with milling media, which can be, but are not limited to, spherical with high wear resistance and in the size range from 0.03 to 0.70 millimeters in diameter. The vessels containing the suspensions are then rotated using aj r mill (US Stoneware, East Palestine, OH USA) while taking samples periodically to assess particle size (LA-950, HORIBA, Kyoto, Japan). When the particle size is sufficiently reduced, or when a particle size minimum is reached, the suspension is strained through a sieve to remove the milling media, and the product recovered.
[00142] Particle Size Reduction using High Energy Wet Milling: Another technique for reducing the particle size of the itraconazole was via high-energy wet milling using a rotorstator, or agitated media mill. Suspensions of the itraconazole were prepared in an anti-solvent, which can be water, or any solvent in which the active agent is not appreciably soluble. Stabilizers, which can be, but are not limited to, non-ionic surfactants or amphiphilic polymers, are then added to the suspension along with milling media, which can be, but are not limited to, spherical with high wear resistance and in the size range from 0.03 to 0.70 millimeters in
diameter. The suspensions are then charged into the mill, which can be operated in either batch or recirculation mode. The process consists of the suspension and milling media being agitated within the milling chamber, which increases the energy input to the system and accelerates the particle size reduction process. The milling chamber and recirculation vessel are jacketed and actively cooled to avoid temperature increases in the product. The agitation rate and recirculation rate of the suspension are controlled during the process. Samples are taken periodically to assess particle size (LA-950, HORIBA, Kyoto, Japan). When the particle size is sufficiently reduced, or when a particle size minimum is reached, the suspension is discharged from the mill.
[00143] Spray Drying: Dry powders were prepared by spray drying on a Buchi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland) with powder collection from either a standard or High Performance cyclone. The system was run with nitrogen as the drying and atomization gas in open-loop (single pass) mode. When run using air, the system used the Buchi B-296 dehumidifier to ensure stable temperature and humidity of the air used to spray dry. Furthermore, when the relative humidity in the room exceeded 30% RH, an external LG dehumidifier (model 49007903, LG Electronics, Englewood Cliffs, NJ) was run constantly. When run using nitrogen, a pressurized source of nitrogen was used. Furthermore, the aspirator of the system was adjusted to maintain the system pressure at -2.0” water column. Atomization of the liquid feed utilized a Buchi nozzle with 1.5mm cap and 0.7 liquid tip. The liquid feedstock solids concentration was 3%, the process gas inlet temperature was 127 °C to 140 °C, the process gas outlet temperature was 60°C, the drying gas flowrate was 17.0 kg/hr, the atomization gas flowrate was 30.0 g/min, and the liquid feedstock flowrate was 6.0mL/min.
[00144] Stability Assessment: The physicochemical stability and aerosol performance of select formulations were assessed at 2-8 °C, 25°C/60% RH, and when material quantities permitted, 40°C/75% RH as detailed in the International Conference on Harmonisation (ICH) QI guidance. Stability samples were stored in calibrated chambers (Darwin Chambers Company Models PH024 and PH074, St. Louis. MO). Bulk powder samples were weighed into amber glass vials, sealed under 30% RH, and induction-sealed in aluminum pouches (Drishield 3000, 3M, St. Paul, MN) with silica desiccant (2.0g, Multisorb Technologies, Buffalo, NY ). Additionally, to assess the stability of the formulations in capsules, the target mass of powder was weighed by hand into a size 3, HPMC capsule (Capsugel Vcaps, Peapack, NJ) with a +/- 0.2
mg tolerance at 30% RH. Filled capsules were then aliquoted into high-density polyethylene (HDPE) bottles and induction sealed in aluminum pouches with silica desiccant.
Example 1: Preparation and characterization of exemplary dry powder Formulation I
A. Powder Preparation.
[00145] The nanocrystalline itraconazole for Formulation I was prepared by compounding 30.090 g of itraconazole (Neuland ITI0114005 and ITI0714011) in 87 g of water and 3 g of polysorbate 80. Polystyrene milling media (130 g of 500 pm; Dow Chemical, Midland MI) was then added to the suspension, and the suspension was milled at 1800 rpm for one hour before being collected. The final median particle size (Dv(50)) of the milled suspension was 132 nm. [00146] A feedstock solution was then prepared and used to manufacture the dry powder. A drug load of 50 wt% itraconazole, on a dry basis, was targeted. The feedstock solution that was used to spray dry particles were made as follows. The required quantity of water (1.18 kg) was weighed into a suitably sized glass vessel. Sodium sulfate (12.8 g) and leucine (3.7 g) were added to the water and the solution allowed to stir until visually clear. The itraconazole- containing suspension (containing 18.3 grams itraconazole and 1.83 grams polysorbate 80) was then added to the excipient solution and stirred until visually homogenous. The feedstock was then spray-dried. Feedstocks were stirred while spray dried. Feedstock mass was approximately 1.22 kg. Dry powders Formulation I was manufactured from the feedstock by spray drying on the Buchi B-290 Mini Spray Dryer (BUCHI Labortechnik AG, Flawil, Switzerland) with cyclone powder collection, following the protocol described above.
[00147] Formulation I has the following dry powder composition (w/w) on a dry basis: 50% itraconazole, 35% sodium sulfate, 10% leucine, and 5% polysorbate 80.
B. Powder Characterization.
[00148] The bulk particle size characteristics for Formulation I is provided below in Table 2. The span at 1 bar of less than 2.10 indicates a relatively narrow size distribution. The 1 bar/4 bar dispersibility ratio less than 1.25 indicates the powder is relatively independent of dispersion energy, a desirable characteristic which allows similar particle dispersion across a range of dispersion energies.
[00149] Table 2: Bulk particle size characteristics of Formulation T
[00150] The geometric particle size and capsule emitted powder mass (CEPM) measured and/or calculated at 60 liters per minute (LPM) and 30 LPM simulated patient flow rates was also measured for Formulation I. At 30 LPM, Formulation I had a CEPM of 99.3% and Dv50 of 4.35 pm. At 60 LPM, Formulation 1 had a CEPM of 99.8% and Dv50 of 3.97 pm. The small changes in CEPM and geometric size from 60 LPM to 30 LPM indicates that the dry powder is relatively independent of patient inspiratory flowrate, indicating that patients breathing in at varying flow rates would receive a relatively similar therapeutic dose.
[00151] The aerodynamic particle size, fine particle fractions and fine particle doses were also measured and/or calculated with a Next Generation Impactor (NGI). Formulation I had a MMAD of 4.22 pm, and an FPD < 5 pm of 38.3% of nominal dose. In other words, more than 30% of the nominal dose reaches the impactor stages and so would be predicted to be delivered to the lungs. The MMAD of 4.22 is also indicative of deposition in the central and conducting airways.
[00152] Thermogravimetric analysis determined the weight loss was 0.1%.
[00153] The crystallinity of Formulation I was assessed via X-ray diffraction (XRD). The diffraction pattern of itraconazole is observed in the formulation, suggesting the milling or spray drying process did not affect the solid-state of itraconazole.
Example 2: Tn silica modelling
[00154] A physiological-based pharmacokinetics (PBPK) model originally developed to simulate the concentration-time profiles of itraconazole and OH-itraconazole after administration of itraconazole as an oral solution (Simcyp Simulator, VI 9) was modified to simulate administration by oral inhalation. The PBPK model parameters describing the fraction absorbed and rate of absorption from the lung, as well as the fraction of inhaled dose swallowed, were optimized by fitting these parameters to the observed plasma concentration data collected in a
clinical study in which 35 mg of Formulation I was administered once a day (QD) for 14 days. Simulated population geometric mean itraconazole and OH-itraconazole area under the curve (AUC)o-24h values at steady state (by Day 14) were within 0.96-fold and 1.68-fold respectively of observed data from a Phase 1 clinical trial using Formulation I. See Hava, supra). The data could be used to determine the DDI potential of a maximum 40 mg dose of orally inhaled itraconazole, by applying basic static model, a mechanistic static model, and a physiologically based pharmacokinetic (PBPK) model of itraconazole and OH-itraconazole, the primary metabolite of itraconazole, to evaluate the potential risk of itraconazole dry powders as “perpetrators” of CYP3A4 DDIs, using midazolam as a “victim” drug and Formulation I as an exemplary itraconazole based dry powder.
[00155] Basic Static Model of Reversible Inhibition'. The basic and mechanistic static equations have been described in the FDA guidance for in vitro drug interaction studies (FDA DDI Guidance (2020). “Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, Guidance for Industry.” U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); incorporated herein by reference in its entirety).
[00156] For Formulation I, the ratio of the intrinsic clearance value of a probe substrate in the absence and in the presence of itraconazole (Rl) was calculated using the observed Cmax of itraconazole and OH-itraconazole, respectively, after 14 days of 35 mg of Formulation I QD. [00157] Calculation of the ratio of the intrinsic clearance value of a probe substrate in the absence and in the presence of an inhibitor in the gut (Rl,gut) was used for Formulation I, as itraconazole and OH-itraconazole are inhibitors of CYP3A4. Equation input values are listed in Table 3.
[00158] Table 3. Parameters used for the calculation of R values for the static equations of reversible inhibition.
[00159] An R1 >1.02 or Rl,gut > 11 indicates that a clinically significant drug-drug interaction may exist and requires further investigation.
[00160] Mechanistic Static Model of Reversible Inhibition'. The area under the plasma concentration-time curve ratio (AUCR) for reversible inhibitors was calculated according to the FDA guidance for in vitro drug interaction studies. As a worst-case scenario, it was assumed that all of the inhaled dose was swallowed and subsequently delivered to the gut. A weak, moderate, or strong DDI is defined as a calculated AUCR (weak: > 1.25-fold, but < 2.00-fold; moderate: > 2.00-fold, but < 5.00-fold; strong: > 5.00-fold).
[00161] PBPK Modelling - Study Design and Setup . To achieve the modelling objectives, this step in the investigation consisted of two parts, model optimization and application. Some of the key factors relating to each step are indicated below. Model optimization and application were performed using Simcyp (2019, Version 19 Release 2, Certara, Sheffield, UK). Data assembly and plotting were performed using RStudio (Version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria). The virtual North European Caucasian population (physiological parameters including liver volume and blood flows, enzyme abundances) within Simcyp was used for all simulations (Howgate E., et al., Xenobiotica (2006) 36(6) 473 497). Except for demographic data, all parameter values for the healthy volunteer (HV) population are the same as those used for the Caucasian population.
[00162] PBPK Modelling - Model Optimization'. To simulate the plasma concentrationtime profiles of itraconazole and OH-itraconazole after the inhaled administration of 35 mg
Formulation T (QD for 14 days), the Simcyp VI 9 itraconazole oral solution PBPK model was adapted to include absorption of itraconazole through the lung as well as the gut. The model assumes first-order absorption from the lungs to the systemic circulation. The structural model is shown in FIG. 1. The trial design used for the optimization of first-order inhalation parameters was based on the study described in Hava et al. (supra) in which subjects received Formulation I at 35 mg QD for 14 days. That study measured itraconazole and OH-itraconazole data as summarized in Table 4.
[00163] Table 4. First order inhalation parameters for itraconazole and OH- itraconazole using Formulation I.
[00164] For the PBPK model development, ten virtual trials of six subjects, aged 21 to 58 years (33.3% female), were generated to assess variability across groups. The population of the virtual trial was selected to match the clinical study subjects. A range of values was tested for the proportion of dose inhaled, the fraction of itraconazole absorbed from the lung (Fa,l), and the first-order rate constant of itraconazole absorption from the lung (ka,l). These parameters were optimized to best fit the observed plasma concentration-time profiles and PK parameters of itraconazole and OH-itraconazole after multiple dose administration of Formulation I on study day 14, after 35 mg Formulation I (QD for 14 days). Briefly, the pro- portion of dose inhaled and Fa,l was optimized to match the itraconazole AUC0-24h on study day 14. Then, ka,l was optimized to capture Cmax. Once the simulated multiple dose and Cmax were within 0.8 to 1.25 of the observed values, the absorption parameters were further optimized to best predict the OH- itraconazole concentration-time profiles. Intestinal absorption, distribution, and elimination parameters of itraconazole and OH-itraconazole were unchanged from the verified itraconazole and OH-itraconazole models, assuming itraconazole follows linear kinetics even at low doses. This model assumes no metabolism of itraconazole to OH-itraconazole in the lung.
[00165] The first-order inhalation parameters were manually optimized by comparing the simulated profiles of Formulation I to observed data. The first-order inhalation parameters used to simulate the plasma concentration profile of Formulation I are shown in Table 5.
[00167] PBPK Modelling - Model Application'. The CYP3A4 inhibition potential of Formulation I was predicted using a representative virtual healthy population consisting of ten virtual trials of ten healthy subjects (50% female), aged 20 to 50 years. The victim drug (midazolam) was administered as a single dose of 5 mg without administration of Formulation I, then again on day 14 of daily administration of Formulation I 35 mg. The virtual DDI trials were repeated with the same virtual trial design and study population, with 40 mg of Formulation I administered daily for 14 days.
[00168] Calculation of the R Value for the Basic Model of Reversible Inhibition'. R1 was calculated for Formulation I using the observed maximum concentration of itraconazole and OH- itraconazole following multiple inhaled doses of Formulation I (35 mg QD) for 14 days. R1 was calculated to be 1.35. Because this value exceeded the cutoff value of 1.02 specified by the FDA guidance document (supra), further investigation of DDI liability was required. Additionally, Rl,gut was calculated to be greater than the threshold value of 11, indicating that additional assessment of DDI liability was required. Based on these results, a mechanistic static model was applied to further investigate the CYP3A4 inhibition potential of Formulation I.
[00169] Calculation ofAUCR for the Mechanistic Static Equation'. AUCR of midazolam was calculated for Formulation I using the observed maximum concentration of itraconazole and OH-itraconazole following multiple simulated inhaled doses of Formulation I (35 mg QD) for 14 days. To calculate the worst-case scenario, it was assumed that all itraconazole absorption occurred through the gut. The AUCR of midazolam was calculated to be 5.36, further indicating a risk of Formulation I as a perpetrator of CYP3A4 DDIs. Based on these results, a PBPK model was developed to further understand the CYP3A4 inhibition potential of Formulation I.
[00170] PBPK Model Optimization and Application'. Simulated itraconazole and OH- itraconazole plasma concentration data are based on the manually optimized proportion of dose
inhaled, (Fa,l), and (ka,l) parameters of Formulation T. Individual mean trial concentrations and the mean concentration-time profdes for the total virtual population (n = 60) were simulated. The simulated profiles of Formulation I and OH-itraconazole after 14 days of dosing with 35 mg/day of Formulation I were comparable to the clinical data as shown in FIGS. 2A and 2B. In addition, the predicted geometric mean Cmax and AUC0-24h values for itraconazole on day 14 were within 0.81- and 0.96-fold, respectively, of the observed values (Table 6).
[00171] Table 6. Predicted and Observed Itraconazole Cmax and AUCo-24h After
[00172] The predicted mean Cmax and AUC0-24h values for OH-itraconazole on day 14 were within 1.47- and 1.68- fold, respectively, of the observed values (Table 7).
[00173] Table 7. Predicted and Observed OH-itraconazole Cmax and AUCo-24h After
[00174] For model application, plasma concentration-time profdes of midazolam following a single oral dose of 5 mg in the absence of Formulation I and on the 14th day of 14 days of dosing of Formulation I (35 mg daily or 40 mg daily) to healthy subjects were simulated.
The mean simulated plasma concentrations of itraconazole and OH-itraconazole after 14 days of 40 mg daily dosing of Formulation I are presented in FIGS. 3A and 3B. Mean simulated plasma midazolam concentrations following a single oral dose of 5 mg in the absence of Formulation I and on the 14th day of 14 days of dosing of Formulation I (35 mg daily or 40 mg daily) to healthy subjects are shown in FIGS. 4A and 4B. The predicted geometric mean Cmax and AUCo-inf values and corresponding geometric mean ratios for midazolam in the presence and absence of Formulation I are shown in Table 8. The threshold for a weak DDI (AUCR and CmaxR < 1.25) was not met when midazolam was coadministered with 35 mg daily of Formulation I. At the higher dose of 40 mg daily Formulation I, a weak DDI is predicted (AUCR > 1.25 but < 2). [00175] Table 8. Predicted geometric mean C max and AUCo-inf values and corresponding geometric mean ratios for midazolam in the absence and presence of
[00176] In conclusion, PBPK modelling of Formulation I after the administration of multiple inhaled doses predicts that effects of Formulation 1 on CYP3A4 substrates are minimal. Based on the criteria of the U.S. Food and Drug Administration (FDA) DDI guidance, no clinically significant CYP3A4 DDI was predicted after the administration of Formulation I QD for 14 days.
Claims
1. A method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole.
2. The method of claim 1, wherein the subject is treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
3. A method of co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
4. The method of claim 2 or 3, wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.
5. The method of any one of claims 2-4, wherein the second therapeutic agent is contraindicated with oral itraconazole (e.g., SPORANOX®).
6. The method of any one of claims 2-5, wherein the second therapeutic agent is an alpha blocker, a beta blocker, an analgesic, an antiarrhythmic, an antibacterial, an anticoagulant, an antiplatelet drug, an anticonvulsant, an antidiabetic drug, an antihelminthic, an antifungal, an antiprotozoal, an antimigraine drug, an antineoplastic, an antipsychotic, an anxiolytic, a hypnotic, an antiviral, a calcium channel blocker, a cardiovascular drug, a contraceptive, a diuretic, an anticonvulsant, an immunosuppressant, a lipid-lowering drug, a respiratory drug (e.g., an asthma treatment), an antidepressant drug (e g., a tricyclic or a selective serotonin reuptake inhibitor (SSRI)), a urologic drug, a vasopressin receptor antagonist, a nonsteroidal anti-inflammatory drug (NS AID), or a gastrointestinal drug.
7. The method of any one of claims 2-6, wherein the second therapeutic agent is alfuzosin, silodosin, tamsulosin, methadone, fentanyl, alfentanil, buprenorphine, oxycodone, sufentanil, disopyramide, dofetilide, dronedarone, quinidine, digoxin, bedaquiline, rifabutin, clarithromycin, trimetrexate, ticagrelor, apixaban, rivaroxaban, vorapaxar, cilostazol, dabigatran, warfarin, carbamazepine, repaglinidea, saxagliptin, isavuconazonium, praziquantel, artemether- lumefantrine, quinine, an ergot alkaloid (e.g., dihydroergotamine, ergometrine, ergonovine, methylergometrine, methylergonovine, ergotamine), eletriptan, irinotecan, axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetiniba, crizotinib, dabrafenib, dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olapariba, pazopanib, regorafenib, sunitinib, trabectedin, trastuzumab-emtansine, vinca alkaloids, bortezomib, brentuximab-vedotin, busulfan, erlotinib, gefitinib, idelalisib, nintedanib, panobinostat, ponatinib, ruxolitinib, sonidegib, vandetanib, imatinib, ixabepilone, alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam, quetiapine, ramelteon, risperidone, suvorexant, zopiclone, lurasidone, pimozide, triazolam, levacetylmethadol (levomethadyl), simeprevir, daclatasvir, indinavir, maraviroc, cobicistat, elvitegravir, ritonavir, saquinavir, tenofovir disoproxil fumarate, nadolol, felodipine, nisoldipine, diltiazem, dihydropyridines, verapamil, ivabradine, ranolazine, aliskiren, riociguat, sildenafd, tadalafil, bosentan, guanfacine, dienogest, ulipristal, eplerenone, cisapride, naloxegol, aprepitant, loperamide, netupitant, everolimus, sirolimus, temsirolimus, budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus, lomitapide, lovastatin, simvastatin, atorvastatin, salmeterol, venlafaxine, avanafil, fesoterodine, solifenacin, darifenacin, vardenafd, dutasteride, oxybutynin, tolterodine, colchicine, eliglustat, lumacaftor, ivacaftor, elexacaftor, tezacaftor, SYMDEKO®, ORKAMBI®, KALYDECO®, alitretinoin, cabergoline, cannabinoids, cinacalcet, conivaptan, volvaptan, Saccharomyces boulardii, meloxicam, ciprofloxacin, erythromycin, clarithromycin, idelalisib, darunavir, fosamprenavir, isoniazid, rifampicin, rifabutin, phenobarbital, phenytoin, efavirenz, nevirapine, or drugs that reduce gastric acidity (e.g., acid neutralizing medicines such as aluminum hydroxide, acid secretion suppressors such as H2-receptor antagonists and proton pump inhibitors), or halofantrine.
8. The method of any one of claims 2-7, wherein the second therapeutic agent is methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, an ergot alkaloid (such as
dihydroergotamine, ergometrine (ergonovine), ergotamine, methyl ergometrine (methylergonovine)), irinotecan, lurasidone, midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafd, ticagrelor, colchicine, fesoterodine, solifenacin, or eliglustat.
9. The method of any one of the preceding claims, wherein the itraconazole is administered to the subject at a nominal dose of between about 1 mg and about 60 mg, between about 5 mg and about 40 mg, between about 1 mg and about 10 mg, between about 10 mg and about 20 mg, between about 20 mg and about 30 mg, or between about 30 mg and about 40 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg.
10. The method of any one of claims 2-9, wherein the itraconazole is administered to the subject no more than about 14 days before or after administering the second therapeutic agent, less than about 14 days, less than about 12 days, less than about 10 days, less than about 8 days, less than about 7 days, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, less than about 2 days, or less than about 1 day before or after administering the second therapeutic agent.
11. The method of any one of claims 2-10, wherein the itraconazole is administered to the subject on the same day as administering the second therapeutic agent, less than about 20 hours, less than about 18 hours, less than about 16 hours, less than about 14 hours, less than about 12 hours, less than about 11 hours, less than about 10 hours, less than about 9 hours, less than about 8 hours, less than about 7 hours, less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, less than about 45 minutes, less than about 30 minutes, less than about 20 minutes, less than about 10 minutes, or less than about 5 minutes, before or after administering the second therapeutic agent.
12. The method of any one of claims 2-11, wherein the itraconazole is administered to the subject less than about 5 minutes before or after administering the second therapeutic agent.
13. The method of any one of the preceding claims, wherein the respirable dry powder comprises homogenous respirable dry particles that comprise crystalline itraconazole, a stabilizer, a sodium salt, and an excipient.
14. The method of claim 13, wherein the sodium salt is sodium sulfate.
15. The method of claim 13 or 14, wherein the itraconazole is a crystalline sub-particle with a size of about 50 nm to about 5,000 nm (Dv50), about 50 nm to about 800 nm (Dv50), about 50 nm to about 300 nm (Dv50), about 50 nm to about 200 nm (Dv50), or about 100 nm to about 300 nm (Dv50).
16. The method of any one of claims 13-15, wherein the itraconazole is present in the respirable dry particles in an amount of about 30% to about 70% by weight, about 40% to about 60% by weight, about 45%, about 50%, or about 55% by weight.
17. The method of any one of claims 13-16, wherein the itraconazole is at least 50% crystalline.
18. The method of any one of claims 13-17, wherein the ratio of itraconazole: stabilizer (wt:wt) in the respirable dry particles is about 10:1.
19. The method of any one of claims 13-18, wherein the stabilizer is present in the respirable dry particles in an amount of about 3% to about 7% by weight or about 5% by weight.
20. The method of any one of claims 13-19, wherein the excipient is present in the respirable dry particles in an amount of about 5% to about 20% by weight or about 10% by weight.
21. The method of any one of claims 13-20, wherein the stabilizer is polysorbate 80.
22. The method of any one of claims 13-21, wherein the excipient is leucine.
23. The method of any one of the preceding claims, wherein the respirable dry powder comprises homogenous respirable dry particles that comprise about 50 wt% crystalline itraconazole, about 35 wt% sodium sulfate, about 10 wt% leucine, and about 5 wt% polysorbate 80.
24. The method of any one of claims 13-23, wherein the respirable dry particles have:
(i) a volume median geometric diameter (VMGD) of about 10 microns or less, or about 5 microns or less;
(ii) a tap density of about 0.2 g/cc or greater, or a tap density of between 0.2 g/cc and 1.0 g/cc;
(iii) a 1 bar/4 bar dispersibility ratio (1/4 bar) of less than about 1.5, as measured by laser diffraction; and/or
(iv) a 0.5 bar/4 bar dispersibility ratio (0.5/4 bar) of about 1.5 or less, as measured by laser diffraction.
25. The method of any one of claims 13-24, wherein the respirable dry powder has:
(i) a mass median aerodynamic diameter (MMAD) of between about 1 micron and about 5 microns; and/or
(ii) a fine particle fraction (FPF) of the total dose less than 5 microns of about 25% or more.
26. The method of any one of claims 13-25, wherein the respirable dry particles have a capsule emitted powder mass of at least 80% when emitted from a passive dry powder inhaler that has a resistance of about 0.036 sqrt(kPa)/liters per minute under the following conditions; an inhalation flow rate of 30 LPM for a period of 3 seconds using a size 3 capsule that contains a total mass of 10 mg, said total mass consisting of the respirable dry particles, and wherein the volume median geometric diameter of the respirable dry particles emitted from the inhaler as measured by laser diffraction is 5 microns or less.
27. The method of any one of claims 13-26, wherein the respirable dry powder is delivered to the respiratory tract of the subject with a capsule-based passive dry powder inhaler.
28. The method of any one of the preceding claims, wherein the subject has an infection, allergic bronchopulmonary aspergillosis, a respiratory disease, an acute exacerbation of a respiratory disease, an immunodeficiency disorder, cancer, a cardiovascular disorder, hypertension, hypercholesterolemia, an autoimmune disorder, diabetes, a gastrointestinal disorder, a thrombotic disorder, epilepsy, a psychiatric disorder, migraine, or pain.
29. The method of any one of claims 1, 2 or 4-28, wherein the disease or disorder is an infection, allergic bronchopulmonary aspergillosis, a respiratory disease, an acute exacerbation of a respiratory disease, or cancer.
30. A respirable dry powder for use in a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject.
31. The respirable dry powder for use of claim 31, wherein the subject is treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
32. A respirable dry powder for use in a method of co-administering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
33. Use of a respirable dry powder in the manufacture of a medicament for treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject.
34. The use of claim 33, wherein the subject is treated with a second therapeutic agent that is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
35. Use of a respirable dry powder in the manufacture of a medicament for co-administering itraconazole and a second therapeutic agent to a subject in need thereof, wherein the respirable dry powder comprises the itraconazole and is administered to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263402577P | 2022-08-31 | 2022-08-31 | |
US63/402,577 | 2022-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024049982A2 true WO2024049982A2 (en) | 2024-03-07 |
WO2024049982A3 WO2024049982A3 (en) | 2024-05-02 |
Family
ID=88207369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/031675 WO2024049982A2 (en) | 2022-08-31 | 2023-08-31 | Methods of using itraconazole dry powders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024049982A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018071757A1 (en) | 2016-10-14 | 2018-04-19 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
WO2019204583A1 (en) | 2018-04-18 | 2019-10-24 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
WO2019204597A1 (en) | 2018-04-18 | 2019-10-24 | Pulmatrix Operating Company, Inc | Methods of treating fungal infections |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2095816A1 (en) * | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
US20190167579A1 (en) * | 2017-10-27 | 2019-06-06 | Pulmatrix Operating Company, Inc. | Itraconazole dry powders |
-
2023
- 2023-08-31 WO PCT/US2023/031675 patent/WO2024049982A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018071757A1 (en) | 2016-10-14 | 2018-04-19 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
WO2019204583A1 (en) | 2018-04-18 | 2019-10-24 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
WO2019204597A1 (en) | 2018-04-18 | 2019-10-24 | Pulmatrix Operating Company, Inc | Methods of treating fungal infections |
Non-Patent Citations (8)
Title |
---|
BERGAGNINI-KOLEV ET AL., THE AAPS JOURNAL, vol. 25, 2023, pages 62 |
BROEDERS ET AL., EUR RESPIR J, vol. 18, 2001, pages 780 - 783 |
CLARKE ET AL., JOURNAL OF AEROSOL MED, vol. 6, no. 2, 1993, pages 99 - 110 |
CONTE, J.E. ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 48, 2004, pages 3823 - 3827 |
HAVA, D.L. ET AL., BRIT. J. CLIN. PHARMACOL., vol. 86, no. 4, 2020, pages 723 - 733 |
HOWGATE E. ET AL., XENOBIOTICA, vol. 36, no. 6, 2006, pages 473 - 497 |
K. MASTERS: "Spray Drying Handbook", 1984, JOHN WILEY & SONS |
TIDDENS ET AL., JOURNAL OF AEROSOL MED, vol. 19, no. 4, 2006, pages 456 - 465 |
Also Published As
Publication number | Publication date |
---|---|
WO2024049982A3 (en) | 2024-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6231022B2 (en) | Inhalable pharmaceutical composition | |
AU2017341815B2 (en) | Antifungal dry powders | |
EA031566B1 (en) | Unit dosage form in the form of a dry powder composition, use of the unit dosage form, and dry powder inhaler filled with the unit dosage form | |
JP2021522161A (en) | Antifungal formulation for intrapulmonary administration containing itraconazole | |
Tarara et al. | Formulation of dry powders for inhalation comprising high doses of a poorly soluble hydrophobic drug | |
CN116687887A (en) | Dry powder formulations for inhalation | |
CA2962531C (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
JP2011500731A (en) | Combination therapy | |
WO2016176552A1 (en) | Dry power formulations for inhalation | |
WO2024049982A2 (en) | Methods of using itraconazole dry powders | |
EA036315B1 (en) | Pharmaceutical composition for inhalatory use containing budesonide and formoterol, use thereof and kit comprising same | |
US20240033218A1 (en) | Dihydroergotamine dry powder formulations and methods of use | |
WO2024040175A1 (en) | Methods for treating cancer using inhaled angiogenesis inhibitor | |
CA2963445C (en) | Pharmaceutical composition containing budesonide and formoterol | |
NZ793053A (en) | Antifungal dry powders |